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Abstract 
 The eukaryotic initiation factor 2B (eIF2B) serves as a vital control point within 
translation initiation. eIF2B initiates translation by exchanging GDP for GTP on eIF2. 
However, this mechanism may be attenuated in response to cellular stress by the 
phosphorylation of eIF2, which paradoxically enhances the translation of stress-specific 
mRNA to instigate a stress response. Autosomal recessive mutations within eIF2B 
result in the disease leukoencephalopathy with vanishing white matter (VWM). 
Current models of VWM disease suggest that abnormal eIF2B results in the cell being 
in a constant state of stress. However, previous biochemical studies have illustrated 
that VWM mutations not only decrease the catalytic activity of eIF2B, but can increase 
activity or not affect it at all.  Furthermore, changes in the activity eIF2B do not 
correlate with disease severity. These observations suggest that there may be 
additional characteristics of eIF2B contributing to VWM pathogenesis which remain to 
be elucidated.  
 In this study, we investigated whether the localisation of eIF2B to eIF2B bodies 
was integral for function. Using the yeast S. cerevisiae, we show that the regulatory 
subunit eIF2Bα is required for localisation. Interestingly, catalytic mutations in eIF2Bα 
localised eIF2B to several smaller foci, termed microbodies. In vivo FRAP analysis 
highlighted that eIF2 shuttles through microbodies slower than eIF2B bodies, 
indicating that localisation to eIF2B bodies may be required for full eIF2B activity. 
Surprisingly, phenotypes from eIF2Bα VWM missense mutations were highly variable 
in localisation, possibly recapitulating variable phenotypes observed in humans. 
 The putative membrane proteins Mst27p, Erp4p and Sac1p have been shown 
to associate with eIF2B. We therefore investigated whether they were required for the 
formation of eIF2B bodies. Deletion of membrane proteins did not significantly alter 
eIF2B localisation. Surprisingly however, deletion of the PI(4)P Sac1p reduced rates of 
translation initiation independently of eIF2B, highlighting a link between membrane 
integrity and translational control.   
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1.1. General Introduction 
 Gene expression is coordinated by the processes of transcription and 
translation which is facilitated by various types of ribonucleic acids (RNA). Transcribed 
and processed in the nucleus before being exported into the cytosol, messenger RNA 
(mRNA) facilitates the flow of genetic information from DNA to protein. Once 
synthesised and exported to the cytosol, mRNA can be degraded, stored or translated 
depending on the integrity of the transcript as well as cellular conditions. During 
steady-state conditions the ribosome is recruited to the mRNA to synthesise the 
desired protein. In times of cellular stress however, transcripts can be translationally 
silenced and stored via translocation to stress granules. Alternatively, mRNAs may be 
targeted for degradation by localisation to processing bodies (P-bodies). Thus, the 
cellular production of proteins is an intricately regulated process that demonstrates 
layers of organisation, allowing cells to adapt and change the translatome in a quick, 
efficient and organised manner.  
 Under normal conditions, mRNA transcripts may undergo concurrent rounds of 
translation which is facilitated and controlled by eukaryotic initiation factors (eIFs). 
One of the key initiation factors is the guanine nucleotide exchange factor (GEF) eIF2B 
which controls the initiation of translation by regulating levels of GTP-bound eIF2. This 
initial event is subject to regulation in response to several cellular stresses, 
subsequently halting global protein synthesis allowing the cell to focus on reinstating 
cellular homeostasis. Intriguingly, inherited autosomal recessive mutations within any 
subunit of eIF2B are thought to result in constitutive stress responses which cause the 
fatal disease leukoencephalopathy with vanishing white matter (VWM).  
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 In 2005, Campbell et al., observed a new layer of translational organisation 
where eIF2B localised to discrete cytoplasmic foci termed eIF2B bodies. eIF2 also co-
localised to these eIF2B bodies leading to the suggestion that eIF2B bodies were sites 
at which eIF2B function is controlled and regulated. Despite eIF2B's pivotal role in 
translation initiation, the exact purpose of the eIF2B body and how and why it is 
assembled remains unclear. In the last 10 years, high resolution structures of eIF2B 
have been solved which may help uncover how the eIF2B body is formed, providing 
novel insights into the role of the eIF2B body and its implication for disease. In this 
thesis, the role of eIF2B bodies in the regulation of translation initiation is further 
investigated with a particular focus on its implication to disease. 
1.2. Protein synthesis 
 Translation is the process where genetic information is decoded from mRNA 
into polypeptide chains, and comprises a series of sub-processes; initiation, elongation, 
termination and ribosome recycling. In all living systems, protein synthesis is facilitated 
by the RNA/protein machinery known as the ribosome. In eukaryotes, the small 40S 
subunit and the large 60S subunit complete the 80S ribosome which contains three 
transfer RNA (tRNA) binding sites: the A, P and E sites. Aminoacyl-tRNAs pre-emptively 
occupy the A site, while the elongating peptide chain or peptidyl-tRNA exists in the P 
site. Finally, uncharged or deacylated-tRNAs exit through the E site. During translation 
initiation, where most mechanisms of translational control exist, the 80S ribosome is 
assembled at the 'start' of the open reading frame with the first aminoacyl-tRNA in 
sequence at the P site. The ribosome subsequently moves across the mRNA in a 5'-3' 
direction during the elongation step, adding an amino acid each time an aminoacyl-
tRNA senses a complementary codon until a stop codon is reached. Finally, the 
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ribosome is removed from the mRNA, or alternatively, the ribosome may reinitiate to 
undergo further rounds of translation.   
1.2.1. Synthesis of messenger RNA (mRNA) 
 In eukaryotes, genes are transcribed from template DNA to mRNA in the 
process of transcription. During transcription, the mRNA is capped at the 5' end, non-
coding introns are spliced out and a polyadenoside (poly-A) tail is added to the 3' end. 
These co-transcriptional modifications enhance the stability of mRNA and play 
important roles in translation initiation. 
 Transcription is initiated by general transcription factors which facilitate the 
recruitment of RNA polymerase II (Pol II) . As soon as the 5' triphosphorylated end of 
the pre-cursor mRNA (pre-mRNA) emerges from Pol II, a three-step enzymatic reaction 
occurs which results in the acquisition of a 5' 7-methyl guanoside (7meGpppN) 
residue(Proudfoot et al., 2002). This unique base resists 3'-5' exonucleases and 
requires specialist decapping enzymes, thereby enhancing the half-life of the mRNA. A 
nuclear cap binding complex associates with the 5' cap until the processed mRNA is 
exported into the cytosol. The nuclear cap binding complex is replaced by the cytosolic 
cap binding protein eIF4E which plays an important role in translation initiation and 
translation regulation (Visa et al., 1996, Fortes et al., 2000). 
  Interrupting sequences, known as introns, may be spliced out of mRNA 
cotranscriptionally or post-transcriptionally. The subsequent coding sequences, known 
as exons, are ligated back together by two transesterification reactions to produce the 
spliced mRNA(Wachtel and Manley, 2009). Introns may be retained in some cases 
which allow a pool pre-mRNA to be maintained within the nucleus, ready to be quickly 
processed and exported to meet instances of high demand. Alternatively, specific 
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introns may be allowed to persist or exons may be spliced out, giving rise to multiple 
proteins from a single gene. 
 The final processing event of mRNA, the addition of the poly-A tail, is closely 
linked to the termination of transcription. Cleavage is dependent on highly conserved 
AU-rich sequences present at the 3' end of the pre-mRNA (Zhao et al., 1999). Following 
cleavage, a poly-A tail is added to the 3' of the mRNA by the polyadenlyate polymerase 
(Pap1p in yeast) (Wahle and Ruegsegger 1999). Poly-A binding proteins (Nab2p and 
Pab1p in yeast) associate with the poly-A tail before the fully matured mRNA is 
exported into the cytoplasm (Dunn et al., 2005, Hector et al., 2002). The poly-A tail is 
an important addition to pre-mRNA as it enhances mRNA stability and plays important 
roles in translation initiation. 
1.2.2. Translation initiation 
 For the translation of mRNA transcripts to occur, the 40S and 60S ribosomal 
subunits must be assembled onto the mRNA at the beginning of the ORF to initiate 
translation. Under normal conditions, the bulk of protein synthesis is mediated by 
eukaryotic initiation factors (eIFs) which directly or indirectly interact with the 5' 
7meGpppN cap. Cap-dependent translation is therefore estimated to account for 95 % 
of proteins synthesised (Merrick, 2004).  
1.2.2.1. Cap-dependent translation 
 The initiation of cap-dependent translation is the most complex and regulated 
process within translation, requiring the coordinated efforts of 10 eIFs (Table 1.1, 
Fig.1.1). The cytosolic cap binding protein eIF4E associates with the 5' end of the 
mRNA which further recruits eIF4G and eIF4A, completing the eIF4F cap binding 
complex. eIF4A is a DEAD box ATP-dependent RNA helicase that unravels secondary 
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structures in the 5' untranslated region (UTR), promoting ribosome recruitment 
(Svitkin et al., 2001). eIF4G primarily serves as a scaffold, binding both eIF4E and eIF4A 
as well as the poly(A)-binding protein (PABP) present at the 3' end of the transcript 
(Tarun and Sachs, 1996). These interactions subsequently produce the closed loop 
complex which is thought to enhance ribosome re-initiation (Wells et al., 1998). Once 
the mRNA is unwound, eIF4G acts as a bridge by interacting with eIF3, allowing the 43S 
pre-initiation complex (PIC) to be stably loaded onto the mRNA.  
 In the first step, eIF2 bound to GTP recruits the initiator methionyl tRNA (Met-
tRNAi
Met) to form a ternary complex (TC). eIFs 1, 3 and 5 associate with the TC to form 
the intermediary multifactor complex (MFC) (Sokabe et al., 2012). Mediated by eIF1A, 
the 40S ribosomal subunit is then loaded on to the MFC to produce the 43S PIC (Asano 
et al., 2000). Interactions between eIF4G and eIF3 lead to the loading of the 43S PIC 
onto the 5' UTR of the mRNA (LeFebvre et al., 2006), which subsequently scans in a 5'-
3' direction to find the optimal AUG 'start' codon (in yeast: 
(A/U)A(A/C)AA(A/C)AUGUC(U/C)) (Miyasaka, 1999), delivering the 40S ribosome 
subunit complexed with the initiator tRNA at the beginning of the ORF. Following AUG 
recognition, the GTPase accelerating protein (GAP), eIF5, hydrolyses the GTP that is 
bound to eIF2, promoting the release of the initiating factors (Unbehaun et al., 2004). 
In addition, eIF5 also forms a complex with the subsequent GDP bound eIF2 providing 
GDP displacement inhibition (GDI), which prevents spontaneous events of translation 
initiation (Singh et al., 2006). When bound with GTP, the GAP eIF5B mediates the 
binding of the large 60S subunit to the small 40S subunit. Auto-hydrolysis promotes 
the release of eIF5B-GDP, thereby completing the assembly of the 80S ribosome. 
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 For subsequent rounds of translation initiation to occur, eIF2 must be recycled 
and converted back from the inactive GDP binary complex to the active GTP bound 
complex (Pavitt, 2005). This process is facilitated by the multi-functioning initiation 
factor, eIF2B, which consists of five subunits that are classified into two groups (Pavitt 
et al., 1998). The eIF2B subunits α, β and δ are considered regulatory subunits whilst γ 
and ε are considered catalytic subunits. All five subunits are highly conserved 
throughout eukaryotes and share significant homology within their groups (Pavitt et al., 
1997) (Fig. 1.2). For instance, eIF2Bγ and ε share similarities between 
pyrophosphorylases suggesting that they both have the capacity to bind GTP (Gomez 
and Pavitt, 2000). Contrary to this, mass spectrometry data showed that GTP readily 
binds to eIF2Bγ, but not to eIF2Bε (Gordiyenko et al., 2014). Therefore, the role of 
eIF2Bγ could be to provide the necessary energy for GEF activity or bind the GTP that 
eIF2Bε places on eIF2. eIF2Bγ has been shown to be important for eIF2B's GDI 
displacement factor (GDF) activity, which frees GDP bound eIF2 from eIF5 (Jennings et 
al., 2013). Exclusive to eIF2Bε are several phosphorylation sites and a catalytic domain 
that contains two aromatic/acidic residue-rich regions (known as AA boxes) which bind 
GDP bound eIF2 for GTP exchange to occur (Gomez et al., 2002, Boesen et al., 2004). 
The dual specific tyrosine kinase (DYRK), glycogen synthase kinase 3 (GSK3) and casein 
kinases (CK) 1 and 2 may phosphorylate eIF2Bε at various positions to reduce the 
catalytic activity of eIF2B in response to insulin and nutrient limiting conditions (Welsh 
et al., 1998, Woods et al., 2001). Similarly, eIF2B activity can be inhibited by the 
phosphorylation of eIF2 which subsequently interacts with another binding domain in 
the regulatory subunits of eIF2B. 
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Table ‎1.1 - eukaryotic initiation factors 
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Figure ‎1.1 - Initiation of translation in eukaryotes. The eIF4F-cap binding complex, consisting 
of eIF4E, 4A and 4G as well as Pab1p associate with the mRNA producing a closed loop 
complex. A ternary complex of GDP-bound eIF2 and Met-tRNAi
Met recruits addition factors 
including the 40S ribosome, forming the 43S PIC. The 43S PIC is loaded onto the closed mRNA, 
which subsequently scans for the optimal AUG start codon. Upon recognising the start of the 
ORF, eIF2-GTP is hydrolysed and the initiation factors are released, allowing the 60S ribosome 
subunit to be recruited, completing the 80S ribosome. GDP-bound eIF2 is recycled by eIF2B for 
concurrent rounds of initiation.  
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Figure ‎1.2 - Homology between the subunits of eIF2B in S. cerevisiae. The regulatory subunits 
eIF2Bα, β and δ share several heptad repeats as well as homologous NTDs and CTDs. The 
catalytic subunits share homology with each other, pyrophosphorylases and acetyl-
transferases.  
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1.2.2.1.1. Regulation of translation initiation through eIF2B  
 Translation is a resource-heavy process that can place an unnecessary burden 
on the cell in times of cellular stress. Whilst proliferating, it is estimated that a yeast 
cell synthesises 13,000 proteins per second, accounting for approximately 76% of the 
cell's total energy expenditure (von der Haar, 2008, Wang and Zhang, 2011). 
Subsequently, eukaryotes have adapted responses that reduce or reprogramme global 
protein synthesis in an attempt to focus resources on neutralising the stress. These 
mechanisms not only ease the burden of protein synthesis, but ensure the cell can 
adapt before irreversible damage occurs. 
 In addition to controlling the initiation of translation via GDP/GTP exchange on 
eIF2, eIF2B also serves as a vital control point where protein synthesis can be regulated 
in response to several stimuli. eIF2B's substrate, eIF2, is a heterotrimeric G-protein 
consisting of the three subunits α, β and γ. In times of cellular stress, eIF2α kinases 
phosphorylate serine 51 within eIF2α (eIF2α-P) (Rowlands et al., 1988), which binds 
eIF2Bα instead of eIF2Bε. eIF2-P has also been shown to bind eIF2B with much higher 
affinity than the non-phosphorylated counterpart, thus allowing eIF2B to be regulated 
rapidly (Sudhakar et al., 1999). Interestingly, eIF2B was recently shown to exist as a 
decameric complex comprising of a regulatory α2β2δ2 core flanked by two εγ catalytic 
dimers at opposing sides (Fig. 1.3) (Gordiyenko et al., 2014, Wortham et al., 2014, 
Kashiwagi et al., 2016). In yeast, all of the subunits of eIF2B are essential with the 
exception of eIF2Bα (Gcn3p in S. cerevisiae). Intriguingly, the loss of eIF2Bα prevents 
eIF2B regulation and also destabilises the decamer into two eIF2Bεγδβ 
heterotetramers (Wortham et al., 2014). Although eIF2Bα is not required for cellular 
growth in yeast, irreparable cellular damage will occur should homeostasis deviate. In 
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mammals however, the destabilisation of the decameric complexes decreases catalytic 
activity by 50 % (Williams et al., 2001, Wortham et al., 2014) 
 Following cellular stress and eIF2α-P-eIF2Bα interaction, a conformational 
change subsequently attenuates the catalytic activity of eIF2B, reducing levels of TCs 
and consequently inhibiting global protein synthesis. This reduction in TC formation 
paradoxically enhances the translation of stress-specific mRNAs, therefore allowing a 
stress response to occur (Hinnebusch, 1997).  
 In yeast, general control nonderepressible 2 (Gcn2p) represents the sole eIF2α 
kinase which responds to the classical cellular stress, amino acid starvation. Following 
the inhibition of eIF2B, the transcriptional activator Gcn4p is paradoxically translated, 
instigating a transcriptional programme that upregulates genes involved in amino acid 
biosynthesis (Fig. 1.4) (Natarajan et al., 2001). Under normal conditions, Gcn4p is 
repressed by the presence of four upstream open reading frames in the 5' UTR 
(Hinnebusch, 1997). When TCs are abundant, 43S PICs initiate at uORF1 which is 
subsequently translated. Post-termination 40S subunits reinitiate after uORF1, binding 
further TCs before reaching the inhibitory uORF4. Here, the ribosome disassociates 
from the mRNA preventing the ribosome from reaching the true ORF (Hinnebusch, 
1997). Under stressful conditions however, fewer TCs are available which allows 
uORF4 to be bypassed by a phenomenon referred to as 'leaky scanning' (Wang and 
Rothnagel, 2004). Binding a TC at the true ORF induces the expression of Gcn4p. This 
mechanism allows specific proteins to persist despite reduced protein synthesis to 
provide a stress-response that returns homeostatic conditions. 
 During the 1990s, studies in the yeast S. cerevisiae underlined how sensitive the 
balance is between a decrease in GTP bound eIF2 and the initiation of a stress 
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response (Hannig et al., 1990). For instance, mutations within the yeast eIF2Bα (known 
as Gcn3p) initiated the translation (or derepression) of GCN4. These mutations, 
dubbed general control nonderepressible constitutive (GCN3c) mutations, reduced GEF 
activity which mimicked eIF2B-eIF2-P binding, a situation that should only occur when 
the cell is under stress.  
 In yeast, eIF2B is also subject to regulation in response to fusel alcohols which 
are produced during amino acid scarcity (Eden et al., 2001). Naturally occurring alleles 
within the catalytic subunit eIF2Bγ have shown to increase (S180) or decrease (P180) 
the cell's translational resistance to butanol (Ashe et al., 2001). Interestingly, additional 
mutations within eIF2Bα were discovered that also produces a resistant phenotype 
(Taylor et al., 2010). However, eIF2B is regulated independent of eIF2α-P in response 
to butanol, thus Gcn4p expression in this instance is independent of an eIF2α kinase. 
 In addition to amino acid starvation, mammals have also adapted similar 
responses to viral infection, ER stress and haem deficiency which are sensed by protein 
kinase R (PKR), PKR-like endoplasmic reticulum kinase (PERK) and haem control 
repressor (HCR), respectively (Dey et al., 2005). Analogous to Gcn4p in yeast, the 
mammalian activating transcription factor 4 (ATF4) is specifically translated following 
the build-up of unfolded proteins in the ER, subsequently leading to the unfolded 
protein response (UPR) (Vattem and Wek, 2004). ATF4 contains two uORFs and 
induces a transcriptional programme that upregulates the chaperones required to fold 
nascent proteins within the ER. GADD34 is also expressed, which when properly folded 
in the ER, provides negative feedback allowing translation to be resumed (Novoa et al., 
2001).
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Figure ‎1.3 - The decameric crystal structure of eIF2B. Two heterotetrameric eIF2Bεγβδ 
complexes are stabilised by a homodimer of eIF2Bα. In the decameric holocomplex, a 
regulatory core is flanked by two catalytic domains on opposing sides. 
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Figure ‎1.4 - Regulation of Gcn4p expression by uORFs. Gcn4p expression is regulated by the presence of four uORFs in mRNA's. Under 
normal conditions with high levels of TCs, ribosomes translate uORF1 and reinitiate afterwards. If the ribosome recruits another TC 
before uORF4, the ribosomes will disassociate. Under stressed conditions with low levels of TC, there is less chance for the ribosome to 
recruit another TC before uORF4, allowing the ribosome to reach and translate the true ORF. 
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1.2.2.1.2. Regulation of translation initiation through 4E-BPs  
 In addition to regulation via eIF2B, translation initiation may also be subject to 
regulation by eIF4E-binding proteins (4E-BPs) following cellular stresses, such as heat 
shock or oxidative stress (Pham et al., 2000, Sukarieh et al., 2009). 4E-BPs compete 
with eIF4G for a shared binding motif on eIF4E (Pause et al., 1994), therefore 
preventing the formation of the closed loop complex (Haghighat et al., 1995). This 
control of translation initiation via 4E-BPs is dependent upon the phosphorylation 
status of the 4E-BPs at several serine/threonine residues (Pyronnet et al., 1999, Holz et 
al., 2005). During steady-state conditions, the 4E-BPs are phosphorylated by the 
mammalian target of rapamycin complex 1 (mTORC1) in response to nutrients or 
growth factors. In this phosphorylated state the 4E-BPs are unable to bind eIF4E, 
allowing translation initiation to continue (Holz et al., 2005). However under stressed 
conditions that inhibits mTOR activity, hypo-phosphorylation results in the attenuation 
of eIF4F-cap binding complexes, consequently preventing the loading of 43S PICs. In 
mammals, three 4E-BPs exist: 4E-BP1, 2 and 3, whereas two 4E-BPs exist in yeast: 
Caf20p and Eap1p. 
 Published data suggests that Caf20p and Eap1p regulate the expression of 
specific subsets of mRNA spanning hundreds of transcripts, thus 4E-BPs play a large 
role in reprogramming the translatome following a cellular stress (Cridge et al., 2010). 
Interestingly, global RNA-binding protein immunoprecipitation sequencing (RIP-seq) 
showed that Caf20p and Eap1p can bind mRNA transcripts in an eIF4E-independent 
manner, although the specific mechanism remains unclear (Castelli et al., 2015). The 
activation of 4E-BPs elicit different stress responses to eIF2α kinases, for instance 4E-
BPs do not instigate the expression of the stress-specific mRNA Gcn4p. Interestingly 
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however, Eap1p may repress Gcn4p expression when TOR is inactivated under 
rapamycin treatment or extreme stresses (Matsuo et al., 2005), suggesting cross-talk 
between the two major regulating mechanisms of translation. Both Caf20p and Eap1p 
can enhance the binding of specialist de-capping enzymes or mediate the association 
of RNA processing enzymes required for mRNA decay (Ferraiuolo et al., 2005). 
Moreover, mRNAs can be translationally silenced by translocation to stress-granules in 
a 4E-BP dependent manner (Fujimura et al., 2012), where mRNA is thought to be 
stored until cellular homeostasis is restored. 
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1.2.2.2. Initiation and regulation of cap-independent translation 
 Initially discovered in the picornavirus, cap-independent translation requires 
the presence of internal ribosome entry sites (IRES) (Jang et al., 1988, Pelletier and 
Sonenberg, 1988). Highly structured IRES elements present in the 5' non-coding region 
(NCR) bypass the host-cells defensive regulatory mechanisms (i.e. PKR) and directly 
recruit ribosomal subunits to initiate translation (Kaminski et al., 1990, Pestova et al., 
1996). Although IRES were thought to be unique to viruses, subsequent studies 
discovered similar IRES elements in eukaryotic mRNA transcripts that encode proteins 
involved in cellular differentiation, apoptosis and stress responses (Komar and 
Hatzoglou, 2005). IRES-mediated ribosome recruitment was thought to be 
independent of initiation factors. However, recent studies have shown that eIF4G and 
the PABP can enhance mRNA expression by several orders of magnitude in both 
mammals and yeast (Smith et al., 2017, Gilbert et al., 2007).  
1.2.3. Translation elongation 
 Following initiation, several ribosomes may be elongating along an mRNA at 
any given time, giving rise to polyribosomes or polysomes. During the elongation step, 
the 80S ribosome moves along the ORF in a 5'-3' direction catalysing the synthesis of 
nascent polypeptide chains. Aminoacyl-tRNA selection as well as ribosome movement 
is mediated by eukaryotic elongation factors (eEFs). GTP bound eEF1A forms a complex 
with aminoacyl-tRNA which enters the A site. Complementary base pairing between 
the mRNA codon and the aminoacyl-tRNA anti-codon induces a conformational change 
which instigates the hydrolysis of eEF1A. Released GDP bound eEF1A is recycled by the 
GEF enzyme eEF1B for concurrent rounds of tRNA selection (Kapp and Lorsch, 2004).  
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 The peptidyl transferase centre (PTC) of the ribosome catalyses the formation 
of a peptide bond between the amino acid in the A site and the elongating polypeptide 
in the P site. This reaction subsequently results in a deacylated-tRNA in the P site 
whilst the elongating peptide is temporarily transferred to the A site. A ratchet-like 
motion reorganises the ribosome by translocating the peptidyl-tRNA (with the 
elongating peptide) to the P site (Ben-Shem et al., 2010), whilst deacylated-tRNA 
moves to the E site. With the A site empty, another round of aminoacyl-tRNA selection 
may begin. Ribosome translocation is facilitated by the hydrolysis of GTP by eEF2 
which can be inhibited by cycloheximide resulting in stalled ribosomes (Rodnina et al., 
1997, Schneider-Poetsch et al., 2010). Specific to yeast, the release of deacylated-tRNA 
is dependent upon the hydrolysis of ATP which is mediated by eEF3 (Triana-Alonso et 
al., 1995). The essential elongation factor eEF3 is a ribosome-dependent ATPase that 
can bind both ATP and ADP, and has also been shown to interact with eEF1A to 
stimulate aminoacyl-tRNA recruitment (Kamath and Chakraburtty, 1989, Anand et al., 
2003). 
1.2.4. Translation termination and re-initiation 
 Translation enters the termination stage once the ribosome encounters one of 
three stop codons: UAG, UGA or UAA. The eukaryotic release factors (eRF) 1 and 3 
(Sup35p and Sup45p in yeast) work together to release the polypeptide chain and 
recycle the ribosome for concurrent rounds of translation (Urakov et al., 2006). The 
tRNA-shaped eRF1 forms a complex with GTP bound eRF3 which directs eRF1 into the 
A site of the ribosome (Bertram et al., 2000). Ribosome interaction promotes the 
hydrolysis and release of eRF3 from eRF1, allowing the ATPase Rli1p to be recruited 
(Salas-Marco and Bedwell, 2004, Preis et al., 2014). The interaction of Rli1p induces a 
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conformational change within eRF1 that allows the N-terminal domain to interact with 
the stop codon, consequently promoting the hydrolysis and release of the complete 
polypeptide chain. 
 Following termination and the release of the polypeptide chain, the ribosome 
may be recycled for the translation of other mRNA, or reinitiated for the translation of 
the same transcript. The latter scenario is suggested to be dependent upon the closed 
loop complex (described in section 1.2.1.1.) which could release ribosomal subunits in 
close proximity to the start codon. Ribosomes are disassembled by Rli1p following the 
hydrolysis of ATP (Preis et al., 2014). Rli1p is also important for ribosome re-initiation 
as its deletion leads to abnormal re-initiation nearby start codons (Shoemaker and 
Green, 2011). In mammals, the individual activity of Ligatin or the complex of MCT-1 
and DENR may promote ribosome release and re-initiation (Skabkin et al., 2010). 
Although yeast orthologues have been described for all three human proteins 
(Tma64p, Tma20p and Tma22p, respectively), their function remains unknown. This 
suggests that ribosome re-initiation is conserved throughout eukaryotes and that 
Tma64p, Tma20p and Tma22p may also be required for stress-specific re-initiation 
mechanisms (Dever et al., 2016), such as those that regulate GCN4 transcripts (see 
section 1.2.1.1.1.). 
1.3. Subcellular organisation of translation 
 Once a newly synthesised mRNA is delivered to the cytosol,  it may be silenced 
and transported to a specific location within the cell before translation occurs. This 
mechanism enhances the efficiency of protein synthesis by expressing the encoded 
protein in a spatial region. Under cellular stress, the inhibition of protein synthesis by 
4E-BPs/eIF2α kinases can promote the translocation of transcripts to specific 
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cytoplasmic granules. Stress granules and processing bodies (P-bodies) are thought to 
store or degrade specific subsets of mRNA transcripts. In addition, the localisation of 
the key translation initiation factor eIF2B to specific cytoplasmic foci has been show to 
control and regulate its function. Together, these observations demonstrate that 
translation is a highly organised process within the cellular cytoplasm during steady-
state growth and during instances of regulation following cellular stress. 
1.3.1. Localisation of mRNA 
 It is estimated that each mRNA transcript can be used to synthesise between 
4000-5000 molecules of the encoded protein (Ghaemmaghami et al., 2003, Lu et al., 
2007). The localisation of proteins can be important for function, especially in the 
context of biochemical reactions as a large amount of energy would be required to 
localise these proteins to the required region. Alternatively, the cell localises the mRNA 
transcript and synthesises proteins at the required site, resulting in a much more 
energy efficient process (Fig. 1.5). 
 The best described example of mRNA localisation is the ASH1 mRNA which is 
solely expressed in daughter cells during cellular division in yeast (Bertrand et al., 
1998, Sil and Herskowitz, 1996). During transcription of ASH1, the RNA-binding protein 
She2p recognises four cis-acting elements within the emerging transcript (Landers et 
al., 2009). Once delivered to the cytoplasm, ASH1 expression is instantly silenced by 
the presence of She2p which also mediates the recruitment of additional translocation 
factors, including the motor protein Myo4p. The ASH1 transcript subsequently transits 
along actin filaments to be relocated at the tip of the bud where Ash1p protein is 
required to transcriptionally repress the homothallic switching (HO) endonuclease (Sil 
and Herskowitz, 1996). Thus, the HO endonuclease is exclusively present in the mother 
22 
 
cell where it mediates the switching of the cells mating type by rearranging the 
genomic MAT locus. 
 This mechanism is highly conserved in mammals whereby the spatial 
organisation of mRNAs is vital for embryo development and synaptic plasticity. 
Moreover, mRNA localisation is also important for the development and function of 
organelles, including peroxisome biogenesis in yeast (Zipor et al., 2009). However, in 
times of cellular stress, the spatially distributed mRNA transcripts may become 
aggregated into RNA granules which serve to store messages for when homeostasis 
returns, or for the degradation of redundant transcripts. 
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Figure ‎1.5 - Localisation of mRNA in budding Yeast. Following the export of mRNA, some 
transcripts are instantly silenced and transported to a specific cytoplasmic location where the 
encoded protein is translated. By synthesising the protein at their required sub-cellular site, 
the proteins do not need to be transported, resulting in a much more energy efficient 
mechanism. Such examples include ASH1 which is transported to the bud tip, Peroxin mRNA 
which are transported to peroxisomes and a whole class of mRNA which are localised to the 
mitochondria (Zipor et al., 2009, Saint-Georges et al., 2008).  
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1.3.2. P-bodies 
 Processing bodies (P-bodies) are highly conserved RNA granules that are 
thought to promote the storage and degradation of translationally-repressed mRNAs 
following various cellular stresses (Sheth and Parker, 2003, Cougot et al., 2004). 
Although the complete configuration of P-bodies is yet to be fully elucidated, they are 
characterised by a core set of fundamental proteins that are involved in mRNA decay, 
such as proteins that promote decapping, Lsm1-7p (Tharun and Parker, 2001), the 
decapping complex: Dcp1p/Dcp2p (van Dijk et al., 2002, Eystathioy et al., 2003), as well 
as the 5'-3' exoribonuclease Xrn2p (Bashkirov et al., 1997). Additionally, eIF4E, eIF4G 
and Pab1p also localise to P-bodies in yeast (Hoyle et al., 2007). As decay factors 
actively repress mRNA translation, the presence of initiation factors suggest that they 
may compete for transcripts in a dynamic cycle (Hoyle and Ashe, 2008).  
1.3.3. Stress granules 
 Similar to P-bodies, stress granules are another class of cytoplasmic RNA 
granule that is conserved across the eukarya domain, and form in response to cellular 
stress. Although P-bodies and stress granules both contain eIF4E, eIF4G and Pab1p, 
stress granules contain additional initiation factors such as eIF2, eIF3 and eIF4A as well 
as 40S ribosomal subunits (Kedersha et al., 2002). Therefore, under cellular stress, it is 
thought that stress granules may be sites where stalled 48S PICs are stored in addition 
to other mRNA.  
 The attenuation of eIF4A can lead to the formation of stress granules, which 
occurs through an unclear mechanism in response to glucose starvation (Castelli et al., 
2011). Furthermore, stress granules can also form in response to environmental 
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stresses that result in the phosphorylation of eIF2α. Experiments using an eIF2α 
phosphomimetic mutant (S51D) and a nonphosphorylatable mutant (S51A) either 
induced or reduced stress granule formation, respectively (Kedersha et al., 2002). In 
mammals, the attenuation of eIF2B activity promotes the T-cell restricted intracellular 
antigen-1 (TIA-1) and the TIA-1 related protein (TIAR) to recruit transcripts to stress 
granules (Gilks et al., 2004, Kedersha et al., 1999). The organisation and localisation of 
mRNA transcripts can therefore be intrinsically linked to eIF2B activity which may be 
controlled at another cytoplasmic locale.    
1.3.4. eIF2B bodies 
 As highlighted in section 1.2.1.1.1, eIF2B controls the initiation of translation by 
recycling eIF2-GDP as well as serving as a vital control point in response to cellular 
stress. Using the model organism S. cerevisiae, Campbell et al., observed that eIF2B 
localised to a specific cytoplasmic focus, termed the eIF2B body (Campbell et al., 
2005). The G-protein eIF2 co-localised with eIF2B bodies, although, under normal 
conditions eIF2 did not remain static. Interestingly, the use of fluorescence recovery 
after photobleaching (FRAP) highlighted that eIF2B remains resident within the foci 
while eIF2 shuttles through, allowing GDP-GTP exchange to occur (Campbell et al., 
2005). The initiating Met-tRNAi
Met does not co-localise to eIF2B bodies, nor does any 
other translation initiation factor (Campbell et al., 2005). Therefore, the eIF2B body 
does not serve as sites for TC, MFC or 43S PIC formation. 
 Whether the eIF2B body contains mRNA transcripts is unknown. Although the 
composition of eIF2B bodies may be different to the aforementioned RNA granules, 
they all respond to translational control and therefore maintain the organisation of 
translation (Fig. 1.6). Using FRAP analysis, Campbell et al., showed the rate of eIF2 
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shuttling could be used to measure the GEF activity of eIF2B in vivo. In the presence of 
constitutively active Gcn2p mutants as well as an eIF2Bε mutant F250L, the cycling of 
eIF2 decreased significantly, highlighting that the use of FRAP could be used to gain 
more insightful measurements where in vitro biochemical assays have been 
predominantly used (Campbell et al., 2005).  
 In mammals, several sub-types of eIF2B bodies exist whereby the increasing 
size of the foci correlates with the number of subunits present (Hodgson et al., 2018). 
Subsequently and in-line with in vitro biochemical assays, FRAP analyses of mammalian 
eIF2B bodies highlighted that changes in the cycling of eIF2 is dependent on the 
subunits present (Hodgson et al., 2018). In yeast however, the eIF2B body is a singular 
aggregate that contains all five subunits of eIF2B, thus it is likely that the eIF2B body 
contains decameric complexes in yeast (Campbell et al., 2005, Gordiyenko et al., 2014, 
Wortham et al., 2014). These differences are likely to be explained by the higher 
eukaryote requiring more complex control to fine-tune the requirements of higher 
rates of protein synthesis. 
 In yeast, the only other known factor required for the integrity of the eIF2B 
body is the initiation factor associated of 38 kDa protein (Ifa38p) (Browne et al., 2013). 
The very-long fatty acid (VLFA) elongase enzyme, Ifa38p does not have a specific role 
in translational control or initiation, but was shown to interact with both catalytic 
subunits of eIF2B (Browne et al., 2013). Gene deletion subsequently resulted in the 
fragmentation of the eIF2B body to several smaller foci. The authors concluded that 
the differential localisation of eIF2B did not affect rates of translation initiation. 
Therefore, Ifa38p could be required to maintain the stability of the eIF2B body, 
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although the current authors note that the cycling of eIF2 through these foci was not 
directly compared. 
 Other features of the eIF2B foci have been described in yeast. The aggregated 
eIF2B displays a filamentous structure which may be affected by changes in cytosolic 
pH (Petrovska et al., 2014). However, the eIF2B body represents the congregation of 
40% of the cells total eIF2B, thus GDP and GTP exchange as well as regulation can 
presumably occur elsewhere in the cytoplasm (Campbell et al., 2005). Thus, the 
specific role of the eIF2B body remains unclear, but could have important implications 
for vanishing white matter disease. 
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Figure ‎1.6 - Organisation and regulation of protein synthesis. Translation consists of 
distinctive cytoplasmic foci where mRNA and translation initiation factors can congregate 
under steady-state growth or rate-limiting stress conditions. eIF2B localises to eIF2B bodies, 
where eIF2 shuttles through for GDP-GTP exchange, or alternatively, where eIF2α-P may 
attenuate eIF2B GEF activity. Inhibition of translation can translocate mRNA to P-bodies which 
may target specific transcripts for degradation. Alternatively, transcripts may localise to stress 
granules to be stored until cellular homeostasis is restored. 
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1.4. Leukoencephalopathy with Vanishing White Matter disease 
 Translation is a core cellular process in all organisms, hence only a small 
number of diseases are attributable to protein synthesis. The most prominent of these 
diseases is the complex neurological disorder leukoencephalopathy with vanishing 
white matter disease (VWM). VWM, also known as childhood ataxia with central 
nervous system hypomyelination (CACH), arises through autosomal recessive 
mutations within any subunit of eIF2B (Leegwater et al., 2001). A hallmark feature of 
VWM is the progressive loss of white matter, which is replaced by cerebral spinal fluid 
(CSF) (Schiffmann et al., 2012). Although VWM is regarded as the most prevalent 
childhood leukodystrophy, it is relatively rare with a limited number of cases recorded 
(Bugiani et al., 2010). Interestingly though, approximately 161 unique mutations have 
been documented across all five eIF2B subunits so far, contributing to the complexity 
of VWM as well as the variability observed in clinical presentation (Pavitt and Proud, 
2009, Shimada et al., 2015, Zhang et al., 2015). From over 30 years of research, there is 
definitive evidence to suggest that the root cause lies within eIF2B's intrinsic role as a 
cellular hub to control translation in response to stress (Pavitt and Proud, 2009). 
However, observations from biochemical experiments do not fully agree with this 
model (Wortham and Proud, 2015). Moreover, published data has highlighted that 
there is no genotype-phenotype correlation, leading to the idea that there may be 
other unknown functions or features of eIF2B not fully understood (van der Lei et al., 
2010, Liu et al., 2011). 
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1.4.1. Disease onset and current diagnosis 
 VWM is defined as a chronic progressive disease that can advance rapidly in its 
most severe antenatal form or more slowly in the adolescent form (Schiffmann et al., 
2012). Affected individuals may rapidly deteriorate following acute traumas, such as 
head trauma, febrile infection or acute fright (van der Knaap et al., 1997, Fogli et al., 
2004a, Kaczorowska et al., 2006). Adverse symptoms may manifest shortly after the 
traumatic event (van der Knaap et al., 1997). There are many symptoms associated 
with VWM, including migraines, psychiatric symptoms, kidney ataxia and seizures (van 
der Knaap et al., 1997). Clinical presentation of VWM strongly correlates with the 
severity of the disease (Table 1.2) (Pavitt and Proud, 2009). Whilst episodes of rapid 
deterioration are not restricted to the three traumas previously mentioned, they are 
the most common as a consequence of inherent environmental factors (e.g. head 
trauma following a fall). Currently, there is no direct link to explain why intercurrent 
trauma exacerbates the condition. One hypothesis that has been suggested is that 
each of these traumas further impairs eIF2B's catalytic activity via regulatory 
mechanisms responding to cellular stress. 
 The most severe forms generally manifest antenatally, congenitally or during 
early childhood (van der Knaap et al., 2003). Milder forms can develop between the 
ages of 1-5 years and from 5 years onwards. Individuals with congenital or antenatal 
forms do not survive past a year, in contrast to those with adolescent onset who 
generally live considerably longer (van der Knaap et al., 2003, Fogli et al., 2004a). One 
exception is a mutation commonly found in the Cree and Chippewayan population 
indigenous to North America (Fogli et al., 2002). The R195H mutation within eIF2Bε, 
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also known as the Cree mutation, causes onset to occur around 3 months after birth, 
with affected infants rarely living past the second year of life (Fogli et al., 2002).  
 Diagnosis of VWM is primarily achieved through mass resonance imagining 
(MRI; Fig. 1.7). The hallmark signs are cystic degeneration and cavitation of the white 
matter surrounding the cerebral hemisphere which is replaced by cerebral spinal fluid. 
Following radiological imaging, suspected VWM patients are genotyped to determine 
whether aberrant eIF2B genes (EIF2B1-5) are present (Schiffmann et al., 2012). 
 
 
Table ‎1.2 VWM Disease Severity 
            *Age in years, unless otherwise stated. 
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Figure ‎1.7 - Comparison of MRI images from VWM and non-VWM brain. Proton density 
weighted images illustrate the extent of white matter loss within affected individuals. T2 
weighted images show that the white matter is replaced by cerebral spinal fluid, indicated by 
the intense white signal (Leegwater et al., 2001). 
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1.4.2. Aetiology of VWM disease 
 A wide variety of eIF2B mutations have been described, including missense, 
nonsense, insertions, deletions and splicing errors (Fig. 1.8) (Pavitt and Proud, 2009). 
Indeed, mutations that result in a frame shift or a premature stop codon produce the 
most severe phenotypes which have never been observed in the homozygous state 
and are likely to be incompatible with life (Pavitt and Proud, 2009, Pronk et al., 2006). 
Instead, severe mutations are generally found to coexist with a missense mutation 
(Pavitt and Proud, 2009). In the compound heterozygous state, both mutations may 
influence the progression of the disease, although some individual mutations are 
known to confer a severe phenotype whether they are in the homozygous or 
compound heterozygous state (e.g. eIF2Bε R195H/Cree mutation) (Takano et al., 2015, 
van der Lei et al., 2010).  
 The majority of mutations found within patients within eIF2B are missense. The 
catalytic subunit, eIF2Bε, contains the most mutations and harbours the most frequent 
amino acid substitution: R113H (Pronk et al., 2006). One study predicted another 
mutation (eIF2Bβ V85E) to be the most frequent throughout the Japanese population 
despite a low cohort number (5 patients) (Shimada et al., 2015). The R113H mutation 
is found in 20 % of all VWM cases and has been reported in both homozygous and 
compound heterozygous states (Pronk et al., 2006). In a genotype-phenotype 
correlation study, patients that were homozygous for R113H were found to have a 
milder disease progression than those who were compound heterozygous for R113H 
(van der Lei et al., 2010). Whilst statistically relevant, there was high variance 
indicating other influencing factors.  
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 Missense mutations have also been identified that are yet to be found 
homozygously. The catalytic domain, present within eIF2Bε, harbours very few amino 
acid residues that are mutated. It is likely that it is spared because mutations within 
this domain would result in the loss of GEF activity. Interestingly, the four amino acid 
substitutions that are present within the catalytic domain have never been observed in 
the homozygous state (Pronk et al., 2006, Pavitt and Proud, 2009). Severe missense 
mutations have also been documented within the regulatory domains (e.g. eIF2Bβ 
V316D), which are likely to impact on eIF2B’s decameric conformation (Richardson et 
al., 2004). 
 Most VWM mutations change amino acid residues that are instrumental to the 
structure and integrity of eIF2B, impacting on its ability to carry out its role (Fig. 1.8). 
As mentioned earlier, the regulatory subunit eIF2Bα and the catalytic subunit eIF2Bε 
both contain putative binding sites for eIF2 (Mohammad-Qureshi et al., 2007). 
Although the three remaining subunits partially bind eIF2, they do influence and 
enhance eIF2B’s activity.  
 The regulatory subunits share large segments of homology, including a large 
amount of homologous heptad repeats and a C-terminal domain that are important for 
dimerization (Pavitt et al., 1997). A VWM mutation, V183F, was recently shown to 
prevent eIF2Bα homodimerisation and subsequently resulted in decreased GEF activity 
(Wortham et al., 2014, Wortham and Proud, 2015). Another eIF2Bα VWM mutation, 
N208V, increased GEF activity during recent biochemical testing (Wortham and Proud, 
2015). This particular VWM mutation is in a region that binds eIF2α-P under cellular 
stress, although no significant decrease of eIF2α-P binding was found. Interestingly, 
the P278R mutation does not decrease or increase GEF activity, nor does it alter 
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eIF2B’s ability to bind eIF2α-P (Wortham and Proud, 2015). Hence, how P278R 
produces the VWM phenotype is unknown. A low number of mutations exist within 
eIF2Bα, with ≤1% of VWM patients characterised with them (Pronk et al., 2006). This 
observation could very well be a testament as to how vital the subunit is to other, yet 
unknown, functions. 
 eIF2Bβ and δ contain many more VWM mutations than eIF2Bα. A large 
proportion of mutations occur throughout the heptad repeats, whilst the N and C-
terminal domains are relatively spared (Pronk et al., 2006). Crystallography 
experiments have shown that these two subunits form a heterodimer which is in line 
with observations from biochemical experiments on the eIF2Bβ V316D VWM 
mutation. This particular mutation abolishes the eIF2Bδ subunit from the eIF2B 
complex (Kashiwagi et al., 2014, Richardson et al., 2004). Introduction of the 
equivalent eIF2Bβ mutation in yeast (V341D) produced the most detrimental 
phenotype in comparison to a small subset of other eIF2Bβ VWM mutations 
(Richardson et al., 2004). Although the severity of V316D is yet to be recorded in 
human patients, prior experimental evidence has shown that the severity of eIF2B 
missense mutations may not necessarily correlate with the severity of VWM (Fogli et 
al., 2004b, Liu et al., 2011).  
 The presence of eIF2Bβ stabilises the interactions between the regulatory 
subunits while eIF2Bδ stabilises the catalytic core. In addition to eIF2Bβ V316D 
affecting eIF2Bδ recruitment, G329V, another eIF2Bβ VWM mutation, prevents eIF2Bα 
interacting with the remaining complex (Liu et al., 2011). eIF2B complexes cannot form 
in the presence of the eIF2Bδ VWM mutations, R357W and R483W, although eIF2Bγε 
dimers are still able to form, lacking all the regulatory subunits. These observations 
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suggest that eIF2Bδ serves as a bridge between the regulatory core and the catalytic 
subunits (Liu et al., 2011).  
 Akin to the regulatory subunits; eIF2Bγ and ε also share large segments of 
homology with one another (Pronk et al., 2006). In contrast to eIF2Bε, eIF2Bγ is 
relatively small and contains fewer VWM mutations. eIF2Bε incurs many mutations 
that have not been observed within eIF2Bγ, suggesting a potential hotspot for 
mutations within the genomic DNA (Gomez and Pavitt, 2000). Many biochemical 
studies have shown eIF2Bε VWM mutations to reduce the GEF activity by up to 70 % 
(Liu et al., 2011, Fogli et al., 2004b). Interestingly, the Cree mutation (R195H), which 
consistently produces a severe phenotype and is not located within the catalytic 
domain, decreases the GEF activity by 30 % (Fogli et al., 2004a). In contrast, the R113H 
eIF2Bε VWM mutation, also reduces GEF activity by 30 %, but is associated with a 
milder disease progression (Fogli et al., 2004a). 
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Figure ‎1.8 - The broad spectrum of eIF2B VWM mutations in Humans. Over 153 VWM 
mutations have been described within the subunits of eIF2B collectively. Of note are the α and 
ε subunits which represent the subunits with the least and most mutations respectively. 
eIF2Bε contains over half of total VWM mutations, however the catalytic domain is relatively 
spared (Shimada et al., 2015). 
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1.4.3. Cellular and molecular pathogenesis of VWM 
 Whilst VWM mutations are ubiquitously expressed throughout all cells, glial 
cells are generally more impeded than any other cell type. There are several 
pathological signs of VWM, including an increase in the number of proliferating cells as 
well as an increase in the number of apoptotic cells. A notable feature of 
oligodendrocytes is a foam-like appearance which is possibly characteristic of 
undeveloped cells (Bugiani et al., 2011). Proteomic, transcriptomic and 
histopathological studies have revealed that the maturation of glia is somewhat 
delayed (Bugiani et al., 2011, Marom et al., 2011).  It is likely that the immature glia 
cannot function properly under the impaired conditions conferred by a deficit in 
protein synthesis, especially considering that oligodendrocytes require a high rate of 
protein synthesis for myelination (Baumann and Pham-Dinh, 2001).  
 As described in section 1.2.1.1.1, the translation of ATF4 is derepressed 
following a build-up of unfolded proteins within the ER (Vattem and Wek, 2004). The 
subsequent stress response prevents the synthesis of nascent proteins, as well as 
concomitantly upregulating the chaperones needed to fold proteins (Walter and Ron, 
2011). The hyper-induction of ATF4 is a notable feature of VWM and could explain why 
further insults exacerbate the condition (Kantor et al., 2005, van Kollenburg et al., 
2006). As mentioned previously, there is no direct evidence currently explaining why 
VWM patients are liable to rapid episodes of deterioration. However one explanation 
is that these additional stresses cause already impaired oligodendrocytes to release a 
key component of myelin, subsequently promoting apoptosis (Baumann and Pham-
Dinh, 2001). Oxidative stress, infection, inflammatory mediators and head injury are all 
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known to potentiate sphingomyelinase, an enzyme that breaks sphingomyelin down 
into ceramide and lipids (Singh et al., 1998, Schenck et al., 2007). The presence of 
ceramide within the cytoplasm promotes apoptosis and oligodendrocyte loss (McTigue 
and Tripathi, 2008). 
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Figure ‎1.9 - Hyper-induction of ATF4 in VWM disease. When there is a build-up of nascent proteins in the ER, global protein synthesis is 
inhibited and ATF4 is specifically expressed for the unfolded protein response (UPR) to occur. However, the rate of protein synthesis is 
reduced when eIF2B is mutated, resulting in the constant expression of ATF4, which is normally regulated by two uORFs. 
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1.4.4. Current models of VWM disease 
 eIF2B is undoubtedly one of the most complex GEF enzymes in nature, 
comprising of five subunits which form a complex that exerts multiple functions. Over 
the last 30 years, in vitro and in vivo experiments utilising cell lines, animal models and 
S. cerevisiae have investigated the underlying mechanism behind VWM disease (Pavitt 
and Proud, 2009). It is generally accepted that abnormal eIF2B reduces rates of global 
protein synthesis which concomitantly enhances the translation of stress-specific 
mRNAs. Cells are therefore in a constant state of stress, hindering cellular 
differentiation and development (Pavitt and Proud, 2009, Bugiani et al., 2011). This 
hypothesis also explains why further trauma exacerbates the condition leading to rapid 
deterioration. However, there are some inconsistencies that cannot be explained by 
current models of eIF2B. 
 The current model of VWM disease presumes that the decline in the catalytic 
activity of eIF2B correlates with the severity of the disease. Contrary to this, 
independent studies have shown that there is no genotype-phenotype correlation (van 
der Lei et al., 2010, Liu et al., 2011). In addition, in vitro biochemical assays found no 
differences in eIF2B's catalytic activity (<30%) when in the presence of moderate or 
severe mutations (Liu et al., 2011). Using similar assays, other mutations have been 
shown to enhance the GEF activity of eIF2B or not affect it at all (Wortham and Proud, 
2015). Hence, the current model of VWM disease cannot explain these discrepancies 
which could imply that there are features yet to be described of VWM disease, or 
alternatively, functions of eIF2B yet to be highlighted. 
 A characteristic of eIF2B that remains to be fully understood is the role of eIF2B 
bodies. eIF2B's substrate, eIF2, co-localises with the eIF2B body and may shuttle 
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through or accumulate within foci depending on cellular conditions. However, this 
eIF2B body only represents a portion of the cells total eIF2B, thus whether localisation 
enhances the various activities of eIF2B remains to be shown (Campbell et al., 2005). In 
addition, how the eIF2B body is formed and whether VWM mutations affect the 
subcellular localisation of eIF2B also remains unknown. Mis-localisation of proteins is 
well-documented in human disease, especially considering that the subcellular 
localisation of proteins is usually crucial to their biochemical function. Accordingly, 
additional studies investigating the function of the eIF2B body as well as the formation 
of the macromolecular structure may help shed light on the contradictions highlighted 
in this section. Subsequently, these data could substantiate hypotheses which may 
explain the variable phenotypes observed within VWM sufferers.  
1.5. Project overview 
 In the following chapters, experiments were carried out to further elucidate 
how eIF2B bodies are formed, with a particular focus on the eIF2Bα subunit. eIF2B 
localisation was investigated in the presence of well-characterised mutations that 
either affect the catalytic activity of eIF2B or its ability to regulate global protein 
synthesis. To determine whether localisation may have a role in disease, VWM 
mutations were additionally generated and characterised. A particular theme in these 
studies was to try and maintain the cellular or in vivo environment. Therefore, the 
localisation of eIF2B was most analysed via live-cell imaging methods. 
 Previously published data has shown that other proteins are required for the 
formation of eIF2B bodies, but that are not necessarily involved in translation initiation 
or translational control. Similarly, the putative membrane proteins Mst27p, Erp4p and 
Sac1p have been shown to associate with eIF2B (Babu et al., 2012). Thus, their role in 
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eIF2B body formation as well translation initiation and translational control was also 
investigated. 
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2. Methods 
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2.1. Culture conditions 
2.1.1. Yeast strains and culture conditions  
The Saccharomyces cerevisiae strain W303-1A was used throughout this study and 
strain genotypes are detailed in Table 2.2. Strains were either generated by 
homologous recombination as previously described, or by mating yeast strains (see 
section 2.5). 
 Yeast strains were typically grown in rich YPD media (1 % (w/v) Yeast extract, 2 
% (w/v) Bacto Peptone and 2 % (w/v) glucose) or in minimal synthetic complete media 
(SCD; 0.17 % (w/v) Yeast nitrogen base without amino acids, 0.5 % (w/v) ammonium 
sulphate, 2 % (w/v) glucose). SCD was supplemented with either all essential amino 
acids or amino acids with specific dropouts (Formedium) depending on the genotype 
of the strain. In liquid media, strains were incubated at 30 °C with agitation (180 RPM). 
When grown on solid media, YPD or SCD media was supplemented with 2 % (w/v) 
agar. 
2.1.2. Analysis of yeast growth rates 
 Individual colonies of yeast strains were inoculated in appropriate media and 
cultivated overnight at 30 °C with agitation (180 RPM). Overnight starter cultures were 
back-diluted to an OD600 of 0.2 and incubated at 30 °C with agitation. Growth was 
measured hourly using a Genesys 10S UV-VIS spectrophotometer (ThermoFisher 
Scientific) or by using a CLARIOstar platereader (BMG Labtech). When using the plate-
reader, 200 μl of the diluted culture was pipetted into a 96 well-plate (ThermoFisher 
Scientific) which was incubated at 30 °C with agitation. 
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2.1.3. Bacterial strains and culture conditions 
 Escherichia coli (E. coli) background strain DH5α was routinely used for the 
amplification of plasmids. For site directed mutagenesis, XL10-Gold Ultracompetent E. 
coli was used to amplify mutant plasmids (Agilent). For cloning and sub-cloning, XL1-
Blue competent E. coli (Agilent) were used to amplify recombinant DNA. Bacteria were 
grown in Luri-Bertani (LB) media (1 % (w/v) Bacto tryptone, 0.5 % (w/v) Yeast extract, 
10 mM NaCl). For bacterial growth on solid media at 37 °C, LB was supplemented with 
2 % (w/v) agar. 
2.1.4. Antibiotics and drug supplements 
 Stock solutions of carbenicillin and kanamycin (Formedium) were prepared in 
distilled H2O (dH2O) at a concentration of 100 mg/ml and used in media at a final 
concentration of 50 μg/ml. Cycloheximide (Calbiochem) was dissolved in 
Diethylpyrocarbonate (DEPC) treated dH2O as a 10 mg/ml stock and used at a final 
concentration of 100 μg/ml. 
2.2. General DNA manipulation 
2.2.1. Purification of plasmid DNA from bacterial cells 
 Plasmid DNA was isolated from bacterial cultures using a GeneJET plasmid 
miniprep kit (ThermoFisher Scientific) as per manufacturer's instructions. The plasmids 
used in this study are detailed in Table 2.3. 
2.2.2. Genomic DNA extraction from yeast cells 
 Overnight starter cultures were pelleted by centrifugation (Eppendorf 5804 R) 
at 2500 x g for 3 minutes, before the media was removed and the DNA was extracted 
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using a MasterPure Yeast DNA purification kit (Cambio) as per manufacturer's 
instructions. The only modification to this protocol was that the precipitated DNA was 
dissolved in sterile dH2O and not Tris-EDTA (TE) buffer. 
2.2.3. Amplification of DNA via polymerase chain reaction 
 Polymerase chain reaction (PCR) was routinely used to amplify deletion 
cassettes using a Roche Expand High Fidelity kit (Sigma-Aldrich). Verification of 
genomic substitutions and colony PCR was carried out using TrueStart Taq polymerase 
(ThermoFisher Scientific). Oligonucleotides (Sigma-Aldrich) used throughout this study 
are listed in Table 2.4.  
 PCR reactions typically consisted of 1X buffer (without MgCl2), 2.5 mM MgCl2, 
2.5 mM dNTP mix, 2 U of polymerase, 0.2 μM of appropriate primers and 2 μl of a 1 in 
100 diluted DNA template. Sterile dH2O was added to a final volume of 50 μl. PCR 
reactions were subjected to the reaction conditions in Table 2.1 by a Techne TC-312 
thermocycler. 
 
Table ‎2.1 - Typical PCR programme 
PCR Step Time (seconds) Temperature (°C) 
Initial denaturation 120 95 
3
0
 c
yc
le
s 
Denaturation 30 95 
Annealing 30 54-56 
Extension 60 / 1kb 68 High Fid / 72 TrueStart 
Final extension 300 As above 
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2.2.4. Agarose gel electrophoresis 
 Amplified PCR products were typically separated through a 1 % (w/v) agarose 
gel containing 1 X TAE buffer (1.85 M Tris, 45 mM EDTA and 1 M Glacial acetic acid). To 
facilitate the visualisation of DNA fragments, 0.5 μg/ml ethidium bromide was used as 
an 'in-gel' stain. The presence of a GeneRuler 1 kB DNA ladder facilitated the 
identification of PCR products, which was pre-mixed with 1 X DNA loading dye 
(ThermoFisher Scientific). Agarose gels were visualised using a NuGenius UV gel 
imaging system (Syngene). 
2.2.5. Site directed mutagenesis 
 Site directed mutagenesis was performed using the QuikChange II XL kit 
(Agilent) as instructed by the manufacturers with slight modifications. To increase the 
efficiency of bacterial transformations with mutated plasmid DNA, reactions were 
concentrated to 1/5th the volume by ethanol precipitation after the DpnI digestion 
step. To precipitate the DNA, 0.1 volume NaAc (3M, pH 5.2) and 2 volumes of cold 100 
% (v/v) ethanol (-20 °C) were added to the digestion reactions and incubated at -20 °C 
for 1 hour. The DNA was pelleted by centrifugation at 17000 x g for 15 minutes. The 
supernatant was removed and the DNA was washed once in cold 70 % (v/v) ethanol 
before being centrifuged again for 5 minutes. The supernatant was removed and the 
pellet was allowed to air dry at room temperature for 10 minutes. DNA was 
resuspended in 10 μl sterile dH2O and stored at 4 °C until transformation. 
 To isolate the mutagenic plasmids, the concentrated DNA was transformed into 
bacteria. XL10-Gold Ultracompetent E. coli were thawed on ice before 50 μl aliquots 
were transferred into sterile microcentrifuge tubes. The concentrated plasmid DNA 
was incubated with the competent E. coli for 1 hour on ice, before being heat-shocked 
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in a water bath at 42 °C for 90 seconds. Bacterial cells were then placed on ice for 2 
minutes. Cells were allowed to recover in 1 ml of SOC media (ThermoFisher Scientific) 
for 1 hour at 37 °C with agitation (180 RPM). Following recovery, bacterial cells were 
gently pelleted by centrifugation at 2000 x g for 5 minutes. 1 ml of supernatant was 
removed before the cells were resuspended and spread onto appropriate solid 
selection media, which was incubated at 37 °C overnight. 
 Plasmid DNA was isolated from a number of colonies as described in section 
2.3.1, and Sanger sequenced gene-wide as described in section 2.4.4. 
2.2.6. Transformation of yeast with PCR product/plasmid DNA 
 Yeast strains were transformed with plasmids and PCR products by the LiOAc 
TRAFO method, as previously described (Gietz, 2014). Strains were cultivated in 50 ml 
of media until an OD600 0.6 was reached at 30 °C. Cells were pelleted by centrifugation 
at 2500 x g for 3 minutes and the media was decanted. The cells were washed in 
sterile dH2O before being pelleted again. Following the removal of the water, the cells 
were resuspended in 100 mM sterile LiOAc and divided into 50 μl aliquots. Cells were 
pelleted once more by a microcentrifuge at 17000 x g for 10 seconds before the LiOAc 
was removed. A 300 μl transformation mix was sequentially added on top of the cells, 
consisting of 38.0 % (w/v) polyethylene glycol, 100 mM LiOAc and 0.46 mg/ml single-
stranded DNA of salmon sperm. Before use, 10 mg/ml of DNA from salmon sperm was 
heated to 95  ̊C for 5 minutes before being snap-cooled on ice for 10 minutes. The PCR 
product, plasmid DNA or sterile dH2O (negative control) was added to corresponding 
tubes. Transformation mixtures were vortexed vigorously to resuspended the cells 
before incubation at 30 °C for 1 hour with agitation. Cells were then heat-shocked at 
42 °C for 20 minutes. Cells that were transformed with plasmid DNA were quickly 
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pelleted at 17000 x g for 15 seconds before being resuspended in dH2O and spread 
onto solid media for selection. Genomically altered cells that were transformed with a 
PCR product were incubated in 2 ml YPD overnight, before being pelleted and spread 
on to solid media for selection. Agar plates were incubated in a static 30 °C incubator 
for 48 hours. 
2.3. Cloning of DNA 
2.3.1. Over-lap extension PCR 
 To produce Mst27p, Erp4p and Sac1p protein fusions with the fluorophore 
mKate2, one-step over-lap extension PCR (OE-PCR) was performed as previously 
described (Bryksin and Matsumura, 2010). PCR conditions were mostly similar to 
section 2.2.3 using the Roche High Fidelity polymerase system with slight 
modifications. In OE-PCR, the concentration of primers and template DNA was halved 
to accommodate two plasmids and four primers. The PCR programme remained 
mostly unchanged with the exception of 60 °C annealing temperature. 
 Following the amplification of PCR products and the separation via agarose gel 
electrophoresis, the corresponding DNA fragment was excised and purified using a 
GeneJet PCR purification kit (ThermoFisher Scientific) as per manufacturer's 
instructions. 
2.3.2. Cloning into TOPO TA pYES2.1 vector 
 Purified mKate2 gene fusions were cloned into a TOPO TA pYES2.1 GAL1 vector 
(ThermoFisher Scientific) as per manufacturer's instructions. Subsequent ligation 
reactions were transformed into bacteria as described in section 2.3.5. Following 
overnight selection on LB agar plates at 37 °C, colonies were resuspended in sterile 
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dH2O which served as template DNA in a PCR reaction to determine colonies that were 
positive for recombinant DNA. DNA fragments from colony PCR were visualised by 
agarose gel electrophoresis. Plasmid DNA was isolated from positive colonies and 
Sanger sequenced prior to use. 
2.3.3. Sub-cloning into pSF-TEF1 vector 
 The SAC1-mKATE2 cassette was sub-cloned into a pSF-TEF1-CEN6ARS4 vector 
(Oxford genetics). As the SAC1-mKATE2 cassette already contained the canonical and 
optimal start codon, an AUG start codon was removed from the vector by KpnI 
restriction digest (New England Biolabs) at 37 °C for 1 hour. The digested vector was 
visualised by agarose gel electrophoresis, and the corresponding vector fragment was 
excised and purified as in section 2.3.1. The vector was ligated using 8000 U of T4 DNA 
ligase (New England Biolabs) supplemented with 1 X T4 DNA ligase buffer. The reaction 
was left overnight at room temperature, before being transformed into bacteria as 
previously described in section 2.2.5. To confirm the removal of the start codon, 
plasmid DNA was purified from selected colonies and digested with NcoI (New England 
Biolabs), which was subsequently visualised via agarose gel electrophoresis. An 
undigested plasmid was taken forward and used to sub-clone SAC1-mKATE2. 
 The SAC1-mKATE2 cassette was digested out of the pYES2.1 vector by 
incubation with SspI and XbaI for 1 hour at 37 °C. Similarly, the pSF-TEF1-CEN6ARS4 
vector lacking any start codon was digested by EcoRV and XbaI. Restriction enzymes 
were heat-inactivated at 80 °C for 20 minutes before DNA fragments were visualised 
and purified by agarose gel electrophoresis. To increase the efficiency of ligation, the 
purified DNA fragment and vector were both concentrated to 1/5th of the original 
volume by ethanol precipitation (see section 2.2.5). The SAC1-mKATE2 cassette was 
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incubated with the linearised vector at a molar ratio of 5:1. The ligation reaction 
included 1X T4 DNA ligase buffer and 8000 U T4 DNA ligase which were subsequently 
incubated at room temperature overnight. The ligation reaction was then transformed 
into bacteria (see section 2.2.5) and incubated overnight. Colony PCR (see section 
2.3.2) was used to identify colonies that contained recombinant DNA. Plasmid DNA 
containing recombinant SAC1-mKATE2 was isolated and Sanger sequenced gene-wide 
prior to use. 
2.3.4. Sanger sequencing 
 Sanger sequencing was performed by Source Biosciences (UK) using an Applied 
BioSystems 3730 DNA analyser with PeakTrace analysis software. A quality value limit 
of 20 was used which calls bases with 99 % confidence. The Staden software package 
(V2.0.0b9) was used to analyse chromatograms. Sequences were identified through 
NCBI Nucleotide-Blast.  
2.4. Strain construction 
2.4.1. Cross mating yeast strains 
 To cross yeast strains, single colonies of Mat a and Mat α strains were 
inoculated into the same 5 ml of YPD which was incubated overnight at 30 °C. Cells 
were pelleted by centrifugation at 2500 x g for 3 minutes before being washed in 
sterile dH2O. Cells were pelleted once more and resuspended in 1 ml of sterile dH2O 
before 50 μl was spread onto appropriate selection plates, which was incubated 
overnight at 30 °C. 
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2.4.2. Tetrad dissection 
 Selected diploid cells were spread onto solid sporulation media (0.1 % (w/v) 
Yeast extract, 0.05 % (w/v) glucose and 100 mM KOAc) and incubated at 30 °C for 5 
days to induce sporulation. Several yeast colonies were resuspended in 50 μl of 1 M 
sorbitol and 1 mg/ml lyticase (Sigma-Aldrich) and incubated for 15 minutes at 37 °C. 
The reaction was slowed by the addition of 400 μl sterile dH2O which was aliquoted 
onto solid YPD media and allowed to dry. To isolate single spores, tetrads were 
dissected using a Singer MSM System microscope (Abelson et al., 2004). Isolated 
tetrads were incubated for 2 days at 30 °C. To determine genotypes, the dissected 
tetrads were replica plated using velveteen cloths onto appropriate selection media 
and incubated at 30 °C for 2 days. 
2.4.3. Mating type assay 
 The mating types of yeast strains were determined using the Mat α tester 
(yMK50) and the Mat a tester (yMK51). Each tester strain was cultivated overnight in 
YPD media. 150 μl of the culture was spread onto solid YPD media and allowed to dry. 
The isolated haploid cells were replica plated onto these plates and incubated at 30 °C 
for 2 days. Cells with a Mat a mating type inhibit the growth of Mat α cells (yMK50). 
Conversely, cells with a Mat α mating type inhibit the growth of Mat a cells (yMK51). 
2.5. Protein analysis 
2.5.1. Extraction of protein from yeast 
 Yeast strains were cultivated in 15 ml of media until an OD600 of 1 was reached. 
Cells were pelleted by centrifugation at 2500 x g for 3 minutes and the media was 
discarded. The cells were washed in ice-cold 1 X lysis buffer (30 mM Hepes KOH pH 7.4, 
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100 mM KOAc, 10 mM MgOAc and 1 mM PMSF) and pelleted in a microcentrifuge at 
2500 x g for 3 minutes, before the supernatant was discarded. Cells were resuspended 
in 1 X lysis before adding 100 μl acid-washed glass beads (Sigma-Aldrich). Cells were 
vortexed for 15 seconds and then placed on ice for 45 seconds. The glass bead beating 
step was repeated for a total of 6 cycles, with the final cycle lasting 20-30 seconds. 
Cellular fragments were pelleted by centrifugation at 17000 x g for 15 minutes at 4 °C. 
The supernatant was transferred to a fresh microcentrifuge tube and 10 μl was 
aliquoted for quantification. Protein extracts were stored at -20 °C and defrosted on 
ice prior to use. 
2.5.2. LacZ assay 
 LacZ assays were carried out to assess the expression levels of Gcn4p-LacZ as 
previously described (Hinnebusch, 1985). Strains were cultivated in appropriate media 
until an OD600 0.7 was reached. Protein extracts were made as in the above section. 20 
μl of crude protein extract was incubated in 980 μl 1X Z buffer (65 mM Na2HPO4, 45 
mM NaH2PO4, 10 mM KCl, 1 mM MgSO4) supplemented with 2 mg/ml Ortho-
Nitrophenyl-β-galactoside (ONPG). The reaction was incubated at 30 °C with agitation 
(180 RPM) for 30 minutes before being stopped by the addition of 1M sodium 
carbonate. Absorbances were measured at OD420 in a Genesys 10S UV-VIS 
spectrophotometer. Miller units were calculated by using the following formula: 
Miller units = 1000 x (Absorbance OD420 / (Volume x Time (mins) x OD600)) 
 The Miller units were calculated and normalised to the concentration of protein 
extracts, which was determined by BCA assay. 
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2.5.3. Quantification of protein extracts 
 The concentration of protein extracts was determined using the Bicinchoninic 
Acid (BCA) assay. A BCA working stock was made by adding 4 % copper sulphate to BCA 
(Sigma-Aldrich) at a ratio of 1:25. Bovine serum albumin (BSA) standards, ranging from 
0.1 mg/ml to 4 mg/ml, were prepared in 1X lysis buffer. Protein extracts and BSA 
standards were aliquoted into 96-well plates. The BCA working stock was then added 
to the protein extracts/BSA standards at a ratio of 1:20. Following an incubation of 30 
minutes at room temperature, absorbances were determined using a Victor2 1420 
multi-label counter (Wallac) at a wavelength of 560nm.  
2.5.4. Western blotting 
 For the analysis of proteins via Western blotting, 30 μg of protein extract was 
boiled in 1X RunBlue LDS sample buffer (Expedeon) at 95 °C for 5 minutes. Boiled cell 
lysates were then separated through a 4-20 % gradient RunBlue SDS protein gel 
(Expedeon) in the presence of 1X RunBlue SDS-Tris-Tricine running buffer. The 
examination of protein molecular weights was facilitated by the presence of 
Chameleon duo pre-stained protein ladder (LiCor). 
 Separated proteins were transferred onto a nitrocellulose membrane (0.2 μm 
pore, ThermoFisher Scientific) in the presence of cold transfer buffer (25 mM Tris, 192 
mM Glycine and 10 % (v/v) methanol). Following transfer, the nitrocellulose 
membrane was blocked for 1 hour in TBST buffer (50 mM Tris, 150 mM NaCl and 0.05 
% (v/v) Tween-20) containing 5 % skimmed milk powder (Marvel). The membrane was 
washed three times in TBST for 10 minutes per wash, before incubating with the 
primary antibody overnight at 4 °C. The Rabbit Gcn3p antibody was gifted by Prof. 
Graham Pavitt (University of Manchester, UK) and used at a 1:1000 dilution. The 
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Mouse Pab1p antibody was gifted by Prof. Mark Ashe (University of Manchester, UK) 
and used at a 1:5000 dilution. Following primary antibody incubation, the membrane 
was washed three times and incubated with a near-infrared 680 anti-Mouse antibody 
and a near-infrared 800 anti-Rabbit antibody (LiCor). Both secondary antibodies were 
used at a 1:1000 dilution. The membrane was washed three times in TBST before 
imaging on a LiCor Odyssey Scanner. 
2.6. Microscopy 
2.6.1. Live-cell imaging and quantification of eIF2B localisation 
 Strains were cultivated in media at 30 °C until they reached an OD600 of 0.6. 
Cultures were placed on a 1 % (w/v) poly-L-lysine coated slide (ThermoFisher, UK) and 
visualised on a Zeiss LSM 510 confocal microscope using a 63 x plan-apochromat oil 
objective lens. To image GFP, an argon laser (488 nm) was typically used at 50 % 
capacity. To image RFP, a helium laser (543 nm) was used at 75 % capacity. Images 
were analysed either using Zeiss 2009 software or the National Institutes of Health 
(NIH) ImageJ software. For each strain/mutant analysed, the localisation of eIF2B was 
assessed for 100 cells per replicate. 
2.6.2. Fluorescent recovery after photobleaching (FRAP) 
 FRAP was performed to measure the shuttling of eIF2α-GTP through eIF2B foci 
as previously described by (Campbell et al., 2005). Cytoplasmic foci were imaged and 
bleached using the argon laser at full capacity. Following the pre-bleach and bleach 
steps, the recovery of eIF2B into the cytoplasmic was followed by taking iterative 
images every 1.8 seconds for 25 cycles. 25 cells were analysed for each replicate. 
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 Fluorescence recovery was normalised to the total fluorescence of the cell. 
Background fluorescence was also measured and subtracted from fluorescence 
recovery. Normalised data was fitted to a one-phase association curve to find mobile 
eIF2 and half-time recovery. A rate of recovery was calculated from the one-phase 
association curves by dividing the plateau by the rate constant (k). The eIF2 content of 
cytoplasmic foci was determined using NIH ImageJ software. 
2.7. Sucrose density gradient analysis 
2.7.1. Extract preparation 
 Yeast strains were typically cultivated in 150 ml of media which was separated 
into 50 ml aliquots. Ice cold cycloheximide (final conc. 0.1 mg/ml) was added to one 50 
ml aliquot and then placed in iced-water for 30 minutes. The remaining were pelleted 
at 2500 x g for 3 minutes and resuspended in SCD lacking amino acids or glucose, 
before being incubated for either 30 minutes or 10 minutes respectively. Ice cold 
cycloheximide was added to the final aliquots and following a 30 minute incubation in 
ice-water, polysome extracts were prepared. 
 To extract the polysomes, cultures were pelleted at 2500 x g for 3 minutes at 4 
°C and washed in 1 X lysis buffer (10 mM HEPES.KOH, pH 7.4, 2 mM MgOAc, 0.1 M 
KOAc, 0.1 mg/mL cycloheximide and 0.5 mM dithithreitol in DEPC treated distilled 
water). Cells were lysed by vortexing for 20 seconds in the presence of 1X lysis buffer 
and glass beads before being incubated back on ice-water for 40 seconds, vortexing 
cycles were performed 6 times. The lysed cells were pelleted by centrifugation at 8000 
x g for 10 minutes at 4 °C. The supernatant was transferred to a fresh pre-chilled 
microcentrifuge tube which was stored at -80 °C to prevent degradation prior to use. 
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2.7.2. Preparation of sucrose density gradients 
 Varied concentrations of sucrose ranging from 15-50 % were prepared from a 
60 % (w/v) DEPC treated sucrose stock and 10X polysome buffer (100mM Tris acetate, 
pH 7.4, 700 mM NH4OAc, 40 mM MgOAc) as detailed in Table #. To generate a 
gradient, 2.25ml of each solution was sequentially dispensed into open-top 12.0 ml 
pollyallomer centrifuge tubes (Seton Scientific), starting with the 50 % (w/v) sucrose 
solution and ending with the 15 % (w/v) solution. Each layer was snap-frozen in liquid 
nitrogen before the next layer was added. Sucrose gradients were stored at -80 °C and 
thawed overnight at 4 °C prior to use. 
2.7.3. Sedimentation of extracts on polysome gradients 
 The concentration of polysome extracts was determined using a NanoDrop 
1000 spectrophotometer (ThermoFisher Scientific). 2.5 A260 units of extract were 
layered on top of sucrose gradients. Sucrose gradients were centrifuged using a Th-641 
swing-out rotor in a Sorvall WX Ultracentrifuge for 150 minutes at 4 °C. Polysomes 
were measured by upward displacement using 60 % (w/v) sucrose; gradients were 
displaced using a fractionator that was connected to a UV-vis detector which 
measured polysomes at 254nm. Monosomes/polysomes were measured and 
compared using NIH ImageJ software. 
 
2.7.4. Statistical analysis 
 To determine statistical significance between the various groups within each 
data set, a shapiro wilk test was performed to test for normality. Data was considered 
to be parametric when p < 0.05. However, all data was found to be non-parametric. 
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Various groups was compared to each other using the Kruskal-Wallis test followed by a 
Conover Inman posthoc test. 
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Table ‎2.2 Yeast strains used in this study 
Name Genotype Source 
yMK50 Mat a 
Campbell strain 
collection 
yMK51 Mat α 
Campbell strain 
collection 
yMK467 Mat α, ura3-52, leu2-3,112, gcn2::LEU2 
Campbell strain 
collection 
yMK880 
Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-
100, GCD1-P180-GFP::G418 
Campbell strain 
collection 
yMK883 
Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-
100, GCD1-P180 SUI2-GFP::G418 
Campbell strain 
collection 
yMK1330 
Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-
100, GCD1-P180, SUI2-GFP::G418, gcn3::URA3 
Campbell strain 
collection 
yMK1402 
Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-
100, GCD1-P180-GFP::G418, gcn3::LEU2 
Campbell strain 
collection 
ySC14 
Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-
100, GCD1-P180-GFP::G418 mst27::URA3 
This study 
ySC16 
Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-
100, GCD1-P180, SUI2-GFP::G418, gcn3::LEU2 
This study 
ySC18 
Mat a, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-
100, GCD1-S180-GFP::G418 sac1::LEU2 
This study 
ySC31 
Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-
100, GCD1-P180-GFP::G418 erp4::URA3 
This study 
ySC85 
Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-
100, GCD1-P180, GCN4-LacZ-TRP1 
This study 
ySC86 
Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-
100, GCD1-P180, GCN4-LacZ-TRP1, gcn3::HIS3 
This study 
ySC97 
Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-
100, GCD1-P180, sac1::LEU2 
This study 
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ySC98 
Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-
100, GCD1-P180, sac1::LEU2, gcn3::HIS3 
This study 
ySC99 
Mat a, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-
100, GCD1-P180, GCN4-LacZ-TRP1 
This study 
ySC100 
Mat a, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-
100, GCD1-P180, GCN4-LacZ-TRP1, gcn3::HIS3 
This study 
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Table ‎2.3 Plasmids used in this study 
Name Genotype Source 
BSC078 p[mKATE2] Addgene; (Lee et al., 2013) 
BSC087 p[GAL1-ERP4-mKATE2 2μ] This study 
BSC088 p[GAL1-MST27-mKATE2 2μ] This study 
BSC090 p[GAL1-SAC1-mKATE2 2μ] This study 
BSC091 p[GAL1-MST27 2μ] Harvard Medical School 
BSC093 p[GAL1-ERP4 2μ] Harvard Medical School 
BSC094 p[GAL1-SAC1 2μ] Harvard Medical School 
BSC116 p[GCN3 K111E URA3 CEN6ARS4] This study 
BSC117 p[GCN3 V184D URA3 CEN6ARS4] This study 
BSC118 p[GCN3 F240V URA3 CEN6ARS4] This study 
BSC119 p[GCN3 Y274C URA3 CEN6ARS4] This study 
BSC128 p[TEF1-SAC1-mKATE2 CEN6ARS4] This study 
pAV1108 p[GCN3(T41A) URA3 2μ] (Pavitt et al., 1997) 
pAV1109 p[GCN3(E44V)URA3 2μ] (Pavitt et al., 1997) 
pAV1110 p[GCN3(E44K)URA3 2μ] (Pavitt et al., 1997) 
pAV1111 p[GCN3(F73L) URA3 2μ] (Pavitt et al., 1997) 
pAV1112 p[GCN3(N80D) URA3 2μ] (Pavitt et al., 1997) 
pAV1113 p[GCN3(F240I) URA3 2μ] (Pavitt et al., 1997) 
pAV1115 pGCN3 (T291P) URA3 2μ] (Pavitt et al., 1997) 
pAV1116 p[GCN3 (S293R) URA3 2μ] (Pavitt et al., 1997) 
pAV1117 p[GCN3 URA3 2μ] (Pavitt et al., 1997) 
pAV1170 p[GCN3 URA3 CEN] (Hannig et al., 1990) 
pAV1239 p[GCN3(AA2526VV) URA3 CEN] (Hannig et al., 1990) 
pAV1240 p[GCN3(A26T) URA3 CEN] (Hannig et al., 1990) 
63 
 
pAV1241 p[GCN3(R104K) URA3 CEN] (Hannig et al., 1990) 
pAV1242 p[GCN3(V295F) URA3 CEN] (Hannig et al., 1990) 
pAV1243 p[GCN3(D71N) URA3 CEN] (Hannig et al., 1990) 
pAV1244 p[GCN3(E199K) URA3 CEN] (Hannig et al., 1990) 
pAV1268 p[GCN3(303//305Δ) URA3 CEN] (Hannig et al., 1990) 
pAV1729 p[GCN4 leader-lacZ-TRP1] (Hinnebusch, 1985) 
pAV1769 p[GCN3 URA3 CEN6ARS4] (Richardson et al., 2004) 
pAV1778 p[GCN3(N209Y) URA3 CEN6ARS4] (Richardson et al., 2004) 
pRS423 p[HIS3] (Christianson et al., 1992) 
pRS424 p[URA3] (Christianson et al., 1992) 
pRS425 p[LEU2] (Christianson et al., 1992) 
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Table ‎2.4 - Oligonucleotides used in this study. 
Name Purpose Sequence 
Mst27DelF Amplification of 
deletion cassette used 
to delete the MST27 
gene. 
CACAGAGACAATCAGGAATACTATAGTCATAGACGATAC
AAGGTATATATTGGTCGCAGATTGTACTGAGAGTGC 
Mst27DelR 
GATTATATATCATACTCTAGTTTATGTTCGCTTTACGTATG
GCAGTGTCTCTAAGCTGTGCGGTATTTCACACCG 
Mst27DelVF External verification 
primers, designed to 
avoid MST28. 
GATGTTAGAGGAAGCTGAAGTG 
Mst27DelVR TGCTGCTTGAAAGTCTCTGC 
Erp4DelF Amplification of 
deletion cassette used 
to delete the ERP4 
gene. 
CGAGCGCTAGTGAAGTTTTTTCATAAATATATATTCCCAA
TCATCGCTAGGAATTGCAGATTGTACTGAGAGTGC 
Erp4DelR 
AGTGCCTTCCCCTTAGCACAGCTGATCCAACAATTTTAAG
AGCTTGAAAAGCAACCTGTGCGGTATTTCACACCG 
Erp4DelVF External verification 
primers to confirm 
ERP4 deletion. 
TGTGCTCTCTCAAGTGCC 
Erp4DelVR TGGACAATGGTTGTTTGTGGCC 
Sac1DelF 
Amplification of 
deletion cassette to 
delete the SAC1 gene. 
ATCCCTATAACAGTAACGATAATATTTATATACACGTATA
TTTTCTCGTCTAGATGCAGATTGTACTGAGAGTGC 
Sac1DelR 
TCGGTTTTACGTTTTGGATTTACAATAATCATCATTTTATC
ACATATAGAACTCACTGTGCGGTATTTCACACCG 
Sac1DelVF External verification 
primers to confirm 
SAC1 deletion. 
TCGTGCCCTTTAAGTGTTGC 
Sac1DelVR ACCAGGGACGATGCTGAAAA 
Gcn3DelF 
Amplification of 
deletion cassette to 
delete the GCN3 gene. 
TAATTGATAGAAAGAATTTTAAAAGTCCTACGTATACCA
GAAATCGAGAGGAAGGGCAGATTGTACTGAGAGTGC 
Gcn3DelR 
GCGCTTTTTCTCCTTTTCTATTAAGTCATTGCGTGCATATA
TTATGTGATTTTTTCTGTGCGGTATTTCACACCG 
Gcn3DelVF External verification 
primers to confirm 
GCN3 deletion. 
ACGTATACCAGAAATCGAGAGGA 
Gcn3DelVR ACTGATGTCTGATGCTGTTCT 
Ura3VF Internal verification 
primers used to verify 
gene deletions. 
GGGATGCTAAGGTAGAGGGTG 
Ura3VR CCCGCAGAGTACTGCAATTTGA 
65 
 
Leu2VF Internal verification 
primers used to verify 
gene deletions. 
CACCGTTCCAGAAGTGCAAA 
Leu2VR CATGGCGGCAGAATCAATCA 
K111E_F Internal primers used 
for site directed 
mutagenesis. 
CAAAAAATCGCGTAACGAGATTGCAGAAATAGG 
K111E_R CCTATTTCTGCAATCTCGTTACGCGATTTTTTG 
V184D_F Internal primers used 
for site directed 
mutagenesis. 
GTCGATAGCGCGGATGGAGCGGTAATC 
V184D_R GATTACCGCTCCATCCGCGCTATCGAC 
F240V_F Internal primers used 
for site directed 
mutagenesis. 
CACAAATTTGTTCGTATGGTTCCATTGTCTTCAGATG 
F240V_R CATCTGAAGACAATGGAACCATACGAACAAATTTGTG 
Y274C_F Internal primers used 
for site directed 
mutagenesis. 
CCCACGATCGACTGTACCGCCCAAGAA 
Y274C_R TTCTTGGGCGGTACAGTCGATCGTGGG 
Mst27F 
Primers used in OE-
PCR to create MST27-
mKATE2 gene fusions. 
ATGCAGACCCCTCTAGAAAGTACC 
Mst27mKR CACCGTCACCTTCCGTCTTTTTAAGAAGCGCATCGAT 
mKMst27F 
CTTAAAAAGACGGAAGGTGACGGTGCTGGTTTAATTAAC
ATG 
Erp4F 
Primers used in OE-
PCR to create ERP4-
mKATE2 gene fusions. 
ATGCGCGTTTTTACTTTGATTGCGATT 
Erp4mKR 
CACCGTCACCTACGTAGTTTTTTTGGCGACTGGTAAAAA
AG 
mKErp4F 
CCAAAAAAACTACGTAGGTGACGGTGCTGGTTTAATTAA
CATG 
Sac1F 
Primers used in OE-
PCR to create SAC1-
mKATE2 gene fusions. 
ATGACAGGTCCAATAGTGTACGTTC 
Sac1mKR CACCGTCACCATCTCTTTTTAAAGGATCCGGCTTGGAA 
mKSac1F 
GATCCTTTAAAAAGAGATGGTGACGGTGCTGGTTTAATT
AACATG 
mKate2R 
mKATE2 primer used 
in OE-PCR to create 
gene fusions 
GGTGACGGTGCTGGTTTAATTAACATGGT 
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3. eIF2Bα is required for the formation of 
 eIF2B bodies 
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3.1. Introduction 
Various cytoplasmic foci such as P-bodies and stress granules have been well 
documented to play roles in the storage and fate of mRNAs. Whilst mRNA transcripts 
and various translation initiation factors are known components of these foci, eIF2B 
mainly localises to eIF2B bodies (Campbell et al., 2005). The importance of eIF2B 
bodies with respect to translational control is still unclear. Thus, important questions 
remain: why localise eIF2B to one singular cytoplasmic body? Which eIF2B subunit is 
responsible for such localisation? Is localisation important for the functional properties 
of eIF2B?  
 The main aim of this chapter was to gain insight into how eIF2B forms eIF2B 
bodies. Recently, the eIF2B body was shown to exhibit features indicative of a 
filamentous structure (Petrovska et al., 2014). Indeed, a hallmark of filamentous 
aggregates is their progression from single molecules to macromolecules, which 
display intrinsic organisation often incorporating intermediate structures. In their 
initial study describing eIF2B bodies in the yeast S. cerevisiae, Campbell et al., (2005) 
showed all eIF2B subunits to co-localise. Since one uniform eIF2B body was present 
within each cell, it is likely that the decameric complex is formed prior to localisation. 
 eIF2B consists of five different subunits that are divided into two categories 
based on their function. The α, β and δ subunits are regulatory subunits whilst γ and ε 
are catalytic. In humans and yeast, eIF2B exists as a decamer comprising two εγδβ 
heterotetramers stabilised by an α-α homodimer (Wortham et al., 2014). Over the last 
10 years, several structural studies investigating eIF2B's crystal structure as well as 
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subunit interactions and stoichiometry have been published. Taken together, they 
imply that eIF2Bα may play a key role in the formation of eIF2B bodies. 
Recent evidence has provided the first model on how the decameric structure 
may be formed with eIF2Bα entering last (Wortham et al., 2016). Wortham et al., 
identified that all eIF2B subunits, except eIF2Bα, are stochastically regulated (Fig. 3.1). 
Stable expression of eIF2Bε relies on similar levels of γ to be co-expressed; 
correspondingly eIF2Bδ requires similar levels of eIF2Bεγ and β (Wortham et al., 2016). 
Any surpluses are degraded by the ubiquitin-proteasome system. This study indicated 
that the eIF2B holocomplex may be built around the catalytic subunits, with eIF2Bβδ 
entering second to form an eIF2Bεγβδ tetramer. Finally, the eIF2Bα2 dimer then binds 
two tetramers to complete the decameric holocomplex. In line with this model, 
observations from crystallography and mass spectrometry highlighted ε-β and γ-δ 
interactions primarily stabilise the tetrameric subcomplex which is unable to dimerise 
in the absence of eIF2Bα (Wortham et al., 2014) (Kashiwagi et al., 2016).   
Under physiological conditions eIF2Bα homodimerises at its C-terminus 
(Kashiwagi et al., 2016). Interestingly, experiments with higher concentrations of 
purified protein have shown eIF2Bα to aggregate and even to form octamers (Bogorad 
et al., 2014). Although these experiments were performed in vitro using purified 
recombinant proteins, similar experiments with eIF2Bβ using physiological and high 
concentrations showed that it is indeed a monomer, highlighting that the ability of 
eIF2Bα to form complexes was not an experimental artefact (Bogorad et al., 2014). It is 
plausible that these experiments are representative of in vivo conditions, with 
physiological conditions representing eIF2Bα forming the decamer and higher 
concentrations representing eIF2Bα forming eIF2B bodies, therefore contributing to 
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the overall organisation of the eIF2B complex as previously described, and potentially 
eIF2B body formation thereafter.   
Within this chapter, experiments were undertaken to test the hypothesis that 
eIF2Bα (Gcn3p in S. cerevisiae) is required for the aggregation of eIF2B to form eIF2B 
body.  
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Figure ‎3.1 eIF2B subunits are stochastically expressed. eIF2Bγ relies on stable expression of the ε subunit, whilst eIF2Bδ relies 
on stable expression of the β subunit in addition to eIF2Bεγ. Any abundances are degraded by the ubiquitin-proteasome 
system. These observations provide the basis for the first model on how eIF2B may be assembled, with eIF2Bα binding two 
eIF2Bεγβδ tetramers to form the complete decameric complex. Whilst some of these subcomplexes are yet to be observed in 
vivo¸ in vitro biochemical testing shows eIF2B activity to increase as more subunits enter the complex, thus in support of this 
model. 
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3.1.1. eIF2Bα is required for the formation of eIF2B bodies 
In their original study identifying eIF2B bodies, Campbell et al., (2005) showed 
eIF2B and eIF2 to co-localise within eIF2B bodies. Using a number of strategies to alter 
the GEF activity of eIF2B, results suggested that these cytoplasmic foci where sites 
were eIF2B activity can be controlled and regulated. These eIF2B bodies can be seen in 
Figure 3.2A. Live-cell imaging was carried out on individual strains containing GFP 
tagged GCD1 (eIF2Bγ) or SUI2 (eIF2α), which were generated prior to this study 
(Campbell et al., 2005). Although eIF2B bodies were visible in exponentially growing 
cultures, they were not present in every cell. Therefore, to examine the prevalence of 
the eIF2B body phenotype, a minimum of 100 GFP tagged GCD1 (eIF2Bγ) cells were 
assessed based upon eIF2B localisation (Fig. 3.2B). It was identified that 55.8% of cells 
formed eIF2B bodies. Intriguingly, eIF2B also localised to multiple foci instead of the 
singular eIF2B body, although this was a rare occurrence (1.8%). 
To investigate whether eIF2Bα was responsible for the formation of eIF2B 
bodies, eIF2B localisation was determined in strains gcn3::LEU2 GCD1-GFP (yMK1402) 
and gcn3::LEU2 SUI2-GFP (ySC16). yMK1402 was generated prior to this study. The 
URA3 cassette within gcn3::URA3 SUI2-GFP (yMK1330) was replaced with LEU2 to 
enable complementation by URA3 based plasmids. To substitute amino acid markers, 
homologous recombination was performed as described in 2.3.6.  
 Both strains were analysed to investigate whether eIF2Bα/Gcn3p is required for 
eIF2B body formation. Live-cell imaging of cells lacking Gcn3p showed eIF2Bγ to be 
dispersed throughout the cytoplasm (Fig. 3.2A). Quantitation of this dispersed 
phenotype is shown in Figure 3.2B. 
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 In-order to confirm that this dispersal was due to the lack of Gcn3p, gcn3Δ 
strains were transformed with low copy (Cen) and high copy (2μ) plasmids containing 
wild-type GCN3, complete with its canonical promoter. Localisation was rescued in the 
presence of Gcn3p (Fig 3.2A). Exogenously expressed GCN3 from a low copy Cen 
plasmid showed a similar localisation pattern to wild-type with 48.5 % of cells 
containing eIF2B bodies (Fig 3.2B). Again like the wild-type, a very small proportion of 
cells containing multiple smaller eIF2B foci were present (1.1 %). eIF2B bodies were 
also rescued when GCN3 was over-expressed on a high copy 2μ plasmid. In contrast to 
wild-type however, there was a decrease in the number of cells with eIF2B bodies (31 
%) and an increase in the number of cells displaying dispersed eIF2B (63.2 %). 
Interestingly, instances of multiple foci also increased slightly (5.4 %). Although this 
was not significant, it suggested that GCN3 over-expression may be detrimental to 
eIF2B localisation. Nevertheless, these experiments showed that eIF2Bα is required for 
the formation of eIF2B bodies. 
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Figure ‎3.2 eIF2Bα is required for eIF2B body formation. (A) Confocal microscopy of GCD1-
yeGFP (yMK880), SUI2-yeGFP (yMK883), GCD1-yeGFP gcn3::LEU2 (yMK1402) and SUI2-yeGFP 
gcn3::LEU2 (ySC16). Null strains were transformed with a low copy Cen plasmid (pAV1170) or a 
high copy 2μ plasmid (pAV1117) both containing WT GCN3. (B) A minimum of 100 cells were 
counted and assessed as to whether eIF2B bodies were present, dispersed or localised to 
microbodies. Overnight cultures were diluted in SCD media to 0.2 OD
600
 
and incubated at 30°C 
with shaking until exponential growth was reached. n=3, error bars are representative of SD, 
ns = not significant, * P=<0.05, ** P=<0.01, *** P=<0.001, **** P=<0.0001. 
A. 
B. 
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3.1.2. Characterisation of gcn3Δ cells growth  
Although Gcn3p/eIF2Bα is required for the regulatory function of eIF2B, it is 
not essential for cellular growth in yeast (Pavitt et al., 1997). In contrast, over 
expression of Gcn3p has been shown to be toxic to cells, slowing growth dramatically 
(Yoshikawa et al., 2011). To ensure our background strain behaved similarly, therefore 
allowing comparisons with previous work, growth curves were generated for the wild-
type and gcn3Δ strains as well as the cells expressing GCN3 exogenously on low or high 
copy plasmids (Fig. 3.3). In line with previous data, deletion of gcn3 did not impact 
upon cellular growth and gcn3Δ cells grew at a similar rate as wild-type cells. In 
addition, when GCN3 was exogenously expressed from a low copy plasmid, cell growth 
was not affected however, the high copy counterpart dramatically decreased cellular 
growth rate, confirming previous observations (Yoshikawa et al., 2011). 
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Figure ‎3.3 Deletion of eIF2Bα does not impact growth. Overnight cultures were diluted to 0.2 
OD
600
 in fresh SCD media before incubation at 30°C with shaking. Growth was monitored over 
eight hours, n=3, error bars are representative of SD. 
B. 
A. 
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3.1.3. Characterisation of eIF2B dependent regulation in cells lacking 
 gcn3 
 
 To assess the efficiency of translation initiation in cells deleted for gcn3, or 
exogenously expressing GCN3, polysome analysis was carried out. Under optimal 
growth conditions, most mRNAs are actively translated. During these steady-state 
conditions, mRNAs may have several ribosomes attached that are at various stages of 
translation. This results in the accumulation of ribosomes on mRNA transcripts, giving 
rise to polyribosomes or polysomes (Fig. 3.4). When translation initiation is inhibited 
however, ribosomes are unable to undergo concurrent rounds of translation, 
subsequently leading them to ‘run-off’ mRNAs resulting in an increase of 80S 
monosomes.  
One of the classic cellular stresses which inhibits protein synthesis is amino acid 
depletion. In yeast, Gcn2p responds to amino acid starvation by phosphorylating serine 
51 on eIF2α (Sui2p in S. cerevisiae). In its phosphorylated state eIF2 binds more tightly 
to eIF2B inhibiting the GEF activity and subsequently decreasing translation initiation 
and global protein synthesis (see section 1.2.1.1.1). eIF2Bα contains the binding site 
for phosphorylated eIF2 and is crucial to eIF2B's ability to respond to this stress. 
Deleting gcn3 therefore renders eIF2B insensitive to eIF2α-P, preventing the 
sequestration of translation initiation. To ensure the gcn3Δ strain used here displayed 
a similar phenotype, polysome profiling was used to analyse whether cells lacking gcn3 
could respond to amino acid starvation (Fig. 3.5). As a control, glucose starvation was 
included as an eIF2B-independent stress which is a potent inhibitor of translation 
initiation. In line with previous observations, amino acid starvation lead to ribosomal 
‘run-off’ within all wild-types expressing GCN3, indicated by the increase in the 80S 
monosome peak (Fig. 3.5A). Quantification of the area underneath the monosome and 
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polysome peaks revealed that the polysome:monosome (P:M) ratio decreased by 
around 50 % (Fig. 3.5B). Consistent with previous findings, the P:M ratio did not 
change in response to amino acid starvation within the gcn3 null strain, indicating that 
these cells are unable to respond to eIF2B-dependent regulation. 
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Figure ‎3.4 Schematic of polysome profiling traces. Following the addition of 
cycloheximide, ribosomes decoding mRNA become stalled. Cell extracts are then 
separated on a sucrose gradient before being passed through a UV detector to produce a 
polysome trace. With the exception of the 40S and 60S peaks, the peaks relate to the 
number of ribosomes attached to any given mRNA. As efficient translation can be 
attributed to multiple ribosomes translating along mRNAs, the area underneath the 
monosome peak can be compared to the polysome peaks to calculate a 
polysome/monosome ratio which can be compared to evaluate translational control and 
translation initiation. 
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Figure ‎3.5 Deletion of eIF2Bα prevents eIF2B from responding to amino acid starvation. (A) 
Polysome profiles of GCD1-yeGFP (yMK880), GCD1-yeGFP gcn3::LEU2 (yMK1402) as well as 
yMK1402 containing exogenous WT GCN3 on low copy Cen (pAV1170) or high copy 2μ 
plasmids (pAV1117). (B) The area underneath the monosome peak and polysome peaks were 
quantified using ImageJ to find the polysome/monosome ratio. Overnight starter cultures were 
diluted to 0.2 OD600 in SCD media and incubated at 30°C with shaking until exponential growth 
was reached. Cultures were divided, pelleted and resuspended in media lacking amino acids or 
glucose, and incubated at 30°C for 30 minutes and 10 minutes respectively. n=3, error bars are 
representative of SD, ns = not significant, * P=<0.05, ** P=<0.01, *** P=<0.001, **** 
P=<0.0001. 
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3.1.4. eIF2Bα mutations alter the localisation of eIF2B 
Having established eIF2Bα to be essential for the formation of eIF2B bodies, we 
wished to further investigate the role of eIF2Bα in the formation of eIF2B bodies. To 
achieve this, a series of previously published Gcn3p mutants were characterised.  
These mutants were originally generated by Hannig et al., (1990) and Pavitt et al., 
(1997) and gave two distinct phenotypes that either affected the regulatory or 
catalytic activities of eIF2B. Both types of mutations influence Gcn4p expression and 
therefore the stress response (see section 1.2.1.1.1). Regulatory mutations (initially 
coined general control nonderepressible (Gcn-) mutations) prevent eIF2B from binding 
eIF2α-P in response to cellular stress (Pavitt et al., 1997), thus Gcn4p expression 
cannot be induced preventing the cell from producing a stress response. Catalytic 
mutations (initially coined general control derepressible (Gcd-) mutations) decrease 
eIF2Bs ability to exchange GDP for GTP on eIF2, reducing global protein synthesis 
which leads to the constitutive expression of Gcn4p (Hannig et al., 1990). The gcn3 
catalytic and regulatory mutants were originally generated via random mutagenesis 
using the low copy (Cen) and high copy (2μ) GCN3 plasmids as respective templates, 
which were characterised during section 3.1.1. 
All gcn3 regulatory and catalytic mutations used in this study were sequenced 
prior to any analyses to ensure additional mutations were not present. The mutations 
are shown in Figure 3.6, modelled on the eIF2Bα homodimer from 
Schizosaccharomyces pombe (Kashiwagi et al., 2016). Highlighted in blue are catalytic 
mutants whilst regulatory mutants are coloured purple. Interestingly, the Gcn3p 
regulatory mutants are mostly located on the distal face where eIF2Bβ and δ docking 
sites exist. Although the Gcn3p catalytic mutants seem to be in close proximity to 
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these pockets, they are mostly located further away and therefore may affect intra-
residue interactions instead. 
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Figure ‎3.6 Structural schematic highlighting eIF2Bα mutations. To observe their effect on 
eIF2B localisation, a series of regulatory (purple and underlined) and catalytic (turquoise) 
mutations were introduced into the deletion strain. Mutated amino acids are modelled on 
crystal structure data derived from Schizosaccharomyces pombe (Kashiwagi et al., 2016). 
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3.1.4.1. Phenotypic confirmation of gcn3 regulatory mutants 
Previously, the Gcn3p regulatory mutants were characterised by their growth 
on 3-amino-1,2,4-triazole (3-AT) which instigates a stress response that is dependent 
upon eIF2B regulation (Pavitt et al., 1997). Accordingly, Gcn3p regulatory mutations 
were unable to grow in the presence of 3-AT. Therefore, eIF2B was unable to be 
regulated in the presence of these mutations. Here, growth curves and polysome 
profiles were generated for three gcn3 regulatory mutants to confirm the mutant 
phenotype. The regulatory mutants E44V, N80D and T291P were chosen as polysome 
profiles are yet to be published.  
To investigate whether the regulatory mutants grew similarly to previously 
published data, plasmids containing the E44V, N80D and T291P mutants were 
transformed into the GCD1-GFP gcn3::LEU2 strain. Growth curves were generated over 
16 hours at 30  ̊C (Fig. 3.7). GCN3 expressed on a high-copy plasmid exhibited a similar 
growth defect to data generated previously within this study (Fig. 3.3). All three gcn3 
regulatory mutants exhibited slower growth rates than the high-copy wild-type 
plasmid, with N80D and T291P growing similarly, whilst E44V grew the slowest.  
Akin to gcn3Δ cells, gcn3 regulatory mutants render cells unresponsive to 
amino acid stress and cannot produce a stress response by inhibiting translation 
initiation (Pavitt et al., 1997). To confirm this for the mutations used here, polysome 
profiles were generated (Fig. 3.8). P:M ratios of the wild-type as well as the gcn3 null 
strain are included for comparison (data from Fig. 3.5). All three regulatory mutants 
failed to respond to amino acid starvation and could not inhibit translation initiation. 
The regulatory mutants still responded to eIF2B independent regulation however, as 
P:M ratios decreased across all mutants under glucose starvation. These data confirm 
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previous observations that the Gcn3p regulatory mutations cannot induce eIF2B-
dependent regulation. 
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Figure ‎3.7 eIF2Ba regulatory mutants grow similarly to the wild-type plasmid. Overnight 
starter cultures were diluted to 0.1 OD600 in fresh SCD media before being incubated at 30°C 
with shaking. Growth was monitored over thirty hours in a 96-well plate; results shown the 
mean of three values from one replicate with bars representing standard deviations. 
 
A. 
B. 
86 
 
 
 
Figure ‎3.8 gcn3 regulatory mutants cannot respond to eIF2B-dependent regulation. (A) 
Polysome profiles of GCD1-yeGFP gcn3::LEU2 (yMK1402) exogenously expressing gcn3 
regulatory mutants (E44V (pAV1109), N80D (pAV1112) and T291P (pAV1115)). (B) The area 
underneath the monosome peak and polysome peaks were quantified using ImageJ to find the 
polysome/monosome ratio. Overnight starter cultures were diluted to 0.2 OD600 in SCD media 
and incubated at 30°C with shaking until exponential growth was reached. Cultures were 
divided, pelleted and resuspended in media lacking amino acids or glucose, which were further 
incubated for 30 minutes and 10 minutes respectively. n=3, error bars are representative of 
SD, ns = not significant, * P=<0.05, ** P=<0.01, *** P=<0.001, **** P=<0.0001. 
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3.1.4.2. eIF2Bα regulatory mutants disperse eIF2B bodies 
Combined, growth curves and polysome profiles confirmed the eIF2Bα 
regulatory mutants displayed similar phenotypes to previous data when expressed in 
our background strain (Pavitt et al., 1997). The mutations were next analysed for their 
impact on eIF2B body formation. Confocal microscopy was used to investigate whether 
eIF2B localisation would change in the presence of a gcn3 regulatory mutation (Fig. 
3.9). Live-cell images of wild-type cells containing exogenous GCN3 expressed from a 
high copy plasmid, as well as the gcn3 null strain are included for comparison (data 
from Fig. 3.2).  
For all mutants analysed, eIF2B body formation was severely impaired (Fig. 
3.9A) as indicated by a significant decrease in the number of cells forming eIF2B 
bodies. Accordingly, a significant increase was observed in the number of cells with 
dispersed eIF2B (Fig. 3.9B). Although there was a distinct lack of eIF2B body formation 
for most regulatory mutants, some eIF2B body formation (6.7 %) was apparent within 
the S293R mutant. Interestingly, the gcn3 regulatory mutants seemed to mirror the 
gcn3 null strain (Fig. 3.2), possibly suggesting a relationship between localisation and 
regulation of eIF2B. 
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Figure ‎3.9 eIF2Ba regulatory mutants are unable to form eIF2B bodies. (A) Confocal 
microscopy of GCD1-yeGFP gcn3::LEU2 (yMK1402) exogenously expressing Gcn- mutations 
(pAV1108 – 13, 15 and 16), which were generated on the high copy 2μ WT GCN3 plasmid 
(pAV1117). (B) A minimum of 100 cells were counted and assessed as to whether eIF2B bodies 
were present, dispersed or localised to microbodies. Overnight cultures were diluted in SCD 
media to 0.2 OD600
 and incubated at 30°C with shaking until exponential growth was reached. 
n=3, error bars are representative of SD. ns = not significant, * P=<0.05, ** P=<0.01, *** 
P=<0.001, **** P=<0.0001. 
A. 
B. 
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3.1.4.3. Phenotypic confirmation of gcn3 catalytic mutants 
 The gcn3 catalytic mutants impair the GEF activity of eIF2B resulting in a 
reduction of GTP-bound-eIF2 and subsequently, reduced global protein synthesis 
(Hannig et al., 1990). To characterise the impaired catalytic phenotype within our 
background strain, growth curves and polysome profiles were generated for the three 
mutants AA25,26VV, E199K and AA 303//305Δ transformed into the GCD1-GFP 
gcn3::LEU2 strain (yMK1402) (Fig. 3.10A).  
 As before, wild-type GCN3 on a low-copy plasmid grew similarly to the deletion 
strain (Fig. 3.10 and Fig. 3.3). AA25,26VV was the only mutant to exhibit slower 
growth, whilst E199K and AA 303//305Δ either grew at the same rate as the wild-type 
plasmid or faster. 
A characteristic phenotype of eIF2B catalytic mutants is that they can grow in 
the presence of 3-amino-1,2,4-triazole (3-AT) due to derepression of GCN4 (Hannig et 
al., 1990). 3-AT is a competitive inhibitor of the enzyme imidazoleglycerol-phosphate 
dehydratase, encoded by the HIS3 gene. This drug therefore mimics an amino acid 
starvation stress. During such a starvation, the transcription factor GCN4 is 
derepressed which in-turn upregulates HIS3, allowing cells to survive by outcompeting 
the toxic 3-AT. eIF2B therefore mimics the occurrence of cellular stress when a 
catalytic mutation is present. In contrast, cells are unable to respond to the 3-AT when 
a regulatory mutation is present, as eIF2B cannot bind eIF2-P. Thus, growth on agar 
containing 3-AT provides a simple qualitative method to establish catalytic mutants.  
As stable expression of HIS3 is required to analyse cellular growth in the 
presence of 3-AT, the strain ySC86, gcn3::HIS3 was made. This gcn3 deletion strain was 
generated via homologous recombination utilising the pRS423 plasmid. Three gcn3 
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catalytic mutations were chosen to establish the gcn3 catalytic phenotype. AA25,26VV, 
E199K and AA 303//305Δ were all chosen as polysome profiles are yet to be published. 
To analyse growth in the presence of 3-AT, the three mutants were transformed into 
the gcn3::HIS3 strain (ySC86). 
In tandem with previously generated growth curves (Fig. 3.10A), AA25,26VV 
grew poorly on SCD agar, whilst AA 303//305Δ grew analogously to the wild-type 
GCN3 Cen plasmid (Fig. 3.10B). A slight growth defect was observed for the E199K 
mutant when grown on solid media. When challenged with 3-AT the gcn3 null strain 
was unable to derepress GCN4, indicated by the complete lack of growth (Fig. 3.10B). 
The addition of Gcn3p from a low copy plasmid allowed growth on 3-AT, but at a lower 
rate, indicating that Gcn3p is required to allow the cells to respond to the stress. 
Although the AA25,26VV and E199K grew poorly on SCD agar, their growth was not 
hindered by the presence of 3-AT, indicating higher levels of GCN4 due to decreased 
levels of eIF2B activity. Whilst these results suggest AA25,26VV and E199K produce the 
catalytic phenotype, the AA 303//305Δ mutant grew slower in the presence of 3-AT, 
conflicting with previously published data where the mutants growth increased. 
Previously published data has shown that catalytic mutations lead to instances 
of ribosomal ‘run-off’, subsequently resulting in a higher number of 80S monosomes 
(Warner et al., 1963, Jackson and Standart, 2015). Therefore, to further characterise 
the catalytic phenotype, polysome profiles were generated for the three mutants 
previously challenged with 3-AT, but in the GCD1-GFP gcn3::LEU2 strain (Fig. 3.11). 
P:M ratios of the wild-type containing endogenous GCN3 as well as the gcn3 null strain 
are included for comparison. Under normal conditions, the three catalytic mutants 
exhibited exaggerated 80S monosome peaks, resulting in decreased P:M ratios under 
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steady-state growth. All three mutants were also able to respond to amino acid 
starvation as well as glucose starvation. These results recapitulate previous 
conclusions, whereby the presence of Gcn3p catalytic mutations do not hinder the 
regulation of eIF2B, but decrease the catalytic activity of eIF2B resulting in ribosomal 
run-off. 
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Figure ‎3.10 eIF2Bα catalytic mutants that grow slow grow better on 3-AT. (A) Overnight 
starter cultures were diluted to 0.1 OD600 in fresh SCD media before being incubated at 30°C 
with shaking. Growth was monitored over thirty hours in a 96-well plate; results shown are the 
mean of three values from one replicate, bars represent standard deviation. (B) Mutants were 
exogenously expressed in a gcn3::HIS3 (ySC86) strain. Starter cultures were backdiluted to 0.3 
OD units before being serially diluted four times and spotted on to SCD agar as well as SCD 
agar containing 30 mM 3AT. Spot plates were incubated at 30 °C for 48 hours. 
 
A. 
B. 
C. 
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Figure ‎3.11 gcn3 catalytic mutants lead to an increase in 80S monosomes. (A) Polysome 
profiles of GCD1-yeGFP gcn3::LEU2 (yMK1402) exogenously expressing gcn3 Gcd- mutants 
(A25,26V (pAV1239), E199K (pAV1244) and 303//305Δ (pAV1268)). (B) The area underneath 
the monosome peak and polysome peaks were quantified using ImageJ to find the 
polysome/monosome ratio. Overnight starter cultures were diluted to 0.2 OD600 in SCD media 
and incubated at 30°C with shaking until exponential growth was reached. Cultures were 
divided, pelleted and resuspended in media lacking amino acids or glucose, which were further 
incubated for 30 minutes and 10 minutes respectively. n=3, error bars are representative of 
SD, ns = not significant, * P=<0.05, ** P=<0.01, *** P=<0.001, **** P=<0.0001. 
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3.1.4.4. eIF2Bα catalytic mutants form microbodies 
Live-cell imaging via confocal microscopy was used to investigate eIF2B 
localisation in the presence of the gcn3 catalytic mutations (Fig. 3.12). Intriguingly, all 
catalytic mutations caused eIF2B to localise to several smaller foci, which we termed 
microbodies (Fig. 3.12A). Analysis of a population of cells revealed eIF2B mainly 
localised to microbodies within most mutants (Fig. 3.12B). However, AA 303//305Δ 
was the only exception, where similar numbers of cells either dispersed eIF2B (33.5 %), 
formed microbodies (38.3 %) or eIF2B bodies (28.2 %). Interestingly, these data imply 
that the localisation of eIF2B may be important for GDP-GTP exchange on eIF2, which 
is required to initiate translation. 
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Figure ‎3.12 gcn3 catalytic mutants localise eIF2B to multiple foci. Confocal microscopy of 
GCD1-yeGFP gcn3::LEU2 (yMK1402) exogenously expressing gcn3 Gcd- mutations (pAV1239 – 
44 and 68), which were generated on the low copy Cen GCN3 plasmid (pAV1170). (B) A 
minimum of 100 cells were counted and assessed as to whether eIF2B was dispersed, localised 
to microbodies or formed eIF2B bodies. Overnight starter cultures were diluted in SCD media 
to 0.2 OD600
 and incubated at 30°C with shaking and allowed to reach exponential growth. n=3, 
error bars are representative of SD. ns = not significant, * P=<0.05, ** P=<0.01, *** P=<0.001, 
**** P=<0.0001. 
A. 
B. 
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3.1.5. Effect of gcn3 VWM- mutations on eIF2B localisation 
 Autosomal recessive mutations within any eIF2B subunit cause the human 
disease VWM (Leegwater et al., 2001). It was therefore valuable to characterise eIF2B 
function and localisation in the presence of a naturally occurring clinical mutation. 
Moreover, these analyses could also provide further insight to the pathogenesis of 
VWM, potentially helping with the elucidation of methods to ameliorate the fatal 
disease. 
  eIF2Bα contains the fewest VWM mutations amongst eIF2B subunits, with 1 
frameshift, 1 deletion and 6 missense mutations reported so far (Pavitt and Proud, 
2009). Mutated residues are mostly conserved between human and yeast, with the 
only exception being P278R (Q277 in gcn3). N208Y (N209Y in gcn3) represents the only 
VWM mutation to be analysed in yeast thus far (Richardson et al., 2004). These gcn3 
VWM missense mutations are shown modelled on the eIF2Bα homodimer crystal 
structure from S. pombe (Fig. 3.13). Interestingly, in contrast to the regulatory and 
catalytic Gcn3p mutations (see Figure 3.6), the VWM mutations are mostly present 
near the α-α dimer interface. Details of VWM mutations and their resulting 
phenotypes observed in humans are shown in Table 3.1. 
To investigate if these mutations impact upon the function and localisation of 
eIF2B, site directed mutagenesis was performed to generate the VWM amino acid 
substitutions using the GCN3 CEN6ARS4 low copy plasmid (pAV1769) as a template, as 
previously described (Richardson et al., 2004). Transformants were selected on LB agar 
containing 50 μg/ml carbenicillin overnight, before purified plasmids were sequenced 
gene-wide to ensure undesired mutations were not present. 
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Figure ‎3.13 Structural schematic highlighting eIF2Bα VWM mutations. Five mutations, 
causative of the Human disease VWM, were generated by site directed mutagenesis to 
investigate their effect on eIF2B localisation and function. Mutated amino acids are modelled 
on crystal structure data derived from Schizosaccharomyces pombe. 
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Table ‎3.1 Genotypes and phenotypes of VWM missense mutations. 
        N/R: Not reported. IVS: Intervening sequence. 
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3.1.5.1. Phenotypic characterisation of eIF2Bα VWM mutations 
 To characterise their effect on eIF2B function and localisation, the VWM 
mutant plasmids were exogenously expressed in the GCD1-GFP gcn3::LEU2 strain for 
live-cell imaging and the generation of growth curves and polysomes profiles. 
Moreover, to investigate GCN4 depression, the plasmid-borne mutants were also 
transformed into the gcn3::HIS3 strain to generate 3-AT spot plates. 
As before, GCN3 expressed from a low copy CEN6ARS4 plasmid (a different low 
copy plasmid to the Cen plasmid characterised in Section 3.2.1) grew similarly to the 
wild-type strain (Fig. 3.14A). All of the VWM mutants grew similarly to the wild-type 
plasmid, with slightly decreased growth rates for F240V and Y274C. 
 When challenged with 3-AT, cells containing the wild-type plasmid were able to 
grow suggesting that a stress response was possible (Fig. 3.14B). In the presence of 3-
AT, growth was dramatically reduced for the gcn3 VWM mutants V184D, N209Y and 
F240V. This suggested that these mutants were unable to derepress GCN4, indicative 
of a regulatory mutant phenotype. K111E and Y274C grew similar to wild-type. 
Polysome profiles were generated to assess whether these VWM mutations in 
eIF2Bα resulted in a translation initiation defect (Fig. 3.15). Under normal steady state 
conditions all mutations produced a polysome trace similar to the wild-type, indicating 
no translational defect. However upon stress, the VWM mutations N209Y and F240V 
were unable to respond to amino acid starvation, as indicated by unaffected P:M ratios 
in comparison to normal conditions. These results were in-line with prior observations 
from 3-AT spot plates. The results of the V184D mutant were rather contradictory. 
Although V184D could not respond to 3-AT, P:M ratios decreased under amino acid 
starvation, suggesting that eIF2B dependent regulation was still possible. Polysome 
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profiles generated for K111E and Y274C were consistent with plasmid-borne wild-type 
and could respond to amino acid starvation. Although, P:M ratios were slightly 
exaggerated for Y274C under amino acid starvation, suggesting a slight hypersensitivity 
to eIF2B dependent regulation. 
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Figure ‎3.14 gcn3 VWM mutants growth on 3AT and growth curve. (A) Overnight starter 
cultures were diluted to 0.2 OD units in SCD media before being incubated at 30 °C with 
shaking. Growth was monitored over eight hours. n=3, error bars are representative of SD. (B) 
Mutants were exogenously expressed in a gcn3::HIS3 (ySC86) strain. Starter cultures were 
backdiluted to 0.3 OD units before being serially diluted 4 times and spotted on to SCD agar 
plates as well as SCD agar containing 30 mM 3-AT. Spot plates were incubated at 30 °C for 48 
hours. 
A. 
B. 
C. 
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Figure ‎3.15 Polysome profiling of gcn3 VWM mutants. (A) Polysome profiles of GCD1-yeGFP 
gcn3::LEU2 (yMK1402) exogenously expressing gcn3 VWM mutants (K111E (bSC116), V184D 
(bSC117), N209Y (pAV1778), F240V (bSC118) and Y274C (bSC119)), which were generated by 
site directed mutagenesis in the low copy CEN6ARS4 WT GCN3 plasmid. The area underneath 
the monosome peak and polysome peaks were quantified using ImageJ to find the 
polysome/monosome ratio. Overnight starter cultures were diluted to 0.2 OD600 in SCD media 
and incubated at 30°C with shaking until exponential growth was reached. Cultures were 
divided, pelleted and resuspended in media lacking amino acids or glucose, which were further 
incubated for 30 minutes and 10 minutes respectively. n=3, error bars are representative of 
SD, ns = not significant, * P=<0.05, ** P=<0.01, *** P=<0.001, **** P=<0.0001. 
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3.1.5.2. eIF2Bα VWM mutations display varied eIF2B localisation 
Overall, these results showed that both N209Y and F240V displayed phenotypic 
patterns consistent with them being regulatory mutants. Although the V184D mutant 
showed 3-AT data which suggested that it also displayed a regulatory phenotype, 
polysome analysis did not reflect this. K111E and Y274C were characteristically similar 
to wild-type, although Y274C displayed some abnormalities that were not consistent 
with either regulatory or catalytic phenotypes described previously.  
 To assess the impact of the VWM mutations on eIF2B localisation, live-cell 
images were taken via confocal microscopy (Fig. 3.16). N209Y was unable to nucleate 
eIF2B, consistent with regulatory mutations previously analysed (as in section 3.1.4.2). 
Whilst eIF2B body formation was absent from N209Y (0.26 %), some eIF2B bodies 
were visible within the F240V mutant (13.1 %). Y274C eIF2B body formation was 
impaired similar to F240V, with dispersed eIF2B being the dominant phenotype (19.9 
% eIF2B bodies, 77.2 % dispersed eIF2B). V184D mostly localised eIF2B to microbodies 
(49.6 %) despite lacking any catalytic mutant characteristics (as in section 3.1.4.3). 
Localisation within the K111E mutant was somewhat similar to wild-type; however 
there was a decrease in the number of cells containing eIF2B bodies (28.8 %).  
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Figure ‎3.16 eIF2B localisation in the presence of gcn3 containing VWM missense mutations. 
(A) Confocal microscopy of GCD1-yeGFP gcn3::LEU2 (yMK1402) expressing gcn3 VWM mutants 
as well as the low copy CEN6ARS4 WT GCN3 plasmid. (B) A minimum of 100 cells were counted 
and assessed as to whether eIF2B was dispersed, localised to microbodies or formed eIF2B 
bodies. WT quantification from figure 3.1 included in graph for comparison. Overnight starter 
cultures were diluted in SCD media to 0.2 OD600
 and incubated at 30°C with shaking until 
exponential growth was reached. N=3, error bars are representative of SD. Ns = not significant, 
* P=<0.05, ** P=<0.01, *** P=<0.001, **** P=<0.0001. 
A. 
B. 
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3.2. Discussion 
3.2.1. eIF2Bα is required for the formation of eIF2B bodies 
These results show for the first time that eIF2Bα is necessary for the formation 
of eIF2B bodies. In the absence of eIF2Bα, localisation was completely abolished, 
exclusively dispersing eIF2B throughout the cytoplasm (Fig. 3.2). Consistent with 
previous data, cells could not respond to eIF2B-dependent regulation when eIF2Bα 
was deleted (Fig. 3.5). The dispersal of eIF2B bodies and inability to regulate eIF2B 
activity suggests the two phenotypes may be linked. 
eIF2B crystal structure data derived from S. pombe represents the most 
complete structure of eIF2B to-date (Kashiwagi et al., 2016). Whilst S. cerevisiae 
regulatory, catalytic and VWM mutations have been investigated within this chapter, a 
substantial proportion of the mutated residues are conserved within S. pombe, 
potentially highlighting the importance of these residues to eIF2Bα’s structure and 
function (Fig. 3.17). Crystal structure data from S. pombe showed eIF2Bα contains 
several β and δ binding pockets (Fig. 3.18). It is therefore plausible that dispersed 
Gcd1-GFP is representative of tetrameric εγδβ complexes, as previous data showed 
holocomplex destabilisation when eIF2Bα is absent (Wortham et al., 2014). However, it 
should be noted that these studies used overexpressed eIF2B subunits purified from E. 
coli and may not represent subcomplexes in vivo. 
106 
 
 
 
 
 
 
 
Figure ‎3.17 eIF2Bα sequence alignment between Human, S. pombe and S. cerevisiae. The 
majority of regulatory (purple), catalytic (blue) and VWM (orange) mutations characterised 
herein are conserved between species, with the only major exceptions being N80D and 
303//305Δ. Asterisks highlight conserved amino acids, whilst : and . represent amino acids that 
are highly or somewhat similar, respectively. 
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Figure ‎3.18 eIF2Bα contains eIF2Bβ/δ docking sites important for decameric stabilisation. 
The eIF2Bα homodimer stabilises two eIF2Bεγδβ heterotetramers through various pockets on 
the eIF2Bα distal face, which interact with eIF2Bβ (pink) and eIF2Bδ (green). 
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3.2.2. Insights into eIF2B body formation from regulatory mutations 
 eIF2Bα regulatory mutants were studied to determine their impact on eIF2B 
localisation when eIF2B could not be regulated. The phenotypical characteristics of 
these mutants found within this chapter are summarised in Table #. The regulatory 
mutants used in this study were unable to respond to amino acid starvation (Fig. 3.8). 
This could either be due to eIF2α-P being unable to bind and interact with eIF2Bα or 
eIF2Bα could be absent from the holocomplex, rendering any interaction redundant. 
Data derived from the regulatory mutants were strikingly similar to the null strain, as 
they were unable to form eIF2B bodies and instead, resulted in eIF2B being dispersed 
throughout the cytoplasm (Fig. 3.9). Growth rates were different between the 
regulatory mutants and the null strain (Fig. 3.7), although this could be attributed to 
the overexpression vector with which the regulatory mutations are present on 
(Yoshikawa et al., 2011). Considering the phenotypic similarities between the null 
strain and the regulatory mutants, eIF2Bα’s ability to bind tetrameric complexes may 
be compromised in the regulatory mutants tested in this chapter. 
 Crystal structure data derived from S. pombe highlighted that some regulatory 
mutations are present on the distal face of eIF2Bα. As β and δ binding pockets are 
present here, mutations located on the distal face could explain why eIF2Bα is unable 
to incorporate itself into the holocomplex, subsequently preventing eIF2B localisation. 
The F240I substitution may affect interactions with eIF2Bδ, whilst the mutants T291P 
and S293R may detrimentally influence interactions with both β and δ (Fig. 3.19). 
Interestingly however, other regulatory mutations do not seem to affect β and δ 
interactions or even span across the distal face. F73L and N80D appear to be near a β 
binding pocket, but only intra-protein interactions seem to be present. These two 
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residues may be important for eIF2Bα’s folding and substituting these amino acids may 
result in a conformational change that prevents nearby α-β interactions.  
Although T41A and E44K/V may also be important for intra-protein interactions 
and therefore protein folding, they are not present along α-β or α-δ interfaces. Whilst 
there is no evidence to suggest a reason why E44V/K may affect the ability of eIF2Bα 
to incorporate itself into the holocomplex, the converse may be true for T41A. 
Previous work investigating translational control in response to butanol highlighted 
Gcn3p amino acid substitutions that influence S. cerevisiae’s response to butanol 
(Taylor et al., 2010). Butanol is a potent inhibitor of translation initiation which leads to 
the derepression of GCN4. Whilst butanol resistance and sensitivity were originally 
attributed to various alleles of Gcd1p/eIF2Bγ (Ashe et al., 2001), mutations in Gcn3p 
were also identified which conferred resistance to butanol. In the study by Taylor et 
al., (2010), a T41K mutation was identified which increased resistance to butanol, 
whilst the wild-type and gcn3 null strains remained sensitive to the translation 
inhibition caused by butanol. Although the small alanine (A) and the basic lysine (K) are 
characteristically dissimilar, both T41A and T41K Gcn3p mutants were unable to 
localise eIF2B and resulted in eIF2B being dispersed throughout the cytoplasm. 
Another explanation for the lack of localisation within the T41A mutant is that the 
threonine residue is directly involved in aggregating eIF2B. Although, this would also 
mean that there is some relationship between localisation and regulation, which 
remains to be elucidated.  
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Table ‎3.2- Phenotypes observed from characterised gcn3 regulatory mutants 
    gcn3 Regulatory Mutants 
 
Wild 
Type 
gcn3::LEU2 
pGCN3 
2μ 
T41A 2μ E44V 2μ E44K 2μ F73L 2μ N80D 2μ F240I 2μ T291P 2μ S293R 2μ 
Growth 
Rate1 
++++ ++++ ++ N/A N/A + N/A + N/A + N/A 
Translational 
Regulation2 
Yes No Yes N/A N/A No N/A No N/A No N/A 
eIF2B 
Localisation3 
eIF2B 
Bodies 
Dispersed 
eIF2B 
Bodies 
Dispersed Dispersed Dispersed Dispersed Dispersed Dispersed Dispersed Dispersed 
N/A: Not analysed 
1As determined by growth curves (see Figure 3.7) 
2As determined by polysome profiling (see Figure 3.8) 
3As determined by confocal microscopy (see Figure 3.9)
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Figure ‎3.19 eIF2Bα regulatory mutants affect α-β and α-δ interactions, but not exclusively. 
Several eIF2Bα regulatory mutations (purple) are present on the distal face of eIF2Bα, 
therefore affecting important interactions with eIF2Bβ (pink) and eIF2Bδ (green). Other 
regulatory mutants are either in proximity of these pockets (i.e. F73L) or far away (i.e. T41A, 
E44K/V). S. cerevisiae amino acid residues are in brackets, whilst the S. pombe homologous 
residue are above. 
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3.2.3. Insights into eIF2B body formation from catalytic mutations 
 eIF2Bα catalytic mutants were also analysed to determine localisation when 
eIF2B GEF activity was hindered (Hannig et al., 1990). Catalytic mutants were unable to 
fully form the singular eIF2B body and instead, localised eIF2B to multiple smaller foci 
termed microbodies (Fig. 3.12). As microbodies were rarely seen within the wild-type, 
it is possible microbody foci are intermediate eIF2B aggregates, whereby the catalytic 
mutations result in a conformational change that prevents eIF2B from fully localising. 
Interestingly, 303//305Δ contained subpopulations of all three phenotypes observed, 
where eIF2B was dispersed or localised to microbodies and eIF2B bodies. In this 
instance, there could be a decrease in the rate of eIF2B localisation, as most other 
catalytic mutants predominantly formed microbodies, indicating that they cannot 
localise eIF2B beyond this intermediary structure. Although 303//305Δ had some 
characteristics indicative of a catalytic mutant, such as higher levels of 80S monosomes 
(a consequence of translation being initiated less frequently) (Fig. 3.11), 303//305Δ did 
not display any increases in tolerance and instead, grew analogously to wild-type (Fig. 
3.10B). Considering the contradiction between polysome analyses and 3-AT spot 
plates, it is possible that alleles elsewhere in the eIF2B complex (within the background 
strain) may be affecting GCN4 expression. Although amino acid substitutions in one 
eIF2B subunit have been shown to affect other subunits, therefore influencing eIF2Bs 
characteristics, a mechanism that affects GCN4 expression without affecting eIF2B 
catalytic activity remains to be found. 
 eIF2B microbody formation has been previously observed when Ifa38p 
was deleted (Browne et al., 2013). Ifa38p is an enzyme involved in the very long fatty 
acid chain (VLFA) synthesis pathway with no current evidence to suggest a role in 
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translation initiation or translational control. However, upon deletion of ifa38 the 
eIF2B body became fragmented into several smaller cytoplasmic foci. Interestingly, the 
change in localisation did not impact upon eIF2Bs catalytic or regulatory functions and 
did not disperse eIF2B throughout the cytoplasm completely, possibly indicating that 
the interaction between eIF2Bε/γ and Ifa38p may be required for the stability of eIF2B 
bodies. In contrast to our study, microbody formation correlates with a decrease in 
eIF2B activity, which is likely to be caused by direct influences on the conformation of 
eIF2B. Catalytic mutations could result in a conformational change that impedes 
interactions with Ifa38p as well as other unidentified proteins that may interact with 
eIF2B, which may affect the localisation, function and regulation of eIF2B.  
 Structurally, the catalytic mutants appear to be positioned in different regions 
to the regulatory mutants (Fig. 3.20). Although most catalytic mutations are located on 
eIF2Bα’s distal face, they do not seem to directly interact with the β or δ subunits. 
Instead, most amino acid residues affected seem to be important for intra-protein 
interactions, therefore affecting the conformational structure of eIF2Bα. The only 
exception to this is R104K, which may be able to form hydrogen bonds with L125 
within eIF2Bβ. R104K does not produce a regulatory phenotype because the arginine is 
substituted for a lysine. As both amino acids are characteristically similar and are 
usually favoured substitutions, it is possible that the lysine can still interact with the 
leucine within eIF2Bβ. 
114 
 
 
Table ‎3.3 - Phenotypes observed from characterised gcn3 catalytic mutants 
    gcn3 Catalytic Mutants 
 Wild Type gcn3::LEU2 
pGCN3 
Cen 
AA25,26VV 
Cen 
A26T Cen D71N Cen R104K Cen E199K Cen V295F Cen 
303//305Δ 
Cen 
Growth 
Rate1 
++++ ++++ ++++ ++ N/A N/A N/A ++++ N/A ++++ 
Growth on 
3AT 
N/A None Inhibited ++ N/A N/A N/A +++ N/A Inhibited 
Translational 
Regulation2 
Yes No Yes Yes N/A N/A N/A No N/A Yes 
eIF2B 
Localisation3 
eIF2B 
Bodies 
Dispersed 
eIF2B 
Bodies 
Microbodies Microbodies Microbodies Microbodies Microbodies Microbodies 
eIF2B Bodies/ 
Microbodies 
N/A: Not analysed 
1As determined by growth curves (see Figure 3.10) 
2As determined by polysome profiling (see Figure 3.11) 
3As determined by confocal microscopy (see Figure 3.12)
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Figure ‎3.20 eIF2Bα catalytic mutants may affect intra-protein interactions. For the most part, 
the eIF2Bα catalytic mutations (blue) seem to affect intra-protein interactions, accounting for a 
conformational change that hinders eIF2Bs GEF activity. The R104K mutation however, seems 
to interact with the beta subunit (pink). S. cerevisiae amino acid residues are in brackets, 
whilst the S. pombe homologous residue are above. 
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3.2.4. Insights into eIF2B body formation and function from VWM 
 mutations 
The eIF2Bα regulatory and catalytic mutations were originally selected based 
on the potency of their phenotypes and may represent extreme situations. Naturally 
occurring missense mutations causative of the human disease VWM were investigated 
to determine their effect on the localisation of eIF2B. Although phenotypical 
correlations were identified between eIF2B localisation and either regulatory 
mutations (where eIF2B is dispersed) or catalytic mutations (where eIF2B localises to 
microbodies), some VWM mutations seem to be more complex.  
Previous characterisation of the N209Y mutation identified the substitution 
acted analogously to the null strain, thus representing a regulatory mutant (Richardson 
et al., 2004). Polysome profiles (Fig. 3.15) and 3-AT spot plates (Fig. 3.14B) in addition 
to the dispersed eIF2B localisation (Fig. 3.16) supported these conclusions. F240V also 
resulted in a similar regulatory phenotype, although intriguingly localisation was not 
completely dispersed as a small subset of cells formed eIF2B bodies (Fig. 3.16). The 
V184D mutant also gave unexpected results with the 3-AT plates suggesting a 
regulatory mutant phenotype while the polysome analysis resulted in a wild-type 
response to the stress. These results were additionally confounded by the localisation 
data, which resulted in the formation of microbodies; a characteristic associated with a 
decrease in catalytic activity. Currently, there is no evidence to support a reason 
behind these contradicting phenotypes, thus further investigation is warranted. The 
remaining VWM mutations did not share any similarities with either phenotypes that 
previously affected eIF2B localisation, even though a slight decrease in the number of 
eIF2B bodies was observed for K111E, which was exacerbated in Y274C.  
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Whilst N209Y and F240V clearly produced regulatory phenotypes, how K111E, 
V184D and Y274C affect eIF2B leading to the pathogenesis of VWM remained elusive. 
Structurally, most VWM mutations (apart from K111E) are distinctively different from 
the regulatory/catalytic mutants and are in close proximity to the α-α interface (Fig. 
3.21), possibly providing an explanation for the varied phenotypes in the V184D or the 
lack of phenotypical differences from Y274C. The VWM mutant F240V mirrored the 
regulatory mutant F240I, thus similar interactions with Q393 within eIF2Bδ may be 
perturbed. N209Y resides within a hydrophobic pocket responsible for binding 
phosphorylated serine 51 within eIF2α in response to cellular stress. Subsequently, 
previously published data suggests eIF2-P cannot interact with eIF2Bα (Kashiwagi et 
al., 2014). Considering that the N209Y mutant dispersed the localisation of eIF2B, data 
presented here also suggests an unknown link between regulation and localisation, as 
eluded to previously. Conversely, experiments performed using HEK293 cells showed 
eIF2B could still bind eIF2-P in the presence of the N208Y (human) mutation (Wortham 
and Proud, 2015). Moreover, the mutation increased eIF2Bs GEF activity by 40 %. 
Although notable differences between yeast and human eIF2B could explain these 
phenotypical differences, it should be noted that these experiments were conducted 
using transiently transfected cells where overexpressed proteins were combined with 
wild-type versions, and therefore may not represent eIF2B complexes in vivo. The 
VWM mutant V184D may interact with Q228 on the opposing eIF2Bα subunit, thus 
representing a unique mutation within this study. Considering the conflicting 
phenotypes observed, it is possible the α-α interaction may be perturbed producing 
either pentameric complexes (εγδβα) or nonameric complex (ε2γ2δ2β2α). In addition to 
eIF2B nonamers being previously observed, data generated using HEK293 cells showed 
V183D reduced interaction of eIF2Bα with the complex, albeit only moderately  
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(Wortham and Proud, 2015). K111E and Y274C do not seem to be involved in any 
subunit-subunit interactions and may only be required for intra-protein interactions or 
protein folding, possibly explaining why eIF2B function/regulation did not seem to be 
impaired. Whilst K111E analyses are novel to this study, Y274C produced similar 
observations in human HEK293 cells.  
A clear correlation seems to exist between localisation, the type of mutation 
(i.e. regulatory or catalytic) and where the mutated residue exists. Indeed, the 
regulatory mutants seem to prevent eIF2B regulation, localisation and subsequently 
eIF2Bα incorporation. The catalytic mutants seem to affect intra-protein interactions, 
subsequently affecting the catalytic activity of eIF2B and localisation. The VWM 
mutations V184D and Y274C did not correlate with either of the aforementioned 
phenotypes. Hence, further analyses of these foci may provide novel observations that 
may help explain the molecular pathogenesis of VWM disease. 
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Table ‎3.4 - Phenotypes observed from characterised gcn3 VWM mutants 
   gcn3 VWM Mutants 
 Wild Type gcn3::LEU2 
pGCN3 
CEN6ARS4 
K111E V184D N209Y F240V Y274C 
Growth Rate1 ++++ ++++ ++++ ++++ ++++ ++++ +++ +++ 
Growth on 3AT N/A None Inhibited Inhibited 
Severely 
Inhibited 
Severely 
Inhibited 
Severely 
Inhibited 
Inhibited 
Translational 
Regulation2 
Yes No Yes Yes N/A N/A N/A No 
eIF2B 
Localisation3 
eIF2B Bodies Dispersed eIF2B Bodies eIF2B Bodies Microbodies Dispersed 
[Reduced] 
eIF2B Bodies 
[Reduced] 
eIF2B Bodies 
N/A: Not analysed 
1As determined by growth curves (see Figure 3.14) 
2As determined by polysome profiling (see Figure 3.15) 
3As determined by confocal microscopy (see Figure 3.16)
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Figure ‎3.21 eIF2Bα VWM mutants are in close proximity of the α-α interface. With the 
exception of K111E, the eIF2Bα VWM mutations (orange) are in close proximity to the 
dimerization interface. F240V seems to interact with eIF2Bδ (green), whilst V184D may 
interact with the other α subunit (black). The remaining mutations may be important for intra-
protein interactions, although no hydrogen bonding could be seen for Y274C. S. cerevisiae 
amino acid residues are in brackets, whilst the S. pombe homologous residue are above. 
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4. eIF2 shuttling is altered by mutations 
 which disrupts the eIF2B body 
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4.1. Introduction 
 eIF2B is a complex enzyme unique amongst GEFs, comprising of multiple 
subunits that exert various functions (i.e. GEF and GDF) and is subject to regulation. To 
measure GEF activity, recombinant protein purified from bacterial expression systems 
is typically used in conjunction with isotopically or fluorescently labelled GTP (Jennings 
et al., 2013, Liu et al., 2011, Jennings and Pavitt, 2010, Wortham and Proud, 2015). 
Previous studies utilising this in vitro biochemical assay have produced valuable 
insights into several aspects of eIF2B, including the effects of VWM mutations (Liu et 
al., 2011, Wortham and Proud, 2015). It is generally accepted that VWM mutations 
decrease the catalytic activity of eIF2B, leading to the cell being in a constant state of 
stress with constitutive expression of stress-specific mRNA transcripts (i.e. GCN4 in 
yeast, ATF4 in humans) (Pavitt et al., 1997). However, some studies argue that this may 
not always be the case. For instance, analysis of eIF2Bα VWM mutations showed that 
N209Y increased eIF2B GEF activity by 40 % while the mutant P278R had no effect on 
eIF2B activity, holocomplex formation or eIF2/eIF2-P binding (Wortham and Proud, 
2015). Moreover, Liu et al., (2011) showed that catalytic deficits caused by VWM 
mutations do not correlate with the phenotypes observed within patients. It is possible 
that although the in vitro biochemical assay may be useful to analyse some mutations, 
it may not be informative for all mutations. Other proteins (i.e. Ifa38p) have also been 
shown to interact with eIF2B (Browne et al., 2013). Although the purpose behind 
eIF2B-Ifa38p interactions remain unclear, other interactors of eIF2B have been 
implicated, all of which are omitted during in vitro analysis (Babu et al., 2012). Thus, a 
method of analysing eIF2B activity in vivo is necessary, ensuring the accurate 
measurement of canonical eIF2B complexes in the presence of required co-factors. 
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 Fluorescence recovery after photobleaching (FRAP) is a technique that analyses 
the movement of fluorescently tagged intracellular proteins. By irreversibly bleaching 
an area of interest, the movement of non-bleached molecules into the foci can be 
measured to gather valuable information, such as the ratio of mobile to immobile 
molecules and the half-time for fluorescence recovery (Fig. 4.1). During the original 
study describing eIF2B bodies, FRAP was highlighted as a novel method to measure 
eIF2B activity in vivo (Campbell et al., 2005). FRAP analyses of GFP tagged eIF2B and 
eIF2 subunits identified that the former remains resident within the discrete 
cytoplasmic foci, whilst the latter shuttled into and out of the eIF2B body. Using three 
different methods, Campbell et al., (2005) highlighted that the shuttling of eIF2 
throughout the eIF2B foci could potentially be used to measure the catalytic activity of 
eIF2B. Firstly, cells depleted for amino acids displayed reductions in mobile eIF2 and 
half-time recovery as well as a two-fold increase of eIF2 within the foci. These results 
correlated with an increase of eIF2α-P, which is known to bind eIF2B with high affinity, 
inhibiting GEF activity. Secondly, under amino acid stress Gcn2p phosphorylates S51 
within eIF2α which then binds and inhibits eIF2B. Using two constitutively active 
Gcn2p mutants, eIF2 shuttling was shown to decrease in tandem with respective 
increases in eIF2α-P levels. Finally, using the Gcd6p (eIF2Bε) mutant F250L, the group 
highlighted eIF2 dynamics dramatically decreased in the presence of a mutation that 
decreased the catalytic activity of eIF2B. Together, these experiments provided strong 
evidence to suggest that eIF2 shuttling is dependent on eIF2B activity, whereby eIF2-
GDP shuttles into the foci for GDP-GTP exchange to occur. Moreover, in-line with 
known mechanisms of eIF2B regulation, eIF2α-P was shown to remain resident within 
the eIF2B body as opposed to shuttling through it. Of importance to the present study, 
the authors showed FRAP could be utilised as an in vivo method to analyse the 
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catalytic activity of eIF2B in the presence of a mutated subunit. Thus, the main aim 
within this chapter was to analyse eIF2 dynamics within eIF2Bα/Gcn3p mutants 
characterised in the previous chapter.  
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Figure ‎4.1 Schematic of measuring eIF2B activity by analysing eIF2 recovery within foci, via 
FRAP.  (A) A cell containing an eIF2B body is selected. The co-localised eIF2, which contains a 
yeGFP tag is bleached. Multiple images are then taken over time to measure the time needed 
for eIF2 to recover. (B) An example of a one-phase association graph depicting the different 
stages of FRAP as well as the various measurements that can be extrapolated. Marked in 
dashed lines; the t½ time defines the half-time for eIF2 to fully recover. Marked by a grey line; 
mobile eIF2 defines the amount of mobile eIF2 within the eIF2B body. Both values are 
important as a rate of recovery may be calculated. 
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4.2. Results 
4.2.1. Amino acid starvation decreases the rate of eIF2 shuttling through 
 eIF2B bodies  
 FRAP analysis was previously validated as a measurement of eIF2B activity by 
subjecting cells to amino acid starvation, leading to the phosphorylation of eIF2α that 
attenuates eIF2B activity and ultimately, the inhibition of translation initiation 
(Campbell et al., 2005). To ensure the background strain behaved similarly to data 
published previously, exponentially growing cultures of wild-type (yMK883) containing 
endogenously GFP tagged SUI2 (eIF2α) were assessed in complete minimal media and 
media lacking amino acids. Following the bleaching step, eIF2 recovery was measured 
every 1.8 seconds over 25 cycles of recovery. For each eIF2B foci analysed, background 
fluorescence was subtracted from the fluorescent recovery, which was then 
normalised to total cellular fluorescence. Generated data was fitted to a one-phase 
association curve to find the percentage of eIF2 that was mobile, as well as half-time 
recovery. As fluctuations in the level of mobile eIF2 may influence the time required 
for eIF2 to recover, the rate of eIF2 recovery was calculated which took both 
measurements into consideration. eIF2α-P accumulates within eIF2B foci following 
cellular stress to reduce the catalytic activity of eIF2B (Campbell et al., 2005), 
therefore, total eIF2 content within eIF2B foci was measured to correlate decreases in 
eIF2 shuttling with eIF2α-P residency.  
 FRAP analysis was carried out on a Sui2p-GFP tagged strain, under normal 
conditions and under amino acid starvation for 30 minutes. Representative images of 
pre-bleach, post-bleach and recovery are shown in. Fig 4.2A, along with the one-phase 
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association curve used to determine percentage mobile eIF2 as well as half-time 
recovery. Under normal conditions, eIF2 recovery within the bleached region was rapid 
with a t½ of 2.3 seconds (Fig. 4.2A and C). eIF2 shuttling decreased following amino 
acid depletion for 30 minutes, with a prolonged t½ of 5.7 seconds (Fig. 4.2A and C). A 
slight decrease was observed in the amount of mobile eIF2, indicating that less eIF2 
was shuttling into these foci (Fig. 4.2B). The rate of recovery was significantly reduced, 
decreasing by approximately 58 %, highlighting a dramatic reduction in the catalytic 
activity of eIF2B (Fig. 4.2C). In tandem with the reduction in mobile eIF2, total eIF2 
content within eIF2B bodies increased, indicative of phosphorylated eIF2 taking 
residency within the foci, subsequently reducing eIF2Bs activity. 
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Figure ‎4.2 eIF2 recovery decreases following amino acid starvation. FRAP analysis of SUI2-
yeGFP (yMK883) under amino acid starvation. (A) Live-cell images representing the pre-
bleach, post-bleach and recovery stages as well as a graph displaying eIF2 recovery over time. 
A * denotes time at which the recovery image was from. (B) Bar chart representing the mobile 
eIF2 within the foci as a percentage. (C) Bar chart representative of half the time needed for 
eIF2 to fully recover. (D) Bar chart representing fluorescence recovery per second. (E) Bar chart 
representing eIF2 content within eIF2B foci. Starter cultures were diluted to 0.2 OD600 in SCD 
media and incubated at 30°C with shaking until exponential growth was reached. Cells were 
pelleted and resuspending in media without amino acids before being further incubated for 30 
minutes. Data are representative of 25 cells, n=3, error bars are representative of SEM, ns = 
not significant, * P=<0.05, ** P=<0.01, *** P=<0.001, **** P=<0.0001. 
  
* 
A. 
B. C. 
D. E. 
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4.2.2. Generation of GCN4-LacZ fusion strain to assess eIF2B activity 
 FRAP assesses the catalytic activity of eIF2B by exploiting the movement of eIF2 
into and out of the body, presumably for GDP-GTP exchange. As this is a novel method 
for potentially measuring in vivo GEF activity, it was important to correlate the 
decrease in eIF2 shuttling with biochemical methods previously used to indicate 
reduced GEF activity. Sequestration of eIF2B activity derepresses GCN4, which is 
normally repressed under physiological conditions by the presence of four uORFs (see 
section 1.2.1.1.1) (Hinnebusch, 1985). To correlate eIF2B activity with GCN4 
repression, a strain was constructed that could analyse Gcn4p expression 
quantitatively via LacZ assay. An integration vector containing GCN4-LacZ-TRP1 
(pAV1729) was linearised by incubation with SnaBI, before being transformed into 
yMK467; a parental strain to the wild-type (yMK883) previously analysed by FRAP. 
Transformants were selected by incubation on SCD lacking tryptophan. Any 
transformants that were present will have genomically integrated the GCN4-LacZ-TRP1 
because the integration vector does not contain a yeast origin of replication (Dever et 
al., 1992). gcn3 was deleted within the newly created strain by substitution with HIS3 
as previously described. 
 Exponentially growing cultures of GCN4-LacZ-TRP1 (ySC87) and GCN4-LacZ-
TRP1 gcn3::HIS3 (ySC88) were subjected to amino acid starvation for 30 minutes 
before protein extracts were assayed to evaluate Gcn4p-LacZ expression levels. Amino 
acid starvation increased Gcn4p expression by 50 % within wild-type cells (Fig. 4.3). In 
contrast, the gcn3 null strain could not derepress GCN4 as no significant differences 
were observed between the two conditions. These results confirm that the exposure 
of cells to amino acid starvation induces the derepression of Gcn4p. Moreover, they 
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show a relationship between eIF2 shuttling and GCN4 derepression, as both responded 
to amino acid starvation which is dependent upon eIF2B regulation. Therefore, these 
results validate analysing eIF2 dynamics as a measurement of eIF2B activity under 
similar conditions. 
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Figure ‎4.3 Gcn4p expression is derepressed during amino acid starvation. LacZ assay using 
GCN4-LacZ (ySC85) and GCN4-LacZ gcn3::HIS3 (ySC86) to analyse Gcn4p expression in 
response to amino acid starvation. Starter cultures were diluted to 0.2 OD600 in SCD media and 
incubated at 30°C with shaking until exponential growth was reached. Cultures were halved, 
pelleted and one aliquot was resuspended in media without amino acids before being further 
incubated for 30 minutes. Following this, protein was extracted by bead beating and used the β-
galactosidase activity was measured to assess Gcn4p expression. Protein was quantified by BCA assay. 
n=3, error bars are representative of SD, ns = not significant, * P=<0.05, ** P=<0.01, *** 
P=<0.001, **** P=<0.0001. 
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4.2.3. eIF2Bα catalytic mutants de-repress Gcn4p expression 
 In Chapter 3 data was presented which showed that gcn3 catalytic mutants 
localised eIF2B to microbodies. As discussed in section 3.1.4.3, reduced eIF2B catalytic 
activity leads to the derepression of GCN4, which eventually results in the upregulation 
of genes involved in amino acid biosynthesis. To determine Gcn4p expression levels in 
the presence of a gcn3 catalytic mutation, quantitative LacZ assays were carried out 
for the three mutants AA25,26VV, E199K and AA 303//305Δ. In addition to the 
plasmid-borne low-copy GCN3 wild-type, the three mutants were exogenously 
expressed in the GCN4-LacZ-TRP1, gcn3::HIS3 (ySC86) strain before protein extracts 
were used for LacZ assays. 
 The gcn3 catalytic mutants AA25,26VV and E199K lead to significant increases 
in the levels of Gcn4p (Fig. 4.4). AA25,26VV produced a 7-fold increase in Gcn4p levels, 
whilst E199K lead to a 10-fold increase, possibly demonstrating differing reductions in 
eIF2B activity. Gcn4p levels failed to fluctuate significantly when the AA 303//305Δ 
mutation was present, implying eIF2B activity may be normal within this mutant. 
Overall, these results show that AA25,26VV and E199K reduce the catalytic activity of 
eIF2B, whilst AA 303//305Δ may not. 
133 
 
 
 
 
 
 
 
Figure ‎4.4 LacZ assay to assess Gcn4p expression in the presence of Gcd- gcn3 mutations. 
Three Gcd- gcn3 mutants were exogenously expressed in the GCN4-LacZ, gcn3::HIS3 (ySC86) 
strain. Cultures were diluted to 0.2 OD600 and incubated at 30°C with shaking until exponential 
growth was reached. Total protein was extracted and the β-galactosidase activity was 
measured to assess Gcn4p expression. Protein concentration was determined via BCA assay. 
n=3, error bars are representative of SD, ns = not significant, * P=<0.05, ** P=<0.01, *** 
P=<0.001, **** P=<0.0001. 
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4.2.4. eIF2B microbodies display reduced eIF2 shuttling 
 As these catalytic mutants showed decreased eIF2B activity (via their increased 
Gcn4p levels) and displayed eIF2B microbodies, it was hypothesised that disruption of 
the large eIF2B body into microbodies may decrease the shuttling of eIF2 through 
eIF2B. To test this hypothesis, FRAP analysis was carried out on the mutants 
AA25,26VV, E199K and AA 303//305Δ. As the mutant AA 303//305Δ also formed eIF2B 
bodies as well as microbodies (see section; 3.1.4.4; Fig. 3.12), this catalytic mutant 
represented a unique opportunity to investigate differences in the shuttling of eIF2 
between the two types of eIF2B localisation. The plasmid-borne catalytic mutants, 
along with the corresponding wild-type GCN3 low-copy Cen plasmid, were 
exogenously expressed in the SUI2-GFP gcn3::LEU2 (ySC16). During FRAP analyses of 
eIF2B microbodies, eIF2 shuttling was measured within two or more microbodies and 
averaged per cell. 
 Representative images from the various stages of FRAP, as well as the 
individual one-phase association curves highlighting differences in eIF2 kinetics are 
shown in Figure 4.5. Analysis of these data sets showed that for all the mutants tested, 
eIF2 shuttling within microbodies was slower than eIF2 shuttling within eIF2B in wild-
type cells (Fig. 4.6). Interestingly the percentage mobile eIF2 did not deviate 
significantly within any of the catalytic mutations tested, indicating similar amounts of 
mobile eIF2 between wild-type and mutants (Fig. 4.6A). AA25,26VV and E199K 
increased the half-time for eIF2 recovery by 2 seconds in comparison to the plasmid-
borne wild-type GCN3 (Fig. 4.6B). Expectedly, rates of recovery inversely correlated for 
both mutants, showing a 33.3 % decline in eIF2 recovery per second (Fig. 4.6C). 
Intriguingly, eIF2 shuttling through eIF2B bodies within the AA 303//305Δ mutant was 
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comparable to wild-type throughout, with no significant deviations observed. 
Conversely however, eIF2 shuttling through microbodies within the same mutant 
declined similarly to AA25,25VV and E199K. Total eIF2 content within eIF2B foci was 
not analysed for the catalytic mutants. Nonetheless, FRAP analyses of eIF2 dynamics 
herein suggest eIF2B localisation may affect the catalytic activity of eIF2B. 
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Figure ‎4.5 FRAP analysis of gcn3 Gcd- mutations. Three gcn3 Gcd- mutations (AA25,26VV 
(pAV1239), E199K (pAV1244) and 303//305Δ (pAV1268)) as well as the GCN3 Cen plasmid 
(pAV1170) were exogenously expressed in SUI2-yeGFP gcn3::LEU2 (ySC16) to measure eIF2 
recovery within eIF2B bodies. Both eIF2B body and microbody foci were analysed for the 
303//305Δ mutant. Live-cell images representing the pre-bleach, post-bleach and recovery 
stages as well as a graph representing eIF2 recovery over time are shown. A * denotes time at 
which the recovery image was from. Data representative of 25 cells, n=3, error bars are 
representative of SEM. 
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Figure ‎4.6 eIF2 shuttles slower through eIF2B microbodies in catalytic mutants. (A) Bar chart 
representing the mobile eIF2 within the foci as a percentage. (B) Bar chart representative of 
half the time needed for eIF2 to fully recover. (C) Bar chart representing eIF2 content within 
eIF2B foci. Data are representative of 25 cells, n=3, error bars are representative of SEM, ns = 
not significant, * P=<0.05, ** P=<0.01, *** P=<0.001, **** P=<0.0001. 
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4.2.5. The effect of eIF2Bα VWM mutants on Gcn4p levels  
 Within chapter 3, the impact of VWM missense mutations on eIF2B localisation 
was assessed, with a range of phenotypes observed. The VWM mutants V184D, N209Y 
and F240V were shown to be regulatory mutants, whilst K111E and Y274C were 
analogous to wild-type. Qualitative assessment of eIF2B catalytic activity via 3-AT spot 
plates indicated there were no deficits in the catalytic activity of eIF2B when any of the 
VWM mutations were present. However as this was not a quantitative assessment of 
the GEF activity of eIF2B, Gcn4p levels were investigated via the LacZ assay. In addition 
to the wild-type GCN3 CEN6ARS4 low-copy plasmid, the VWM mutants were 
exogenously expressed in the GCN4-LacZ-TRP1, gcn3::HIS3 (ySC86) before protein 
extracts from exponentially growing cultures were used for LacZ assays. 
 Interestingly, Gcn4p levels within the VWM mutations remained similar to wild 
type, with slight fluctuations from V184D and Y274C (Fig. 4.7). These results suggest 
that under steady state conditions the majority of the VWM mutations do not induce 
Gcn4p expression, with the exception of the Y274C mutant where a 20 % increase was 
observed.  
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Figure ‎4.7 LacZ assay to assess Gcn4p expression in the presence of VWM gcn3 mutations. 
Five gcn3 VWM mutants were, as well as the WT GCN3 CEN6ARS4 plasmid, were exogenously 
expressed in the GCN4-LacZ, gcn3::HIS3 (ySC86) strain. Cultures were diluted to 0.2 OD600 and 
incubated at 30°C with shaking until exponential growth was reached. Total protein was 
extracted and the β-galactosidase activity was measured to assess Gcn4p expression. Protein 
concentration was determined via BCA assay. n=3, error bars are representative of SD, ns = not 
significant, * P=<0.05, ** P=<0.01, *** P=<0.001, **** P=<0.0001. 
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4.2.6. FRAP analysis of eIF2Bα VWM mutations 
 During the analysis of eIF2B localisation in chapter 3, N209Y exclusively 
dispersed eIF2B throughout the cells, hence FRAP analysis was not performed on this 
mutant as there were no eIF2B cytoplasmic locus to focus on. However, the remaining 
mutations localised eIF2B either to microbodies (V184D) or to eIF2B bodies in varying 
numbers (K111E, F240V and Y274C) (see section 3.2.5.2; Figure 3.16). Although these 
mutations cause a range of disease severities in humans, under steady state growth in 
yeast, no decrease in cell growth was observed (Fig. 3.14A). FRAP was performed to 
investigate eIF2 dynamics when VWM mutations were present. In addition to the wild-
type GCN3 low-copy CEN6ARS4 plasmid, the VWM mutations were exogenously 
expressed in the SUI2-GFP, gcn3::LEU2 (ySC16) strain for FRAP analysis. 
 Although eIF2B bodies were present within the mutants V184D and F240V, 
eIF2α-GFP did not localise to discrete cytoplasmic bodies and instead was dispersed 
throughout the cytoplasm (Fig. 4.8). Therefore FRAP analysis was not carried out on 
these mutant strains. This is despite eIF2B localising to microbodies when V184D was 
present, or eIF2B bodies when F240V was present, although F240 localised eIF2B at 
lower levels than wild-type (see section 3.2.5.2, Fig. 3.16).  
 However eIF2α-GFP did localise to eIF2B bodies in the presence of the mutants 
K111E and Y274C, therefore FRAP analysis was carried out to determine the rate of 
eIF2 shuttling in the presence of these mutations. Representative images from the 
various stages of FRAP are displayed in Figure 4.10, as well as one-phase association 
curves representing the recovery of eIF2 within eIF2B foci. Mobile eIF2 increased by 12 
% when K111E was present, whilst the Y274C mutation increased by 24.6 % (Fig. 
4.11A). Half-time recovery of eIF2 increased by 2.9 and 5.2 seconds for K111E and 
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Y274C respectively (Fig. 4.11B). Despite half-time recovery being dramatically 
increased, recovery rates of eIF2 per second decreased only slightly for both mutants 
(Fig. 4.11C). Interestingly, whilst no change was observed for the K111E mutant, eIF2 
content within eIF2B foci increased by 4.5 % in the Y274C mutant (Fig. 4.11D). These 
results show that VWM mutations may affect the shuttling of eIF2 through the eIF2B 
body in different ways than the Gcn3p catalytic mutants analysed previously. 
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Figure ‎4.8 V184D and F240V do not localise eIF2 within eIF2B foci. Exponential cultures of 
GCD1-GFP gcn3::LEU2 (yMK1402) and SUI2-GFP gcn3::LEU2 (ySC16) containing the plasmid-
borne V184D and F240V VWM mutants were live-cell imaged via confocal microscopy. 
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Figure ‎4.9 FRAP analysis of eIF2 cycling through eIF2B foci in the presence of a VWM gcn3 
mutation. The VWM mutants K111E and Y274C were exogenously expressed in a SUI2-yeGFP 
strain lacking any gcn3. Live-cell images representing the pre-bleach, post-bleach and recovery 
stages as well as a graph representing eIF2 recovery over time. An * denotes time at which the 
recovery image was from. Data are representative of 25 cells, n=3, error bars are 
representative of SEM. 
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Figure ‎4.10 Analysis of eIF2 shuttling through eIF2B foci in the presence of a VWM gcn3 
mutation.  (A) Bar chart representing the mobile eIF2 within the foci as a percentage. (B) Bar 
chart representative of half the time needed for eIF2 to fully recover. (C) Bar chart 
representing eIF2 content within eIF2B foci. Data are representative of 25 cells, n=3, error bars 
are representative of SEM, ns = not significant, * P=<0.05, ** P=<0.01, *** P=<0.001, **** 
P=<0.0001. 
 
A. B. 
C. D. 
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4.2.7. Intracellular movement of eIF2B bodies may be important to eIF2B 
function 
 A characteristic of eIF2B bodies whose function remains unclear is the fact that 
eIF2B bodies are mobile within the cell. Interestingly, previous studies have shown that 
butanol, a potent inhibitor of translation initiation, inhibits eIF2B body movement 
(Taylor et al., 2010). Moreover, butanol has been shown to reduce eIF2 shuttling 
through the eIF2B body via FRAP analysis. During FRAP analyses of the catalytic and 
VWM gcn3 mutations, noticeable differences were observed between eIF2B foci 
movement.  
 Figure 4.10 shows representative live-cell images highlighting eIF2B body 
movement over 45.7 seconds, during amino acid starvation conditions as well as when 
gcn3 catalytic and VWM mutations are present. Intriguingly, eIF2B bodies were still 
motile following amino acid starvation for 30 minutes, possibly indicating that 
movement is not directly linked to eIF2B regulation. In comparison to the movement 
of eIF2B body foci from exogenously expressed plasmid-borne wild-type Gcn3p, 
AA25,26VV and E199K microbody foci remained still within the cytoplasm. The 
localised eIF2B from the VWM mutant K111E rarely moved, whilst Y274C eIF2B bodies 
remained still throughout. The catalytic and VWM mutants suggest a link between 
eIF2B activity and foci movement, although no significant catalytic defect has been 
found in the previous analyses for K111E.  
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Figure ‎4.11 Representative images highlighting movement of eIF2B foci. Images were taken 
every 1.8 seconds over 25 cycles via confocal microscopy and flattened into one image using 
ImageJ to see the extent of eIF2B body movement. ‘Still’ images were the first image taken 
within that series. 
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4.2.8. Effect of gcn3 mutations on Gcn3p expression 
 Previous studies investigating the functional consequences of eIF2B mutations 
have highlighted alterations in the steady-state levels of the mutated subunit. In 2004, 
Richardson et al., showed that expression levels of the Gcn3p mutant, N209Y, 
decreased quite significantly from wild-type. In these instances, whether phenotypical 
differences are a result of the mutation or a decrease in expression will likely be 
unknown, therefore conclusions derived from observed phenotypes can be 
confounding. It was therefore important to investigate what impact the mutations had 
on Gcn3p expression levels. Cell extracts from the regulatory, catalytic and VWM 
mutants were compared to their respective wild types by Western blotting. The blots 
were probed for Gcn3p as well as Pab1p. The latter was used as a loading control and 
allowed quantitative analysis of Gcn3p expression by densitometry. 
 Expression levels of the Gcn3p regulatory mutants have not been documented 
thus far. In comparison to wild-type, the high-copy GCN3 plasmid dramatically 
increased Gcn3p levels 20-fold (Fig. 4.12A). For most of the regulatory mutants, 
expression levels of Gcn3p decreased in comparison to the expression levels of the 
plasmid-borne wild-type. Although expression levels were lower, they remained higher 
than endogenous levels. The S293R mutant was the only mutant to increase Gcn3p 
levels.  
 Previously published data has shown that some catalytic mutants (AA25,26VV, 
A26T and V295F) decrease Gcn3p expression, whilst the AA 303//305Δ mutant 
increased Gcn3p levels (Hannig et al., 1990). In comparison to the plasmid-borne wild-
type, the catalytic mutants AA25,26VV and E199K reduced Gcn3p levels by a third and 
two-thirds respectively (Fig. 4.12B). The mutant AA 303//305Δ increased expression 
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levels, although not as high as previously reported. The A26T substitution was the only 
mutant to remain similar to exogenous wild-type levels, whilst R104K, V295F and D71N 
increased levels by a factor of two or more. 
 As mentioned earlier, the N209Y mutation is the only eIF2Bα VWM mutant to 
be investigated in yeast prior to this study (Richardson et al., 2004). The N209Y 
mutant, along with the V184D and F240V mutations, substantially decreased Gcn3p 
levels in comparison to exogenously expressed wild-type levels (Fig. 4.12C). The Y274C 
mutant remained similar to wild-type, although K111E increased levels 1.5-fold. 
Interestingly, the K111E and V184D mutations seemed to exhibit slight differences in 
their molecular weight, as indicated by slight shifts in the Gcn3p band, in comparison 
to wild-type. 
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Figure ‎4.12 Western blotting analysis of gcn3 Gcn-, Gcd- and VWM mutants. Analysis of 
Gcn3p expression from GCD1-yeGFP (yMK880), GCD1-yeGFP gcn3::LEU2 (yMK1402), as well as 
yMK1402 exogenously expressing gcn3 regulatory (A), catalytic (B) and VWM (C) mutations. 
Cultures were grown to an OD600 of 1 before total protein was extracted via bead beating. 
Protein extract concentration was assessed via BCA assay. A total of 30μg protein extract was 
separated throughout a 4-20% SDS gel before being transferred onto a nitrocellulose 
membrane. The membrane was probed for Gcn3p and Pab1p using primary antibody 
concentrations of 1/1000 and 1/5000 respectively. Pab1p expression was utilised as a loading 
control and used to quantitatively assess Gcn3p expression by densitometry. 
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4.3. Discussion 
 eIF2B activity can be measured biochemically by using purified recombinant 
eIF2B, or by assessing expression levels of GCN4 or HIS3. Although drawbacks to the 
former have already been noted, expression levels of GCN4 or HIS3 can only be used to 
infer defects in the catalytic activity of eIF2B and may be prone to downstream 
effectors. Thus, a more direct approach to measure GEF activity is necessary which 
maintains an in vivo environment. In keeping with this, FRAP analysis was employed 
which has shown promising results during the original study characterising eIF2B 
bodies. FRAP was previously validated as a measurement of eIF2B activity by analysing 
eIF2 shuttling following amino acid starvation, a stress which decreases eIF2B activity 
(Campbell et al., 2005). In this study, FRAP analysis was validated using similar 
conditions (Fig. 4.2 and 4.3). Whilst the original study correlated reduced eIF2 shuttling 
with an increase in eIF2α phosphorylation via immunoblotting, we correlated the 
decrease in eIF2 shuttling with the concomitant derepression of GCN4 via LacZ assay 
(Fig. 4.3). Although these observations were expected, they reiterated conclusions 
from previously published FRAP analysis. In addition, these results validated the 
background strain to allow further functional analyses of the effects of eIF2Bα catalytic 
and VWM mutations on eIF2 shuttling and therefore, eIF2B activity. 
4.3.1. eIF2B microbodies decrease the shuttling of eIF2 
 For the catalytic mutants, FRAP analyses correlated with Gcn4p expression 
levels in the presence of AA25,26VV and E199K Gcn3p mutations, with results 
indicating decreased eIF2B activity (Fig. 4.4, 4.5 and 4.6). Although Gcn4p levels were 
higher in the E199K than AA25,26VV, FRAP analyses indicated similar decreases 
between the two mutations. This suggested eIF2B was impaired more within E199K 
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than AA25,26VV. These differences can be explained by the differences in eIF2B 
measurement. FRAP is a direct real-time measurement of eIF2 cycling into (eIF2-GDP) 
and out of (eIF2-GTP) the eIF2B body. In contrast, GCN4 accumulates throughout the 
cells lifespan and can be considered an endpoint assessment of eIF2B activity (see 
section 1.2.1.1.1). Thus, small variations of eIF2B activity may not be distinguished via 
FRAP but may be detectable by exacerbated Gcn4p levels. Nonetheless, measuring 
eIF2 dynamics is preferable considering the information that can be derived from such 
data which maintains an in vivo environment. 
 The 303//305Δ mutant previously displayed subpopulations of cells that either 
localised eIF2B to several small foci or the singular eIF2B body, therefore allowing the 
analysis of microbodies with the presence of eIF2B bodies serving as an internal 
control. The shuttling of eIF2 through 303//305Δ microbodies was decreased in 
comparison to 303//305Δ eIF2B bodies, which were analogous to wild-type (Fig. 4.5 
and 4.6). These results suggest that GEF activity may be decreased when eIF2B 
localises to microbody foci and that the eIF2B body is necessary for the enzyme to 
elicit GEF activity to its fullest. Since eIF2B foci were completely absent from cells that 
were deleted for Gcn3p (see Chapter 3, Figure 3.2), the decameric holocomplex is 
likely to be complete when eIF2B localises to microbody foci. Therefore there may be 
additional factors required to fully form the eIF2B body. Although previous 
perturbation of Ifa38p-eIF2B interactions correlated microbody formation with no 
decreases of eIF2B GEF activity, other interactions with other proteins have been 
suggested (Browne et al., 2013).  
 During the analysis of eIF2Bα catalytic mutations, we observed an interesting 
correlation between foci movement and catalytic activity (Fig. 4.11). Previously, mean 
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square displacement (MSD) experiments showed that the eIF2B body moves via 
random diffusion throughout the cytoplasm (Taylor et al., 2010). In addition, MSD 
results also suggested that the body was tethered to a membrane; an observation that 
was reiterated by another study (Browne et al., 2013). In yeast eIF2 moves via 
diffusion, therefore eIF2B body movement could serve to encourage eIF2-GDP to enter 
the body for GTP exchange. How eIF2B moves around is currently unknown, although 
the regulation of eIF2B via eIF2-P did not seem to be a factor. Amino acid starvation 
did not seem to hinder movement, which is in-line with previous observations 
surrounding butanol. Although butanol leads to reduced eIF2B activity, increased 
Gcn4p levels and inhibits body movement, butanol’s effects are independent of 
phosphorylated eIF2 (Taylor et al., 2010). 
4.3.2. Impact of eIF2Bα VWM mutations on eIF2 shuttling 
 Further investigation of eIF2Bα VWM mutations resulted in observations that 
were distinct from the catalytic mutations. Characterisation of V184D and F240V 
previously showed characteristics of a regulatory mutant, yet eIF2B localisation 
resulted in the formation of microbodies and eIF2B bodies respectively. Rather 
surprisingly, eIF2 did not localise to these foci (Fig. 4.8). Mutational analyses in human 
eIF2Bα suggest these two mutations may affect eIF2B-eIF2 binding and this may 
possibly account for the lack of eIF2 within eIF2B bodies (Wortham and Proud, 2015). 
 For the most part, FRAP analyses of the VWM mutations K111E and Y274C 
indicated subtle fluctuations in the dynamics of eIF2 (Fig. 4.9 and 4.10). K111E 
increased eIF2 recovery time within eIF2B foci, however as more eIF2 was mobile 
within the foci, only a slight decrease in the rate of recovery was observed (Fig. 4.10A, 
B and C). This showed that eIF2B GEF activity may be enhanced as a consequence of 
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mutations, by allowing a higher amount of eIF2 to shuttle through the eIF2B body. 
Conversely, total eIF2 content did not increase within this mutant (Fig. 4.10D). If more 
eIF2 was allowed to shuttle through the eIF2B body, an increase in total eIF2 would be 
expected, therefore bringing these conclusions into question. The mutant Y274C 
displayed a similar pattern of recovery to the mutant K111E, whereby the half-time 
recovery showed a significant decline in tandem with increases in mobile eIF2, 
equating to a slight yet significant decrease in the rate of eIF2 recovery. Total eIF2 
content within eIF2B bodies was significantly increased, therefore aligning with earlier 
ideas surrounding K111E. Whether this increase in eIF2 content was caused by the 
cycling of additional eIF2 or the influx of inhibitive eIF2-P is unknown. Considering 
slight increases in Gcn4p levels correlated with slight decreases in eIF2 shuttling, the 
presence of additional eIF2-P is unlikely.  
4.3.3. gcn3 regulatory, catalytic and VWM mutations may destabilise 
Gcn3p 
 Investigations into eIF2B mutations have highlighted numerous instances 
where missense mutations affect expression levels (Hannig et al., 1990, Richardson et 
al., 2004, Wortham and Proud, 2015). The very same observation was reiterated here 
from several Gcn3p mutants, although not all mutations decreased expression levels. 
For the majority of regulatory mutations, which were expressed on a high-copy 
plasmid, expression levels decreased in comparison to the exogenous wild-type Gcn3p 
(Fig. 4.12A). However, Gcn3p levels were still higher than the wild-type expressing 
endogenous GCN3. Since eIF2B bodies were formed within both wild-types (see 
section 3.2.1; Fig. 3.2), the change in expression level cannot solely account for the 
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dispersal of eIF2B but rather these missense mutations are likely to affect eIF2Bα 
incorporation.  
  Several catalytic mutants also reduced Gcn3p levels, but others remained 
similar to wild-type (Fig. 4.12B). In yeast, eIF2B tetramers (εγβδ) do not exhibit any 
catalytic deficiency when lacking eIF2Bα in vitro (Hannig et al., 1990). Lower levels of 
the subunit are therefore unlikely to cause the catalytic phenotype. Decreased 
expression of the catalytic mutants could produce two pools of eIF2B complexes with 
different configurations, including the tetrameric complex which exerts full catalytic 
activity and cannot be regulated, as well as the decameric (ε2γ2β2δ2α2) complex which 
has decreased catalytic activity but can be regulated. Therefore, the full extent of 
eIF2B’s decreased catalytic activity could be understated as there may be a larger pool 
of eIF2B complexes lacking the alpha subunit in comparison to wild-type cells. To 
determine the effects decreased expression levels had on the formation of decameric 
complexes, native cell extracts were analysed by immunoblotting (results not shown). 
Despite efforts to optimise the experiment by including different detergents in the lysis 
buffer, native immunoblots were unsuccessful as the eIF2B complexes were unable to 
separate through the polyacrylamide gel and seemed to aggregate in the well.  
 The VWM mutants V184D, N209Y and F240V, shown within this study to be 
regulatory mutants, decreased Gcn3p expression substantially (Fig. 4.12C). For these 
mutants, it is possible that regulation is not possible due to the lack of eIF2Bα. 
Therefore, eIF2B may exist as tetrameric complexes when these mutants are present. 
However, as some Gcn3p was still present, a Gcn3p-dose-dependent regulatory effect 
might be expected as opposed to a complete lack of regulation which was observed 
during polysome profiling (see section 3.2.4.1; Fig 3.8). To shed light on these 
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conflicting conclusions, additional experiments such as immunoprecipitation assays are 
required to investigate eIF2B complexes in the presence of VWM mutations.  
 Intriguingly, the VWM mutants K111E and V184D exhibited slight changes in 
the size of Gcn3p in comparison to wild-type (Fig. 4.12C). It is unlikely that the amino 
acid substitutions account for these shifts, as K111E decreases the mass of Gcn3p by 
0.94 Da and V184D increases the mass by 2.06 Da. It is possible that the mutations 
have introduced (i.e. K111E) or abolished (i.e. V184D) post-translational modifications. 
The T291 residue within Gcn3p has been suggested to be phosphorylated 
(Albuquerque et al., 2008). Apart from the ubiquitinated K37 residue, the T291 residue 
currently represents the only amino acid within Gcn3p implicated for post-
translational modification (Swaney et al., 2013). More investigations into these 
mutants are required, as these observations could have important implications for the 
pathogenesis of VWM. 
 Of the 20 mutants analysed, 12 resulted in decreased expression levels of 
Gcn3p. It is unlikely that the cause is due to codon biases, as such a large number of 
different mutations decreased Gcn3p levels. Nucleotide base changes could produce 
unstable mRNA transcripts (Russell et al., 1997). Similarly, amino acid substitutions 
could result in unstable Gcn3p (Tokuriki and Tawfik, 2009). Further experiments such 
as real-time qPCR or pulse-chase assays could elucidate why Gcn3p expression is low, 
which may shed light on why there are so few VWM mutations within eIF2Bα (Pavitt 
and Proud, 2009). 
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5.1. Introduction 
 Macromolecular structures containing aggregated protein often include 
additional co-factors to maintain structure as well as cytoplasmic location. For 
instance, the most characterised intracellular filamentous structure, F-actin, requires a 
host of actin-binding proteins to build a stable structure (Winder and Ayscough, 2005). 
Stress granules and P-bodies also require scaffold proteins to maintain structure, such 
as TIA-1 and GW182 respectively (Gilks et al., 2004, McDonald et al., 2011). Currently, 
the eIF2B body is known to comprise of eIF2B as well as the VLFA elongase enzyme 
Ifa38p (Browne et al., 2013). Previous studies suggest that the eIF2B body is tethered 
to a membrane, with Brown et al., (2013) suggesting the endoplasmic reticulum (ER) 
(Campbell et al., 2005). Additional proteins, such as Mst27, Erp4p and Sac1p, have 
been shown to associate with eIF2B, but whether they are required for eIF2B body 
formation remains unknown. 
 A survey of 1590 TAP-tagged putative membrane proteins (MPs) showed that 
all five subunits of eIF2B co-precipitated with Mst27p, Erp4p and Sac1p (Babu et al., 
2012). Proteins are known to be inherently 'sticky' and can sometimes interact non-
specifically leading to false-positive protein-protein interactions (PPIs). Hence Babu et 
al., took a multi-step approach to calculating confidence scores with an accuracy of 
95.45%. The authors noted that the precision of their study was similar to high-quality 
data from large surveys of soluble PPIs. Although there was still a 1 in 22 chance of a 
false-positive PPI, several other studies have been published verifying observed 
interactions.  
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 Specific roles for Mst27p and Erp4p within protein transport are yet to be 
described. Mst27p is predicted to contain two transmembrane domains (TMDs) with a 
short cytoplasmic domain (CD) at the N-terminus and a long CD at the C-terminus. 
Mst27p is known to form a heterodimer with its paralog Mst28p which interact with 
COPI and COPII coated vesicles (Sandmann et al., 2003). Erp4p is predicted to contain 
one TMD, a short 8 amino acid CD and a long non-cytoplasmic domain. Erp4p is a 
member of the p24 family which are a group of MPs responsible for regulating protein 
transport across the secretory system (Marzioch et al., 1999). To date, no report has 
linked Mst27p or Erp4p with translation initiation or translational control. Instead, 
these MPs are involved in vesicular mediated protein transport, potentially suggesting 
that the subcellular localisation of eIF2B bodies may play a role in their function. 
Endocytosed vesicular cargo contained within endosomes may be unpackaged in the 
Golgi and then transported to the ER by retrograde protein transport which utilises 
COPI coated vesicles. Newly folded proteins within the ER may be transported to the 
Golgi utilising COPII coated vesicles via retrograde protein transport. Proteins may also 
be secreted and are therefore transported from the Golgi apparatus to the plasma 
membrane. This process is reliant on steady state levels of phosphatidylinositol 4-
phosphate (Ptdins(4)P) in the Golgi apparatus. 
 Sac1p is a phosphatidylinositol (PI) phosphate phosphatase (PI(4)P) responsible 
for regulating Ptdins(4)P levels within the Golgi apparatus.  Ptdins(4)P is a membrane 
bound lipid important for actin cytoskeleton organisation, cell wall integrity and 
vesicular mediated protein transport (D'Angelo et al., 2008). In S. cerevisiae, two PI4 
kinases (PI4K) exist; Stt4p and Pik1p (Audhya et al., 2000). Stt4p generates Ptdins(4)P 
at the plasma membrane whilst Pik1p maintains levels at the Golgi apparatus. 
Interestingly, temperature sensitive Stt4p/Pik1p mutants, which lead to 10-fold 
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Ptdins(4)P decrease, have been shown to impair translation initiation (Audhya et al., 
2000, Cameroni et al., 2006). Whether Sac1p is involved in translation or whether it 
confers a similar translational response to abnormal PI4Ks remains to be elucidated. 
 Within this chapter, experiments were undertaken to provide further insights 
into the interactions between the MPs and eIF2B, as well as their role in translational 
control. We hypothesised that Mst27p, Erp4p and Sac1p may co-localise with the 
eIF2B body, either providing structural support or acted to tether the filamentous 
structure to a membrane.   
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5.2. Results 
5.2.1. eIF2B localisation is unaffected within cells lacking Mst27p, Erp4p 
 or Sac1p 
 All five eIF2B subunits previously co-precipitated with the TAP tagged putative 
membrane proteins (MPs); Mst27p, Erp4p or Sac1p (Babu et al., 2012). As all five 
subunits were identified, interactions could exist when eIF2B is in the decameric 
conformation. Therefore, we initially sought to determine whether the MPs were 
required for the formation of eIF2B bodies. Each MP was individually deleted in a 
strain (yMK880) containing GFP tagged GCD1 (eIF2Bγ). MST27 and ERP4 were 
substituted with a URA3 marker whilst SAC1 was replaced with LEU2. Following 
confirmation of successful homologous recombination, the MP deletion strains 
underwent live-cell imaging via confocal microscopy to assess the impact of the 
deletion on eIF2B localisation. 
 Representative live-cell images are shown in Figure 5.1A. Quantitation of eIF2B 
localisation showed wild-type cells formed eIF2B bodies within 50 % of the cell 
population analysed, with rare instances of microbody formation (Fig. 5.1B). The MP 
deletion strains were similar to wild-type, although slightly higher levels of microbody 
formation were observed for mst27Δ and erp4Δ. However, these variations were not 
statistically significant. Although these results suggested that the MPs were not 
required for the formation of eIF2B bodies, they do not rule out a role in translation 
initiation or translational control. 
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Figure ‎5.1 Deletion of mst27, erp4 or sac1 does not affect eIF2B localisation. MST27, ERP4 
and SAC1 were individually deleted within a strain harbouring a genomically GFP tagged GCD1 
to visualise eIF2B localisation. (A) Representative live-cell images were taken via confocal 
microscopy. (B) A minimum of 100 cells were counted and assessed as to whether eIF2B was 
dispersed, localised to microbodies or formed eIF2B bodies. n=3, error bars are representative 
of SD. ns = not significant, * P=<0.05, ** P=<0.01, *** P=<0.001, **** P=<0.0001. 
 
WT 
mst27Δ erp4Δ 
sac1Δ 
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5.2.2. sac1Δ impairs translation initiation 
 Although there is little known about Mst27p and Erp4p, deletion of other 
enzymes within the phosphatidylinositol pathway that are linked to Sac1p (i.e. Pik1p) 
detrimentally affect rates of translation initiation, leading to ribosomal run-off and 
consequently increasing levels of 80S monosomes (Cameroni et al., 2006). Similarly, 
the effects of mst27Δ and erp4Δ on cellular growth are unknown, whilst sac1Δ has 
been shown to severely impair growth rates (Yoshikawa et al., 2011). To further 
characterise the MP deletion strains and ensure the sac1Δ mutant displayed similar 
growth patterns as previous, growth curves and polysome profiles were generated.  
 Growth rates were measured over 8 hours in SC media lacking appropriate 
amino acids at 30  ̊C (Fig. 5.2). mst27Δ and erp4Δ cells grew slightly faster than wild-
type. In contrast, the sac1Δ mutant exhibited a severe growth defect, in agreement 
previously published data (Yoshikawa et al., 2011). 
 Polysome profiles were generated to determine whether deletion of the MPs 
affected translation initiation or translation regulation. As before (see section 3.2.3), 
cells were starved of amino acids for 30 minutes to elicit an eIF2B-dependent 
response, whereas glucose starvation for 10 minutes was included as an eIF2B-
independent control. For the mst27Δ and erp4Δ mutants, similar responses to wild-
type were observed for both amino acid and glucose starvation (Fig. 5.3). Both 
mutants were able to respond to amino acid starvation similar to wild-type, as 
indicated by increases in the 80S monosome peak, resulting in P:M ratios decreasing 2-
fold. Interestingly, the sac1Δ strain exhibited a much higher 80S monosome peak than 
wild-type under normal conditions, producing a P:M ratio 2.5-fold lower than wild-
type. Intriguingly sac1Δ cells were still able to respond to stress, but the generated 
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polysome profiles indicated sac1Δ cells may be hypersensitive to eIF2B-dependent 
stress, as the P:M ratio decreased by 75 %; a decrease 1.5-fold higher than similarly-
stressed wild-type cells. Together, these results show Sac1p is required for efficient 
translation initiation and that the absence of Sac1p may exaggerate translational 
regulation to cellular stresses.  
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Figure ‎5.2 Growth curve of strains lacking Mst27p, Erp4p or Sac1p. Overnight starter cultures 
were backdiluted to 0.2 OD units in fresh media before being incubated at 30°C with shaking. 
Growth was monitored over eight hours, n=3, error bars are representative of SD. 
 
A. 
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Figure ‎5.3 Polysome profiling of putative membrane protein deletes. Polysome profiling was 
used to assess whether eIF2B could respond to stress when Mst27p, Erp4p and Sac1p was 
absent. Amino acid starvation antagonises an eIF2B-dependent response, whilst glucose 
starvation antagonises an eIF2B-independent response. n=3, error bars are representative of 
SD, ns = not significant, * P=<0.05, ** P=<0.01, *** P=<0.001, **** P=<0.0001. 
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5.2.3. Analysis of co-localisation between eIF2B bodies and membrane 
 proteins 
 In their study investigating interactors of putative membrane proteins, Babu et 
al., (2012) used tandem affinity purification by virtue of endogenously TAP tagged 
proteins. To further investigate the observed interactions between eIF2B and the MPs, 
we investigated whether the MPs co-localised with the eIF2B body. To investigate co-
localisation between the MPs and eIF2B, MST27, ERP4 and SAC1 were individually 
fused to mKATE2; a highly photostable monomeric RFP capable of withstanding high 
pHs indigenous to some organelles (Lee et al., 2013). Gene fusions were created by 
'one-step' over-lap extension PCR (OE-PCR), which were purified by agarose gel 
electrophoresis before being cloned into a high-copy TOPO TA pYES2.1 vector 
containing a GAL1 promoter (Fig. 5.1). Colony PCR was performed to find 
transformants that were positive for the MP-mKATE2 insertion into the pYES2.1 vector. 
pYES2.1 plasmids containing MST27/ERP4/SAC1-mKATE2 were Sanger sequenced 
gene-wide to ensure the gene fusion was in-frame and could therefore be exogenously 
expressed. 
 The newly generated plasmids (BSC87, 88 and 90) were transformed into their 
respective deletion strains. Expression was induced by incubating transformants in SC 
media containing 1 % (w/v) raffinose and 1 % (w/v) galactose overnight at 30  ̊C. 
Starter cultures were then diluted in SC media containing 2 % (w/v) galactose, before 
undergoing live-cell imaging via confocal microscopy (Fig. 5.2A).  
 Mst27p and Sac1p appeared to localise to the ER or the plasma membrane, 
while Erp4p seemed to localise to the Golgi apparatus. Quantitation of cells indicated 
that Erp4p lacked any co-localisation with eIF2B, whilst few instances of co-localisation 
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were observed for Mst27p. Data suggested that Sac1p may transiently co-localise with 
eIF2B, with 30 % of cells displaying Sac1p localisation within the eIF2B foci. As limited 
numbers of cells could be found expressing MST27/ERP4-mKATE2, over-expression of 
Mst27p/Erp4p may be detrimental to cells, leading to suppressor mutations.  
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Figure ‎5.4 Schematic of OE-PCR and cloning to produce mKATE2 tagged membrane proteins. 
(A) Diagram to show positioning of primers (half arrows), as well as the primers that contained 
homologous sites to the other gene (dotted lines). (B) Agarose gel showing the membrane 
protein genes fused to the mKATE2 gene via OE-PCR. (C) The membrane protein genes fused to 
mKATE2 were then purified from the agarose gel and cloned into a TOPO TA pYES2.1 high copy 
vector, which contains an inducible galactose promoter.  
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Figure ‎5.5 Co-localisation of putative membrane proteins and eIF2B.  (A) Putative membrane 
proteins tagged with mKATE2 were exogenously expressed in their respective deletion strains 
which already contained genomically yeGFP tagged GCD1 (see figure 5.1). To induce 
expression, starter cultures were made in SC media containing 1% raffinose and 1% galactose. 
Starter cultures were then backdiluted to 0.2 OD units in SC media containing 2% galactose. (B) 
A number of cells were imaged via confocal microscopy to see if any co-localisation with the 
eIF2B body occurred. 
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 170 
 As polysome profiling showed a negative impact on translation initiation when 
Sac1p was absent and co-localisation studies showed transient co-localisation with 
eIF2B, Sac1p was the focus of further investigation. 
 To ensure the deletion of Sac1p caused the impaired translational effects 
observed earlier, a plasmid was required to complement the gene deletion. 
Considering different carbon sources can elicit different translational responses, the 
galactose induced pYES2.1 plasmid was not appropriate for this purpose (Ashe et al., 
2000). Therefore, the SAC1-mKATE2 was sub-cloned into a pSF1 low-copy CEN6ARS4 
vector containing a constitutively active TEF1 promoter. The SAC1-mKATE2 cassette 
was isolated from the pYES2.1 vector (BSC90) by SspI and XbaI restriction digest, 
before being purified by agarose gel electrophoresis. Purified SAC1-mKATE2 was 
recombined into a pSF1-TEF1-CEN6ARS4 vector (Fig. 5.6A). Transformants were 
screened by colony PCR for the presence of recombinant DNA. Purified plasmids were 
Sanger-sequenced gene-wide to ensure an in-frame insertion. 
 The newly generated TEF1-SAC1-mKATE2 plasmid (BSC128) was exogenously 
expressed in the sac1Δ strain. Localisation was reassessed to determine whether Sac1p 
co-localised with the eIF2B body or whether the transient co-localisation observed 
earlier was due to over-expression. Representative images of Sac1p-mKate2 and eIF2B-
GFP are shown in Figure 5.6. Sac1p appeared to mainly localise to the ER or the plasma 
membrane. The eIF2B body occasionally co-localised with Sac1p, suggesting transient 
co-localisation.  
 To ensure growth defects as well as the impaired translational effects were 
caused by the lack of Sac1p, growth curves and polysome profiles were generated 
utilising the TEF1-SAC1-mKATE2 plasmid. Under normal conditions, complementation 
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of Sac1p fused with mKate2 produced polysome profiles similar to wild-type; 
confirming that earlier translational defects were caused by a lack of Sac1p (Fig. 5.7A). 
Cells were also able to respond to amino acid and glucose starvation, although 
hypersensitivity to amino acid starvation was still apparent, as indicated by a 
heightened 80S monosome peak in comparison to wild-type (Fig. 5.7B). Whilst 
polysome profiles returned similar to wild-type under normal conditions, growth rates 
remained lower than wild-type (Fig. 5.7B). Together, these results suggested that the 
TEF1-SAC1-mKATE2 plasmid could rescue translation initiation defects under normal 
conditions. However, the exogenous Sac1p-mKate2 was unable to complement the 
decreased growth rate or hypersensitivity to eIF2B-dependent cellular stresses, 
potentially due to low expression or C-terminal mKate2 fusion hindering phosphatase 
activity. 
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Figure ‎5.6 Co-localisation of Sac1p and the eIF2B body.  (A) The constitutive SAC1-mKATE2 
expression cassette. (B) SAC1-mKATE2 was exogenously expressed in the deletion strain to 
assess co-localisation with Gcd1p-GFP. Live-cell images were taken via fluorescence 
microscopy. 
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Figure ‎5.7 Complementation of the Δsac1 phenotype. (A) Polysome profiling was performed 
to see whether the plasmid could rescue the sac1Δ phenotype (see figure 5.3). (B) Growth was 
monitored over eight hours to see whether the plasmid could rescue sac1Δ’s growth deficit, 
n=3, error bars are representative of SD. 
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5.2.4. sac1Δ impairs translation initiation independent of eIF2B 
 Since co-localisation experiments only indicated transient interactions between 
Sac1p and eIF2B bodies, investigations focused on the impaired translation initiation 
conferred by the absence of Sac1p. Previously, Cameroni et al., (2006) suggested that 
translation initiation may be liable to regulation in response to varying Ptdins(4)P 
levels. Results from experiments showed translation initiation was impaired when cells 
lacked Pik1p; an essential PI 4-kinase (PI4K) responsible for maintaining Ptdins(4)P in 
the Golgi apparatus. Within this study, a similar translational response was discovered 
in cells deficient for Sac1p; a non-essential phosphatase responsible for regulating 
Ptdins(4)P levels in the Golgi apparatus. Temperature sensitive Pik1p mutants have 
been shown to decrease Ptdins(4)P levels 10-fold, whilst sac1Δ cells increase levels 10-
fold (Foti et al., 2001, Audhya et al., 2000). These observations suggest that an optimal 
concentration of Ptdins(4)P may be required for cellular homeostasis. Temperature 
sensitive Pik1p mutants have already been shown to affect translation initiation 
independent of eIF2B. However, whether a similar mechanism is instigated in the 
absence of Sac1p remains unknown.  
 To determine whether translation is regulated independent of eIF2B in the 
absence of Sac1p, additional strains were generated to investigate translational control 
without gcn3 (eIF2Bα). As mentioned earlier (see section 3.2.3), eIF2Bα contains the 
binding site for eIF2α-P, thus cells lacking eIF2Bα will be unresponsive to eIF2B-
dependent stresses. The Mat a, sac1::LEU2 GCD1-GFP (ySC18) strain was crossed with 
Mat α, gcn3::HIS3 GCN4-LacZ-TRP1 (ySC86). Diploid cells were selected and 
sporulated, before tetrads were dissected and isolated on solid rich media. To 
determine genotypes, tetrads were replicated onto solid SC media individually lacking 
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leucine, histidine or tryptophan. Four new strains were created: GCN4-LacZ-TRP1 
(ySC99), gcn3::HIS3 GCN4-LacZ-TRP1 (ySC100), sac1::LEU2 GCN4-LacZ-TRP1 (ySC97) 
and sac1::LEU2 gcn3::HIS3 GCN4-LacZ-TRP1 (ySC98). 
 To investigate whether the absence of Sac1p resulted in the downregulation of 
translation initiation via eIF2B-dependent regulation, growth curves and polysome 
profiles were generated using sac1Δ gcn3Δ (ySC98) cells to test whether deleting 
eIF2Bα would complement the absence of Sac1p. In comparison to wild-type under 
normal conditions, sac1Δ gcn3Δ cells exhibited reduced rates of translation initiation, 
as shown by a larger 80S monosome peak (Fig. 5.8A). As this observation was 
reminiscent of sac1Δ cells, additional deletion of gcn3 did not impact upon this 
phenotype. Expectedly, sac1Δ gcn3Δ cells could not respond to amino acid starvation 
(see section 3.2.3), with an 80S monosome peak similar to normal conditions. A 
growth curve for the sac1Δ gcn3Δ mutant is shown in Figure 5.8B, wild-type data from 
Figure 5.7B is included for comparison. In line with generated polysome profiles, sac1Δ 
gcn3Δ cells exhibited slower growth. Together, these results suggest translation 
initiation is regulated independent of eIF2B when Sac1p is absent. Moreover, these 
results suggest that the translational regulation observed in sac1Δ cells is the same 
translational control mechanism previously observed in the Pik1p temperature 
sensitive mutant (Cameroni et al., 2006). 
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Figure ‎5.8 Complementation of SAC1. A sac1::LEU2, gcn3::HIS3 strain was produced to see 
whether the sac1 null phenotype could be rescued by deleting gcn3. (A) Polysome profiling. (B) 
Growth was monitored over eight hours to see whether deleting gcn3 could rescue sac1Δ’s 
growth deficit. n=3, error bars are representative of SD. ns = not significant, * P=<0.05, ** 
P=<0.01, *** P=<0.001, **** P=<0.0001. 
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 As mentioned in section 4.2.2; the transcription factor GCN4 is derepressed 
when eIF2B activity is downregulated, conferred by the binding of phosphorylated eIF2 
or a catalytic mutation in eIF2B. Generated polysome profiles of a sac1Δ gcn3Δ double-
deletion under normal conditions remained similar to sac1Δ cells. Correspondingly, we 
hypothesised that Gcn4p levels in sac1Δ cells would remain comparable to wild-type 
cells. We also hypothesised that the sac1Δ gcn3Δ double-deletion would remain 
similar to gcn3Δ cells. To investigate this hypothesis, GCN4-LacZ-TRP1 (ySC99), 
gcn3::HIS3 GCN4-LacZ-TRP1 (ySC100), sac1::LEU2 GCN4-LacZ-TRP1 (ySC97) and 
sac1::LEU2 gcn3::HIS3 GCN4-LacZ-TRP1 (ySC98) cells were depleted of amino acids for 
30 and 60 minutes at 30  ̊C to instigate the derepression of GCN4, before protein 
extracts were analysed via LacZ assay (Fig. 5.8A). Expectedly, wild-type cells increased 
Gcn4p levels 2-fold following amino acid starvation for 30 minutes. Gcn4p levels 
additionally increased following amino acid starvation for 60 minutes. As expected, 
gcn3Δ cells exhibited lower Gcn4p levels under normal conditions and were unable to 
respond to amino acid stress. Although gcn3Δ cells slightly increased Gcn4p levels 
following amino acid depletion for 60 minutes, the increase remained insignificant. In-
line with our hypothesis, sac1Δ cells in the absence of stress did not increase levels of 
Gcn4p. Unexpectedly however, levels of Gcn4p seemed to be reduced similar to cells 
lacking Gcn3p, suggesting Gcn4p was actively repressed in the absence of Sac1p. sac1Δ 
cells were also unresponsive to amino acid depletion for 30 minutes, as no significant 
changes were observed. Gcn4p levels increased following 60 minute amino acid 
starvation, although the response still seemed weak in comparison to wild-type. 
Considering cells individually deleted for sac1Δ and gcn3Δ decreased Gcn4p levels 
under normal conditions, results indicating increased Gcn4p expression in the sac1Δ 
gcn3Δ double-deletion were intriguing. Interestingly, sac1Δ gcn3Δ increased Gcn4p 
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levels slightly higher than wild-type under normal conditions. Although, as expected; 
sac1Δ gcn3Δ cells were unresponsive to amino acid starvation. The double-deletion 
was subsequently spotted onto solid SC media containing 10 mM 3-AT and incubated 
at 30  ̊C for 48 hours (Fig. 5.8B). Slight growth was observed, reiterating the slight 
increase in Gcn4p levels.  
 These data further reiterate that translation is regulated by a mechanism that is 
independent of eIF2B within sac1Δ cells as Gcn4p was not expressed. Moreover, the 
expression of Gcn4p seemed to be actively repressed by a mechanism that is 
dependent upon eIF2B as Gcn4p levels increased in the sac1Δ gcn3Δ mutant. 
Interestingly, this suggests that these regulatory mechanisms of global translation may 
intersect with each other, reducing the levels of Gcn4p under specific conditions. 
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Figure ‎5.9 Gcn4p expression is repressed when sac1 is deleted, which is dependent on 
Gcn3p.  (A) To assess whether the loss of sac1 derepresses the expression of GCN4, as well as 
GCN3’s influences in this, a sac1::LEU2 strain harbouring a genomically LacZ tagged GCN4, with 
and without GCN3, were used to perform a LacZ assay. Starter cultures were backdiluted to 0.2 
OD and allowed to reach exponential growth before the cultures were divided and starved of 
amino acids for either 30 or 60 minutes. n=3, error bars are representative of SD. ns = not 
significant, * P=<0.05, ** P=<0.01, *** P=<0.001, **** P=<0.0001. (B) Starter cultures were 
backdiluted to 0.3 OD units before being serially diluted 4 times and spotted on to SCD agar 
plates as well as SCD agar containing 30 mM 3AT. Spot plates were incubated at 30°C for 48 
hours.
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5.3. Discussion 
 
5.3.1. Mst27p and Erp4p are not involved in translation initiation. 
 Although associations between eIF2B and the putative membrane proteins 
Mst27p, Erp4p and Sac1p were previously observed by pull-down methods, 
individual gene deletions suggested that they are not required for the formation of 
eIF2B bodies (Fig. 5.1). Cellular growth was also found to be normal in mst27Δ and 
erp4Δ cells, as was translation initiation and translational control (Fig. 5.2 and 5.3). 
Although very little is known about Mst27p and Erp4p, with phenotypical 
characteristics mostly suggested from large-scale surveys, Mst27p is known to 
heterodimerise with its paralog Mst28p (Sandmann et al., 2003). Taking into account 
the similarities between Mst27p and Mst28p, it is possible that Mst28p 
homodimerises in the absence of Mst27p, thereby functionally complementing the 
loss of Mst27p. This hypothesis could be tested by a double deletion of Mst27p and 
Mst28p. 
 Previous work by Browne et al., suggested the eIF2B body may be tethered 
to the endoplasmic reticulum (ER). Under normal conditions, Mst27p and Erp4p 
localises to the ER and the Golgi apparatus respectively. Sac1p mainly localises to the 
Golgi apparatus, but can also localise to the plasma membrane and ER. The ER 
localisation of Sac1p has been shown to occur under carbon limiting conditions; 
however the function behind this translocation remains unknown (Faulhammer et 
al., 2005). Co-localisation studies showed that Mst27p and Erp4p do not co-localise 
with the eIF2B body (Fig. 5.5), and that Sac1p displays only transient co-localisation 
(Fig. 5.6). Co-localisation studies are typically performed using fluorescently tagged 
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endogenous proteins, whilst exogenously expressed proteins lacking canonical 
promoters was utilised within this study. It should be noted that Discosoma RFP 
(dsRFP) was genomically incorporated with SAC1, but no fluorescent signal was 
observed, leading to the generation of plasmids instead. Whilst these experiments 
should be repeated, preliminary results suggest that Mst27p, Erp4p and Sac1p do 
not co-localise with the eIF2B body. 
5.3.2. Sac1 may be involved in the control of translation initiation 
 There are two pools of Ptdins(4)P within yeast cells, present at the plasma 
membrane and the Golgi apparatus (D'Angelo et al., 2008). Ptdins(4)P is required for 
anterograde protein transport between the ER and the Golgi apparatus, as well as 
retrograde transport and the secretion of vesicular cargo at the plasma membrane 
(D'Angelo et al., 2008). The PI(4)K Stt4p is responsible for the production of 
Ptdins(4)P at the plasma membrane (Audhya and Emr, 2002), whilst Pik1p maintains 
a concentration gradient of Ptdins(4)P across the Golgi apparatus (Strahl et al., 
2005). Temperature sensitive variants of either PI4K were shown to dramatically 
reduce Ptdins(4)P levels at their respective locations (Strahl et al., 2005, Audhya and 
Emr, 2002). In a later study, temperature sensitive PI(4)K mutants were found to 
impair translation initiation leading to the suggestion that translation may be 
regulated in response to Ptdins(4)P fluctuations (Cameroni et al., 2006). The PI 
phosphatase Sac1p is responsible for the regulation of Ptdins(4)P levels at the Golgi 
apparatus (Roy and Levine, 2004). Analysis of cells lacking Sac1p resulted in similar 
polysome profiles to the temperature sensitive PI4K mutants, presenting with larger 
80S monosome peaks than wild-type under normal conditions (Fig. 5.3). This novel 
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result suggests high levels of Ptdins(4)P potentiates a translational response. 
Therefore, an optimal concentration of Ptdins(4)P must be present at the Golgi 
apparatus for cellular homeostasis. 
 To ensure the translational response was caused by the absence of Sac1p, 
sac1Δ cells were complemented by exogenously expressed Sac1p-mKate2 via a 
constitutively active TEF1 promoter. The low-copy CEN6ARS4 plasmid was utilised to 
prevent over expression that may be conferred by a constantly active promoter. The 
exogenous Sac1p was able to recover the translational defect under normal 
conditions, but was unable to recover the growth defect as well as hypersensitivity 
to amino acid stress. This could be due to low expression levels of Sac1p because of 
the low-copy vector. Additionally, the integration of mKate2 to the C-terminus of 
Sac1p could be hindering phosphatase activity. Although these experiments should 
be repeated whereby Sac1p is expressed through its canonical promoter which 
responds to Ptdins(4)P levels, the exogenous expression of SAC1-mKATE2 did restore 
translation initiation under normal conditions (Fig. 5.7) (Knodler et al., 2008). This 
supports the hypothesis that the translational defect was indeed caused by the lack 
of Sac1p. 
5.3.3. Ptdins(4)P translational response is controlled independent of 
 eIF2B. 
 A translational control mechanism in response to Ptdins(4)P fluctuations was 
originally identified by a study investigating the specific target of wortmannin. 
Wortmannin is a natural molecule produced by the fungus Penicillium funiculosum 
and was found to primarily target Stt4p in S. cerevisiae (Cameroni et al., 2006). 
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Interestingly, temperature sensitive Pik1p mutants exhibited a resistant phenotype 
to wortmannin. By mutating the residue in eIF2α (S51A) that is phosphorylated in 
response to cellular stress, the group showed translation was downregulated 
independent of eIF2B. Similar results were observed here with sac1Δ cells lacking 
Gcn3p (Fig. 5.8). Under normal conditions, polysome profiles did not change when 
Gcn3p was absent; confirming the sac1Δ translational response was independent of 
eIF2B. This result also indicated that the absence of the PI4 phosphatase is likely to 
result in the same translational response when an abnormal PI4 kinase is present.  
 In addition to eIF2B, global protein synthesis is subject to regulation by eIF4E-
binding proteins (4E-BPs), which competitively bind eIF4E preventing the assembly 
of the eIF4F complex, subsequently attenuating translation initiation. Two 4E-BPs 
exist in yeast: Eap1p and Caf20p. During a genetic screen of knock-out mutants; 
sac1Δ cells were shown to be hypersensitive to wortmannin, whilst cells lacking 
Eap1p were resistant (Zewail et al., 2003). Corresponding with results presented 
here, Eap1p may be responsible for translational control in response to varying 
Ptdins(4)P levels. 4E-BPs do not result in the derepression of GCN4. As the 
translational response in sac1Δ cells was shown to be independent of eIF2B, it was 
hypothesised that Gcn4p levels would remain unchanged. Interestingly, quantitative 
analyses of Gcn4p expression showed levels decreased, indicating GCN4 repression 
(Fig. 5.9A). This provides further evidence for a role for Eap1p in the translational 
regulation of Sac1p, as the 4E-BP can attenuate Gcn4p expression when the target of 
rapamycin (TOR) is inactivated following a cellular stress (Matsuo et al., 2005). How 
Eap1p attenuates Gcn4p expression is unknown. Unexpectedly, Gcn4p levels 
increased when Gcn3p was absent from sac1Δ cells, suggesting eIF2Bα is required 
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for Eap1p-dependent GCN4 repression. As there is no evidence directly showing 
Eap1p attenuates translation in response to varying Ptdins(4)P levels, more 
investigations are warranted. Nonetheless, results presented here suggest a novel 
mechanism independent of eIF2B. Gcn4p expression was also repressed, insinuating 
cross-talk between the two mechanisms of global translational control. 
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6. General Discussion 
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6.1. General Discussion 
 eIF2B is a complex GEF essential for initiating and controlling protein 
synthesis that localises to discrete cytoplasmic foci (Campbell et al., 2005). The 
macromoleular filamentous eIF2B body aggregate comprises all five subunits. In 
addition other proteins such as the VLFA enzyme Ifa38p has been reported to 
associate with eIF2B (Browne et al., 2013). Published data has highlighted that these 
discrete cytoplasmic foci are sites of GEF exchange for eIF2B's substrate eIF2, as well 
as sites of regulation where eIF2α-P binds to attenuate eIF2B activity (Campbell et 
al., 2005). Although a number of characteristics and features have already been 
described surrounding eIF2B bodies, how the eIF2B complex forms these large 
aggregates is unknown. Therefore, the main aim within this study was to investigate 
how eIF2B bodies are formed.  
6.2. eIF2Bα localises eIF2B in a controlled two-step process 
 The eIF2B body contains all five subunits of eIF2B; it was therefore predicted 
that the formation of decameric complexes would precede localisation. In this study 
demonstrated eIF2Bα to be essential for the formation of eIF2B bodies; as eIF2B was 
dispersed throughout the cytoplasm when eIF2Bα was absent. Recent mass 
spectrometry analyses and crystallography have highlighted that the regulatory 
subunit eIF2Bα is integral to forming the eIF2B decamer; where eIF2Bα2 homodimers 
stabilise two eIF2Bεγβδ tetrameric subcomplexes (Wortham et al., 2014). It is 
therefore reasonable to hypothesise that localised eIF2B represents decameric eIF2B 
complexes, whereas dispersed eIF2B represents tetrameric complexes. 
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 Analysis of eIF2Bα mutations indicated that localisation was important for 
the regulation and catalytic activity of eIF2B. Similar to the deletion strain, regulatory 
mutants dispersed eIF2B throughout the cytoplasm whereas catalytic mutants 
formed microbodies. Sub-populations of cells were observed within wild-type 
cultures that displayed dispersed eIF2B, formed microbodies or formed eIF2B 
bodies. Subsequently, it is hypothesised that eIF2B bodies may be formed in two 
steps: firstly, tetrameric eIF2B is dispersed throughout the cytoplasm before eIF2Bα2 
stabilises eIF2B decameric complexes which congregate to form several smaller foci, 
secondly, eIF2B microbodies further aggregate together to form the singular 
filamentous eIF2B body. In support of this model, FRAP analysis of eIF2 cycling 
through eIF2B microbodies showed decreased rates of shuttling in comparison to 
eIF2B bodies, thus eIF2B may only be able to elicit full GEF activity when fully 
localised. This two-step accumulation has also been shown for the formation of 
aggregation of other translational components. Stress granules firstly form a core of 
untranslated mRNAs congregate before forming a shell, which aggregates further to 
produce a fully mature biphasic stress granule (Wheeler et al., 2016).   
 Intriguingly, analysis of eIF2B localisation within populations of cells from all 
wild-type variants, catalytic mutants, some VWM mutants and the MP deletion 
strains indicated that eIF2B may localise in a controlled manner. Irrespective of 
microbody or eIF2B body formation, the number of cells localising eIF2B was mostly 
consistent throughout. Moreover, the number of cells displaying dispersed eIF2B 
was consistent across all wild types, catalytic mutants and MP deletion strains. As 
cultures were analysed under exponential growth, it is plausible that the cell cycle 
could be a driving factor that dictates eIF2B localisation. In support of this and in-line 
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with published data (Campbell et al., 2005), eIF2B body formation was mainly limited 
to the mother cell. However, unique to the catalytic mutants A26T, D71N and V295F 
(Fig. 3.13A), as well as the VWM mutant V184D (Fig. 3.17B), were observations of 
microbodies within daughter cells. Whilst these mutants seemed to lack control of 
eIF2B localisation, others seemed unable to induce localisation. For instance, 
K111E/Y274C resulted in decreases in the number of foci, possibly suggesting an 
inability to induce localisation. Further investigation is warranted, as the elucidation 
of influencing factors that drive eIF2B localisation may provide novel insights into the 
role of eIF2B bodies.  
6.3. The role of the eIF2B body in the control of translation initiation 
Based on data from this study, it appears that two pools of eIF2B exist within 
the cell: the unregulatable tetrameric complexes that are dispersed; and regulatable 
decameric complexes localised to microbodies or eIF2B bodies. Hence a relationship 
seems to exist between localisation and regulation. However, eIF2B body formation 
has been shown to occur irregardless of eIF2α-P interaction (Campbell et al., 2005). 
One possible reason for localising regulatable eIF2B may be to prime the cell for 
stress, which may be able to attenuate the catalytic activity of eIF2B more promptly. 
As mentioned earlier, deletion of eIF2Bα and the eIF2Bα regulatory mutations all 
displayed dispersed eIF2B localisation, suggesting that these regulatory mutant 
eIF2Bα subunits may be absent from the eIF2B holocomplex. In contrast however, 
there are some inconsistencies between particular eIF2Bα regulatory mutants and 
their resistance to butanol (i.e. T41K; see section 3.2.2), which attenuates eIF2B 
independent of eIF2α-P (Taylor et al., 2010). If eIF2Bα regulatory mutants cannot 
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interact with eIF2B tetramers, how do these specific mutants affect eIF2B activity in 
the presence of butanol? It is plausible butanol resistant eIF2Bα regulatory 
mutations could form the decameric complex without localising to eIF2B bodies. 
Correspondingly, there may also be a connection between localisation and eIF2B 
sequestration that is independent of eIF2α-P. Further experiments could shed light 
on these ideas, such as the immunoprecipitation of eIF2Bγ subunit to test whether 
eIF2Bα is associated with the eIF2B complex.  
An association was also observed between localisation and catalytic function, 
whereby eIF2Bα catalytic mutations lead to the formation of microbodies, thereby 
reducing rates of eIF2 cycling. Additional co-factors may be required for the 
transition between the intermediary microbody and the fully localised eIF2B body, 
possibly enhancing GEF activity. In support of this, eIF2Bα catalytic mutations 
produce conformational changes that detrimentally affect the catalytic subunits, 
which are known to interact with Ifa38p (Browne et al., 2013). The absence of Ifa38p 
leads to two effects that were also common to eIF2Bα catalytic mutants; the 
formation of microbodies as well as reduced polysome:monosome ratios, indicative 
of decreased GEF exchange. Despite this, it was concluded that the catalytic activity 
of eIF2B remained unaffected based on GCN4-LacZ assays. It should be noted, 
however, that the authors did not investigate the rate of eIF2 cycling through 
microbody foci, which we found to be slower in comparison to eIF2B bodies 
(discussed further in section 4.3.1). The MPs Mst27p, Erp4p and Sac1p were 
previously shown to associate with eIF2B. However, within this research a specific 
interaction and role in eIF2B body formation could not be established (Babu et al., 
2012). Further investigations studying the differences between eIF2B microbodies 
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and eIF2B bodies could uncover additional eIF2B co-factors required to fully localise 
eIF2B. 
Although there seems to be relationships between localisation and the 
catalytic activity and regulation of eIF2B, the specific mechanism(s) that explains 
these associations remains unknown. One hypothesis is cooperative binding, which 
is a common feature of multimeric proteins and has been shown to occur within the 
ADP-glucose-pyrophosphorylase, a distant relative of eIF2B that shares homology 
with the ε and γ subunits (Gomez and Pavitt, 2000). In the decameric form, eIF2B has 
the capacity to bind two eIF2-GDP substrates or two eIF2α-P inhibitors. It is plausible 
that eIF2-GDP or eIF2α-P interaction within one binding domain could influence the 
other, potentially increasing affinity for either substrate or inhibitor. In-line with this 
idea, the catalytic activity of human eIF2B is reduced by 50% in the absence of 
eIF2Bα, which destabilises the decamer into two tetramers (Wortham et al., 
2014)(Williams et al., 2001). Furthermore, several small molecules have been shown 
to allosterically regulate eIF2B activity, including NADPH and AMP-PNP (Bogorad et 
al., 2017). Cooperative binding has even been shown to occur within protein 
aggregates. Thus when eIF2B is localised, positive or negative cooperativity could 
influence nearby eIF2B complexes (Curtain et al., 2001). Although cooperativity is yet 
to be shown within eIF2B, this is currently the best theory to unite eIF2B catalytic 
and regulatory activities with eIF2B body formation. 
6.4. The impact of eIF2Bα VWM mutants on eIF2B localisation 
 Inherited autosomal mutations within eIF2B cause the fatal disease VWM. 
The localisation of eIF2B with eIF2Bα VWM missense mutations was inconsistent 
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with correlations made from eIF2B catalytic and regulatory mutants. For instance, 
V184D localised eIF2B to microbodies, yet catalytic activity was not measurable as 
eIF2 did not co-localise to these foci. The VWM mutations could be hindering eIF2Bα 
homodimerisation, as the majority of affected residues reside within the α-α 
interface. Recent crystallography data from human eIF2B also suggests that the 
eIF2Bα2
 dimer must form prior to the stabilisation of two eIF2B tetramers, therefore 
perturbation of eIF2Bα dimerisation could lead to other unknown effects and 
subsequently, variable phenotypes (Zyryanova et al., 2018, Tsai et al., 2018).  
 The VWM mutations K111E and Y274C exhibited decreased eIF2 shuttling 
and eIF2B body formation. Interestingly, the Y274C eIF2B bodies contained higher 
amounts of total eIF2 within the foci. Although it is unknown whether-or-not the 
additional eIF2 was phosphorylated, it would explain why the catalytic activity of 
eIF2B was decreased. Whilst the underlying mechanism explaining this phenomenon 
is unknown, it could be explained by cooperative binding as described earlier. Upon 
amino acid starvation, Y274C exhibited hypersensitivity to the stress, hinting 
additional eIF2α-P may be able to enter the foci. Future experiments into these 
hypotheses could help explain why VWM sufferers suddenly deteriorate following 
intercurrent trauma that antagonises an eIF2B stress response (Pavitt and Proud, 
2009).  
 The VWM mutants N209Y and F240V largely lead to the dispersal of eIF2B 
throughout the cytoplasm, correlating with a regulatory phenotype. Intriguingly, the 
N209Y mutation in human eIF2Bα does not affect eIF2α-P binding or eIF2Bα 
incorporation (Wortham and Proud, 2015). Regulation of eIF2B is not only important 
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to neutralise cellular stresses but is also vital for the development of cells, 
particularly in the brain (Marom et al., 2011). These observations within yeast are 
therefore likely to be reminiscent of severe VWM mutations which may be 
incompatible with life. The VWM mutation G204Δ (G205 in S. cerevisiae) abolishes 
eIF2Bα incorporation and affects eIF2Bα-eIF2-P interaction, possibly simulating the 
regulatory phenotype (Wortham and Proud, 2015). However, G204Δ may be 
incompatible with life, as it is yet to be found in the homozygous state and is usually 
heterozygous with another mutation (i.e. Y274C). These severe phenotypes may be 
ameliorated by compound heterozygosity, a layer of complexity which has not been 
investigated within yeast thus far. Integration vectors could be used to generate 
VWM mutations in haploid yeast cells which could be crossed to produce compound 
heterozygous diploid cells. FRAP analysis on these strains could provide novel and 
fascinating observations which may help elucidate underlying mechanisms of VWM 
disease. 
6.5. eIF2 shuttling as a measure of in vivo GEF activity 
 The eIF2B body represents 40 % of a cell's total eIF2B, with the remainder of 
eIF2B dispersed throughout the cytoplasm (Campbell et al., 2005). Data presented 
within this study suggests that there are two pools of eIF2B subcomplexes present 
within cells. However, in vitro biochemical assays assume that eIF2B subunits are 
present in equimolar ratios and therefore do not account for this extra layer of in 
vivo complexity (Jennings and Pavitt, 2010, Wortham et al., 2014). To assess the GEF 
activity of eIF2B foci, FRAP analysis was employed to measure the efficiency of eIF2 
cycling. Biochemical assays measuring GCN4/HIS3 expression, as well as FRAP 
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analysis indirectly measure GEF activity whilst maintaining an in vivo environment, 
but under the proposed model of localisation, the latter analyses both complexes 
whilst the former scrutinises decameric complexes exclusively. In vivo analysis of GEF 
activity may therefore require careful consideration depending on the eIF2B subunit 
under investigation. Nonetheless, based on these conclusions, both experiments 
should be undertaken to ensure a comprehensive examination of eIF2B.    
6.6. The impact of altering the levels of cellular Ptdins(4)P on 
 translational control 
 Two independent studies reported that the eIF2B body may be membrane 
bound (Campbell et al., 2005, Browne et al., 2013). In light of the observed 
interactions between eIF2B and Mst27p, Erp4p and Sac1p, it was expected that 
these putative membrane proteins may tether the eIF2B body to an organelle. To 
investigate this, gene fusions were produced between the MPs and the monomeric 
RFP, mKate2. Exogenously expressed mKate2-tagged MPs did not specifically co-
localise with eIF2B. Absence of a single MP did not affect the formation of eIF2B 
bodies. Therefore, in this study, we conclude that eIF2B does not have stable 
associations with Mst27p, Erp4p or Sac1p. 
 Interestingly, deletion of the PI(4) phosphatase Sac1p led to similar effects of 
temperature sensitive PI(4)K Pik1p and Stt4p mutants, which lead to the 
accumulation of 80S monosomes (Cameroni et al., 2006). In this instance, there is 
strong evidence to suggest translation is attenuated independent of eIF2B. Upon 
dephosphorylation, eIF4E binding proteins (4E-BPs) can also regulate global protein 
synthesis by attenuating the interaction between eIF4E and the 5' cap structure on 
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mRNA. In line with published data, we propose the phosphorylation status of the 4E-
BP Eap1p is dependent upon Ptdins(4)P levels, attenuating protein synthesis under 
high or low cellular concentrations. Concentrated at the Golgi and plasma 
membrane, Ptdins(4)P is required for a host of cellular processes including actin-
cytoskeleton arrangement, protein trafficking and the secretory system. Abnormal 
Ptdins(4)P levels may cause a back-log of protein cargo that require transporting, 
which may then trigger a translational response to inhibit protein production in an 
attempt to clear the back-log. In line with this idea, defective secretory (Sec) 
proteins were shown to downregulate translation initiation in an Eap1p-dependent 
manner (Deloche et al., 2004). Disorganisation of the actin-cytoskeleton has also 
been suggested to inhibit translation at the initiation stage, although the specific 
mechanism remains uncertain. Inhibition of G-actin polymerisation through the drug 
Latrunculin A does not induce eIF2α-P, thus a 4E-BP such as Eap1p may be 
responsible for attenuating translation instead (Cameroni et al., 2006).  
 There is a substantial body of evidence to suggest Eap1p is responsible for 
attenuating translation initiation in response to fluctuating levels of Ptdins(4)P. 
However a direct link between Eap1p and Sac1p, Stt4p and Pik1p remains to be 
shown. Addition analysis of double-deletion strains may be an effective approach to 
elucidate this novel translational control pathway.  
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7. Conclusions 
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 The work within this thesis has highlighted the importance of eIF2Bα in the 
formation of eIF2B bodies. We hypothesise that eIF2Bα associates with tetrameric 
eIF2B complexes to form eIF2B bodies in a two-step process. Mutational analyses 
highlighted that the localisation of eIF2B is integral for function. Although the 
localisation of VWM mutants was surprisingly variable, this potentially recapitulated 
the variability in VWM disease. Intriguingly, data presented here suggests that eIF2B 
localises to two pools where only one may be subject to regulation. In conclusion, 
this work further underlines how important eIF2Bα is as the master regulator of 
eIF2B, and possibly explains why eIF2Bα contains the least VWM mutations out of all 
eIF2B subunits.  
 Although the putative membrane proteins Mst27p, Erp4p and Sac1p were 
shown to associate with eIF2B, a role in the formation of eIF2B bodies was not 
found. Surprisingly however, the PI(4)P Sac1p was shown to be required for efficient 
translation initiation. We conclude that the loss of Sac1p is likely to trigger a 
translational response dependent upon the 4E-BP Eap1p in response to altered 
Ptdins(4)p content at the Golgi apparatus.  
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